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vAbstract In this book a story is told about the psychological traits associated with drug consumption. The
book includes:
• A review of published works on the psychological profiles of drug users.
• Analysis of a new original database with information on 1885 respondents and usage of 18 drugs. (Database
is available online.)
• An introductory description of the data mining and machine learning methods used for the analysis of this
dataset.
• The demonstration that the personality traits (five factor model, impulsivity, and sensation seeking),
together with simple demographic data, give the possibility of predicting the risk of consumption of
individual drugs with sensitivity and specificity above 70% for most drugs.
• The analysis of correlations of use of different substances and the description of the groups of drugs with
correlated use (correlation pleiades).
• Proof of significant differences of personality profiles for users of different drugs. This is explicitly proved
for benzodiazepines, ecstasy, and heroin.
• Tables of personality profiles for users and non-users of 18 substances.
The book is aimed at advanced undergraduates or first-year PhD students, as well as researchers and practi-
tioners. No previous knowledge of machine learning, advanced data mining concepts or modern psychology
of personality is assumed. For more detailed introduction into statistical methods we recommend several
undergraduate textbooks. Familiarity with basic statistics and some experience in the use of probabilities
would be helpful as well as some basic technical understanding of psychology.

Preface
Each set of data can tell us a story. Our mission is to extract this story from the data and translate it into more
readily accessible human language. There are a number of tools for such a translation. To prepare this story
we have to collect data, to ask interesting questions and to apply all the possible data mining technical tools
to find the answers. Then we should verify the answers, exclude spurious (overoptimistic) correlations and
patterns, and tell the story to users.
The topic of mining interesting knowledge remains very intriguing. Many researchers have approached this
problem from a plethora of different angles. One of the main ideas in these approaches has been information
gain (the more information gain there is, the more interesting the result is). Nevertheless, we need a good
understanding of what makes patterns that are found interesting from the end-user’s point of view. Here
various perspectives might be involved, from practical importance to aesthetic beauty. The extraction of deep
and interesting knowledge from data was formulated as an important problem for the 5th IEEE International
Conference on Data Mining (ICDM 2005) [1]. Nowadays, the fast growth of the fields of data science and
machine learning provides us with many tools for answering such questions, but the art of asking interesting
questions still requires human expertise.
The practical importance of the problem of evaluating an individual’s risk of consuming and/or abusing
drugs cannot be underestimated [2]. One might well ask how this risk depends on a multitude of possible
factors [3]? The linking of personality traits to risk of substance use disorder is an enduring problem [4].
Researchers return again and again to this problem following the collection of new data, and with new
questions.
How do personality, gender, education, nationality, age, and other attributes affect this risk? Is this
dependence different for different drugs? For example, does the risk of ecstasy consumption and the risk of
heroin consumption differ for different personality profiles? Which personality traits are the most important
for evaluation of the risk of consumption of a particular drug, and are these traits different for different drugs?
These questions are the focus of our research.
The data set we collected contains information on the consumption of 18 central nervous system psychoac-
tive drugs, by 2,051 respondents (after cleaning, 1,885 participants remained, male/female = 943/942). The
database is available online [5, 6].
The questions we pose above have been reformulated as classification problems and many well-known
data mining methods have been employed to address these problems: decision trees, random forests, k-nearest
neighbours, linear discriminant analysis, Gaussian mixtures, probability density function estimation using
radial basis functions, logistic regression and naı¨ve Bayes. For data preprocessing, transformation and ranking
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we have used methods such as polychoric correlation, nonlinear CatPCA (Categorical Principal Component
Analysis), sparse PCA, and original double Kaiser’s feature selection.
The main results of the work are:
• The presentation and descriptive analysis of a database with information on 1,885 respondents and their
usage of 18 drugs.
• Demonstration that the personality traits (Five Factor Model [7], impulsivity, and sensation-seeking)
together with simple demographic data give the possibility of predicting the risk of consumption of
individual drugs with sensitivity and specificity above 70% for most drugs.
• The construction of the best classifiers and most significant predictors for each individual drug in question.
• Revelation of significantly distinct personality profiles for users of different drugs; in particular, groups of
heroin and ecstasy users are significantly different in Neuroticism (higher for heroin), Extraversion (higher
for ecstasy), Agreeableness (higher for Ecstasy), and Impulsivity (higher for heroin); groups of heroin and
benzodiazepine users are significantly different in Agreeableness (higher for benzodiazepines), Impulsivity
(higher for heroin), and Sensation-Seeking (higher for heroin); groups of ecstasy and benzodiazepine users
are significantly different in Neuroticism (higher for benzodiazepines), Extraversion (higher for ecstasy),
Openness to Experience (higher for ecstasy), and Sensation-Seeking (higher for ecstasy).
• The discovery of three correlation pleiades of drugs; these are the clusters of drugs with correlated
consumption centered around heroin, ecstasy, and benzodiazepines. The correlation pleiades should
include the mini-sequences of drug involvement found in longitudinal studies [8], and aim to serve as
maps for analysis of different patterns of influence.
• The development of risk map technology for the visualization of the probability of drug consumption.
Four of the authors (ANG, JL, EMM, and AKM) are applied mathematicians and two are psychologists
(EF and VE). Data were collected by EF and processed by EMM and AKM. The psychological framework
for this study was developed by EF and VE, and the analytic methodology was selected and developed by
ANG and EMM. The final results were critically analysed and described by ANG, JL, EMM, and AKM from
the data mining perspective, and EF and VE provided the psychological interpretation and conceptualization.
For psychologists, the book gives a new understanding of the relationship between personality traits and
the usage of 18 psychoactive substances, provides a new openly available database for further study, and
presents many useful methods of data analysis. For applied mathematicians and statisticians, the book details
a case study in a fascinating area of application, exemplifying the use of various data mining methods in such
scenarios.
This book is aimed at advanced undergraduates or first-year PhD students, as well as researchers and
practitioners in data analysis, applied mathematics and psychology. No previous knowledge of machine
learning, advanced data mining concepts or psychology of personality is assumed. Familiarity with basic
statistics and some experience of the use of probability is helpful, as well as some basic understanding of
psychology. Two books [9, 10] include all the necessary prerequisites (and much more). Linear Discriminant
Analysis (LDA), Principal Component Analysis (PCA), and Decision Trees (DT) are systematically employed
in the book. Therefore, it may be useful to refresh the knowledge of these classical methods using the textbook
[10], which is concentrated more on the applications of the methods and less on the mathematical details.
A preliminary report of our work was published as an arXiv e-print in 2015 [11] and presented at the
Conference of International Federation of Classification Societies 2015 (IFCS 2015) [12].
This book is not the end of the story told by the data. We will continue our work and try to extract more
interesting knowledge and patterns from the data. Moreover, we are happy for you, the readers, to join us in
this adventure. We believe that every large annotated dataset is a treasure trove and that there is an abundance
of interesting knowledge to discover from them. We have published our database online [5, 6] and invite
References ix
everybody to use it for their own projects, from BSc and MSc level to PhD, or just for curiosity-driven
research. We would be very happy to see the fascinating outcomes of these projects.
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Chapter 1
Introduction: drug use and personality profiles
1.1 Definitions of drugs and drug usage
Since Sir Karl Popper, it has become a commonplace opinion in the philosophy of science that the ‘value’ of
definitions, other than for mathematics, is generally unhelpful. Nevertheless, for many more practical spheres
of activity, from jurisprudence to health planning, definitions are necessary to impose theoretical boundaries
on a subject, in spite of their incompleteness and their tendency to change with time. This applies strongly to
definitions of drugs and drug use.
Following the standard definitions [1],
• A drug is a ‘chemical that influences biological function (other than by providing nutrition or hydration)’.
• A psychoactive drug is a ‘drug whose influence is in a part on mental functions’.
• An abusable psychoactive drug is a ‘drug whose mental effects are sufficiently pleasant or interesting or
helpful that some people choose to take it for a reason other than to relieve a specific malady’.
In our study we use the term ‘drug’ for abusable psychoactive drug regardless of whether it is illicit or not.
While legal substances such as sugar, alcohol and tobacco are probably responsible for far more premature
death than illegal recreational drugs [2], the social and personal consequences of recreational drug use can be
highly problematic [3].
Use of drugs introduces risk into a life across a broad spectrum; it constitutes an important factor for
increasing risk of poor health, along with earlier mortality and morbidity, and has significant consequences
for society [4, 5]. Drug consumption and addiction constitutes a serious problem globally. Though drug use is
argued by civil libertarians to be a matter of individual choice, the effects on an individual of drug use such as
greater mortality or lowered individual functioning, suggest that drug use has social and interpersonal effects
on individuals who have not chosen to use drugs themselves.
Several terms are used to characterise drug use disorder: addiction, dependence, and abuse. For a long
time, ‘substance abuse’ and ‘substance dependence’ were considered as separate disorders. In 2013, The
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) joined these two diagnoses into ‘Substance
Use Disorder’ [6]. This is a more inclusive term used to identify persons with substance-related problems.
More recently, abuse and dependence have been defined on a scale that measures the time and degree of
substance use. Criteria are provided for substance use disorder, supplemented by criteria for intoxication,
withdrawal, substance/medication-induced disorders, and unspecified substance-induced disorders, where
relevant. Abuse can be considered as the early stage of substance use disorder.
1
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In our study we differentiate the substance users on the basis of recency of use but do not identify existence
and depth of the substance dependence.
For prevention and effective care of substance use disorder, we need to identify the risk factors and develop
methods for their evaluation and control [7].
1.2 Personality traits
Sir Francis Galton (1884) proposed that a lexical approach in which one used dictionary definitions of
dispositions could be a means of constructing a description of individual differences (see [8]). He selected the
personality-descriptive terms and stated the problem of their interrelations. In 1934, Thurstone [9] selected
60 adjectives that are in common use for describing people and asked each of 1300 respondents to think of
a person they knew well and to select the adjectives that can best describe this person. After studying the
correlation matrix he found that five factors are sufficient to describe this choice.
There have been many versions of the five factor model proposed since Thurston [10], for example:
• Surgency, agreeableness, dependability, emotional stability, and culture;
• Surgency, agreeableness, conscientiousness, emotional stability, and culture;
• Assertiveness, likeability, emotionality, intelligence, and responsibility;
• Social adaptability, conformity, will to achieve, emotional control, and inquiring intellect;
• Assertiveness, likeability, task interest, emotionality, and intelligence;
• Extraversion, friendly compliance, will to achieve, neuroticism, and intellect;
• Power, love, work, affect, and intellect;
• Interpersonal involvement, level of socialization, self-control, emotional stability, independence.
There are also systems with different numbers of factors (three, seven, etc.). The most important three-factor
system is Eysenck’s model comprising extraversion, psychoticism, and neuroticism.
Nowadays, after many years of research and development, psychologists have largely agreed that the
personality traits of the modern Five Factor Model (FFM) constitutes the most comprehensive and adapt-
able system for understanding human individual differences [11]. The FFM comprises Neuroticism (N),
Extraversion (E), Openness to Experience (O), Agreeableness (A), and Conscientiousness (C).
The five traits can be summarized thus:
N Neuroticism is a long-term tendency to experience negative emotions such as nervousness, tension,
anxiety and depression (associated adjectives [12]: anxious, self-pitying, tense, touchy, unstable, and
worrying);
E Extraversion manifested in characters who are outgoing, warm, active, assertive, talkative, and cheer-
ful; these persons are often in search of stimulation (associated adjectives: active, assertive, energetic,
enthusiastic, outgoing, and talkative);
O Openness to experience is associated with a general appreciation for art, unusual ideas, and imaginative,
creative, unconventional, and wide interests (associated adjectives: artistic, curious, imaginative, insightful,
original, and wide interest);
A Agreeableness is a dimension of interpersonal relations, characterized by altruism, trust, modesty,
kindness, compassion and cooperativeness (associated adjectives: appreciative, forgiving, generous, kind,
sympathetic, and trusting);
C Conscientiousness is a tendency to be organized and dependable, strong-willed, persistent, reliable, and
efficient (associated adjectives: efficient, organised, reliable, responsible, and thorough).
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Individuals low on the A and C trait dimensions have less incidence of the reported attributes, so, for example,
lower Agreeableness is associated with greater antisocial behaviour [89].
1.3 How many inputs do the predictive models have: 5, 30, 60, or 240?
The NEO PI-R questionnaire was specifically designed to measure the FFM of personality [11]. It provides
scores corresponding to N, E, O, A, and C (‘domain scores’). The NEO PI-R consists of 240 self-report items
answered on a five-point scale, with separate scales for each of the five domains. Each scale consists of six
correlated sub-scales (‘facets’). A list of the facets within each domain is presented in the first column of
Table 1.1.
There are several versions of the FFM questionnaire: NEO PI-R with 240 questions (‘items’), 30 facets,
and five domains; the older NEO-FFI with 180 items, etc. A shorter version of the Revised NEO Personality
Inventory (NEO-PI-R), the NEO-Five Factor Inventory (NEO-FFI), has 60 items (12 per domain and no facet
structure) selected from the original items [11]. This shorter questionnaire was revised [16] after Egan et al.
demonstrated that the robustness of the original version should be improved [17]. NEO-FFI was designed as a
brief instrument that provides estimates of the factors for use in exploratory research.
The values of the five factors are used as inputs in numerous statistical models for prediction, diagnosis, and
risk evaluation. These models are employed in psychology, psychiatry, medicine, education, sociology, and
many other areas where personality may be important. For example [13], academic performance at primary
school was found to significantly correlate with Emotional Stability (+), Agreeableness (+), Conscientiousness
(+), and Openness to Experience (+) (the sign of correlations is presented in parentheses). Success in
primary school is also significantly and highly correlated with intelligence (+), the Pearson correlation
coefficient r > 0.5. For higher academic levels, correlations of Academic Performance with Emotional
Stability, Agreeableness, and Openess, significantly decreases (r / 0.1). Correlation with Intelligence also
decreases by two or more, but correlation with Conscientiousness remains almost the same for all academic
levels (r ≈ 0.21−0.28). Correlations between Conscientiousness and Academic Performance were largely
independent of Intelligence. This knowledge can be useful for educational professionals and parents.
Another example demonstrates how personality affects career success [14]. Extraversion was related
positively to salary level, promotions, and career satisfaction, and Neuroticism was related negatively to
career satisfaction. Agreeableness was related negatively only to career satisfaction and Openness was
related negatively to salary level. There was a significant negative relationship between Agreeableness and
salary for individuals in people-oriented occupations (with direct interaction with clients, for example)
but no such relationships were found in occupations without a strong ‘people’ component. At the same
time, Agreeableness is positively correlated with performance in jobs involving teamwork (interaction with
co-workers) [15]. These result are of interest to Human Resources departments.
Most of the statistical models use the values of five factors (N, E, O, A, C) as the inputs and produce assess-
ment, diagnosis, recommendations or prognosis as the outputs (Fig. 1.1a). For the NEO PI-R questionnaire
this means that we take the 240 inputs, transform them into 30 facet values, then transform these 30 numbers
into five factors and use these five numbers as the inputs for the statistical or, more broadly, data analytic
model. To construct this model with five inputs and the desired outputs, one should use data with known
answers and supervising learning (or, more narrowly, various regression and classification models). The
crucial question arises: is it true that for all specific diagnosis, assessment, prognosis, and recommendation
problems the facets should be linearly combined with the same coefficients?
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An alternative version is the facet trait model (Fig. 1.1b), where combining of facets into the final output
depends on the problem and data [18]. We can go further and consider flexible combination of the raw
information, the questionnaire answers for each problem, and dataset (Fig. 1.1c) [19, 20].
One of the most developed area of FFM application is psychiatry and psychology, for example, for the
assessment of personality psychopathology. The facet trait model created for 10 personality disorders [18, 35]
demonstrates that optimal combinations of facets into predictors is not uniform inside the domains (Table 1.1).
Some facets are more important for assessment than the others and the selection of important facets depends
on the specific personality disorder (see Table 1.1). Nevertheless, there are almost no internal contradictions
inside domains in Table 1.1: for almost each domain and any given disorder all significant facets have the
same sign of deviation from the norm: either all have higher values (⇑ ) or all have lower values (⇓). The only
exclusion is the contradiction between facets ‘Warmth’ and ‘Assertiveness’ from the domain ‘Extraversion’:
both are important for the diagnosis ‘Dependent’ but for this diagnosis ‘Warmth’ is expected to be higher
than average and ‘Assertiveness’ is expected to be lower.
In 1995, Dorrer and Gorban with co-authors [19] employed neural network technology and the original
software library MultiNeuron [20] for direct prediction of human relations on the basis of raw questionnaire
information. A specially reduced personality questionnaire with 91 questions was prepared. The possible
answers to each question were: ‘yes’, ‘do not know’, and ‘no’, which were coded as +1, 0, and −1,
correspondingly. The neural networks (committees of six networks of different architecture) were prepared
to predict results of sociometry of relations between university students inside an academic group. Neural
networks had to predict students’ answers to the sociometric question: “To what degree would you like to
work in your future profession with this group member?” The answer was supposed to be given as a 10-point
estimate (0 - most negative attitude to a person as a would-be co-worker, 10 - maximum positive). The status
and expansivity of each group member were evaluated from the answers to these questions. Sociometric
status is a measurement that reflects the degree to which someone is liked or disliked by their peers from a
group. Social expansivity is the tendency of a group members to choose and highly evaluate many others.
These two characteristics were used as elements of neural network output vector for each person. The inputs
were 91 answers of this person to the pesonality questionnaire. The neural networks were trained on data
from several academic groups and tested on academic groups never seen before.
The 91 questions from the questionnaire were ranked by importance for the neural networks prediction.
Cross-validation showed that reduction of the questionnaire to 46 questions (the empirically optimal number
in these experiments) gave the best prediction result. Committees of networks always gave better results than
a single network.
While such (relatively novel) systems are often more accurate they are more costly in two ways: they are
hungrier in terms of data requirements and computational resources.
In this book, we focus on the classical systems with explicitly measured personality, which have bottleneck
of five (or seven) factors (Fig. 1.1a). Nevertheless, modern development of artificial intelligence and neural
network systems ensures us that the computational models, which process raw information without explicitly
describing personality (Fig. 1.1c), could be important elements of future personality assessment.
1.4 The problem of the relationship between personality traits and drug
consumption
There are numerous risk factors for addiction, which are defined as any attribute, characteristic, or event in
the life of an individual that increase the probability of drug consumption. A number of such attributes are
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Fig. 1.1 Three types of predictive models based on the FFM NEO PI-R questionnaire: (a) statistical models which uses five
FFM inputs prepared by the standard FFM procedure, (b) facet-based predictors [18, 35], and (c) direct predictors, which avoid
the step of explicit diagnosis and work with multidimensional raw input information (usually, Artificial Intelligence models like
neural networks [19, 20]).
correlated with initial drug use, including genetic inheritance as well as psychological, social, individual,
environmental, and economic factors [7, 21–23]. Modest genetic and strong environmental influences on
adolescent illicit substance use and abuse is impressively consistent across multiple substances [23].
The important risk factors are likewise associated with a number of personality traits [24, 25].
There is a well-known problem in analysing of the psychological traits associated with drug use: to
distinguish the effect of drug use from the cause of [26]. To solve this problem, we have to use relatively
constant psychological traits. Another solution is to organise large longitudinal studies which will analyse the
traits of the persons at the different stages of drug use (such an approach seems to be more or less impossible
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Table 1.1 FFM facet trait predictor set for DSM-IV PD [18, 35].
FFM PAR SZD SZT ATS BDL HST NAR AVD DEP OBC
Neuroticism
Anxiety ⇑ ⇑ ⇑ ⇑
Angry Hostility ⇑ ⇑ ⇑ ⇑
Depression ⇑ ⇑ ⇑
Self-consciousness ⇑ ⇑ ⇑ ⇑ ⇑
Impulsiveness ⇑
Vulnerability ⇑ ⇑ ⇑
Extraversion
Warmth ⇓ ⇓ ⇑ ⇑
Gregariousness ⇓ ⇓ ⇑ ⇓
Assertiveness ⇓ ⇓ ⇑
Activity
Excitement seeking ⇑ ⇑ ⇓
Positive emotions ⇓ ⇓ ⇑
Openness to Experience
Fantasy ⇑ ⇑ ⇑
Aesthetics
Feelings ⇓ ⇑
Actions ⇑
Ideas ⇑
Values ⇓
Agreeableness
Trust ⇓ ⇓ ⇓ ⇑ ⇑
Straightforwardness ⇓ ⇓
Altruism ⇓ ⇓ ⇑
Compliance ⇓ ⇓ ⇓ ⇑ ⇓
Modesty ⇓ ⇑
Tender mindedness ⇓ ⇓
Conscientiousness
Competence ⇓ ⇑
Order ⇑
Dutifulness ⇓ ⇑
Achievement striving ⇑ ⇑
Self-discipline ⇓
Deliberation ⇓
⇑=high values; ⇓=low values; Personality disorders: PAR=Paranoid;SZD=Schizoid; SZT=Schizotypal; ATS=Antisocial;
BDL=Borderline; HST=Histrionic; NAR=Narcissis-Narcissistic; AVD=Avoidant; DEP=Dependent;
OBC=Obsessive-compulsive.
for a number of reasons). The concepts of states, traits, and of causality, are crucial for a psychological theory
of personality and drug use. They remain part of the focus of ongoing research [27].
Stability of personality traits is one of the keystones of personality measurement and is indicated by the
importance placed on the reliability and validity of psychometric measurement. The stability problem of
measured personality was approached many times within the FFM framework, from the very beginning. The
hypothesis was that in ‘normal’ individuals the stable self-concept is crystallized in early adulthood [28]. The
results were summarised in four items [29]. In brief: (1) “The mean levels of personality traits change with
development but reach final adult level at about age 30.” (2) “Individual differences in personality traits, which
show at least some continuity from early childhood on, are also essentially fixed by age 30.” (3) “Stability
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appears to characterize the major domains of personality” – N, E, O, A, C. (4) “Generalizations about stability
apply to virtually everyone” (to all healthy adults) [31].
Leading experts examined various theories of personality change and stability, and state-of-the-art mea-
surement issues in a special volume [30]. Costa and McCrae reviewed evidence suggesting that, in most
cases, personality traits are indeed unchanging [32]. On another hand, Weinberger [33] presented an elegant
argument: “Psychotherapy represents the most sustained and well-documented effort to trigger psychological
change.” Therefore, we can conclude that there is a place for doubt: either personality can change or psy-
chotherapy cannot provide personality change (i.e. it can be only superficial). However, the evidence that
therapy may change persons is limited; psychological and pharmacological treatment led persons treated for
depression to become more extraverted, open to experience, agreeable and conscientious, and substantially
more emotional stable after treatment, though these changes were largely unrelated to initial depression
severity [36].
Stability of personality has been tested with samples of drug users in several studies. For example, 230
opioid-dependent patients completed NEO Pl-R at admission and again, approximately 19 weeks later. Results
indicated fair to good stability for all NEO PI-R factor domain scores (N, E, O, A, C) [34]. Stability of the
scores was not significantly affected by drug-positive versus drug-negative status at follow-up.
A number of studies have illustrated that personality traits are associated with drug consumption. Meta-
analysis of associations between personality traits and specific depressive, anxiety, and substance use disorders
in adults showed that all diagnostic groups were high on N and low on C [37]. This analysis involved 175
studies published from 1980 to 2007.
Several studies of opioid dependent samples demonstrate high N, low C, and average O [34, 38, 39]. There
are also some differences betweens studies and cohorts: a Norwegian group of opioid users demonstrated
lower E [39], whereas USA groups did not significantly deviate in E from the norm [34, 38]. O and A were
observed lower in Norwegian drug dependent patients than in controls, but given the sample size (65 patients)
the difference was not significant.
The combination N⇑, A⇓, and C⇓ for substance abusers was reported by [40] (here, and below arrows
indicate direction of deviation from the mean level). According to [40], the cocaine users were characterized
by higher levels of E and O, whereas polysubstance users were characterized by lower levels of A and C .
We expected that drug usage would be associated with high N, low A, and low C ( N⇑, A⇓, and C⇓).
This combination was observed for various types of psychopathy and deviant behavior. For example, in the
analysis of the ‘dark triad’ of personality, Machiavellianism, Narcissism and Psychopathy were evident [41].
• Machiavellianism refers to interpersonal strategies that advocate self-interest, deception and manipulation.
A questionnaire MACH-IV is the most widely used tool to measure MACH, the score of Machiavellianism
[42]. Persons high in MACH are likely to exploit others and less likely to be concerned about other people
beyond their own self-interest.
• The concept of narcissism comes from the Greek myth of Narcissus who falls in love with his own reflec-
tion. Formalised in psychodynamic theory, it describes a pathological form of self-love. One commonly
used operational definition of narcissism is based on the Narcissistic Personality Inventory, that measures
persistent attention seeking, extreme vanity, excessive self-focus, and exploitativeness in interpersonal rela-
tions. It comprises four factors: Exploitativeness/Entitlement, Leadership/Authority, Superiority/Arrogance
and Self-Absorption/Self-Admiration [43].
• Psychopathy can be measured as a detailed structured interview, or as a brief self-report. The key constructs
are operationalised in Levenson’s self-report measure of psychopathy which measures two facets of
psychopathy. Factor 1 reflects primary psychopathy (e.g., selfishness, callousness, lack of interpersonal
affect, superficial charm and remorselessness), and Factor 2 measures antisocial lifestyle and behaviours,
and is akin to secondary psychopathy (excessive risk-takers who exhibit usual amounts of stress and guilt).
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• In clinical practice, Hare’s Psychopathy Checklist Revised (PCL-R) [44] is ‘the-state-of-the-art’. The PCL-
R uses a semi-structured interview and case-history information summarised in 20 items scored by trained
professional. It also measures two correlated factors. Factor 1 (the core personality traits of psychopathy)
is labelled as “selfish, callous and remorseless use of others”. Factor 2 is labelled as “chronically unstable,
antisocial and socially deviant lifestyle”. It is associated with reactive anger, criminality, and impulsive
violence.
Analysis of the ‘dark triad’ of personality showed that N was positively associated with psychopathy and
Machiavellianism (Table 1.2). The dark dimension of personality can be described in terms of low A, whereas
much of the antisocial behaviour in ‘normal’ people appears underpinned by high N, low A, and low C [41].
Table 1.2 PCC between NEO-FFI trait scores and the ‘dark triad’ scores (n=82). PP stands for primary psychopathy, SP for
secondary psycholathy, M for Machiavellianism, and Nar for narcissism scores.
N E O A C
PP 0.30*** 0.08 −0.21* −0.43*** −0.21*
SP 0.47*** 0.04 −0.21* −0.23** −0.19*
M 0.38*** −0.13 −0.17 −0.41*** −0.27**
Nar −0.10 0.10 0.10 −0.43*** −0.24**
*p < 0.1, **p < 0.05, ***p < 0.01
More detailed factor analysis found that Machiavellianism and psychopathy shared common variance and
were primary defined by a very high loading (-0.725) for Agreeableness, whereas narcissism was primarily
defined by it’s high loadings for extroversion and intellect, once the common psychopathic variance associated
with narcissism was rotated to the antisocial element of the dark triad (psychopathy and Machiavellianism)
[45].
The so-called ‘negative urgency’ is the tendency to act rashly when distressed, and is also characterized by
high N, low A, and low C [46]. Negative urgency predicted alcohol dependence symptoms in personality
disordered women, drinking problems and smoker status in pre-adolescents, and aggression, risky sex, illegal
drug use, drinking problems, and disordered behavior in college students.
Thus, the hypothesis about the personality profile N⇑, A⇓ and C⇓ for drug users has a reliable background.
We validated this hypothesis with our data and found, indeed, that for some groups of drug users it holds true.
For example, for heroin and methadone users, we found this typical combination. At the same time, we found
various deviations from this profile for other drugs. For example, for groups of recent LSD users (used less
than a year ago, or used less than a month ago, or used less than a week ago), N does not deviate significantly
from the mean but O and C do: O⇑, C⇓. Our findings suggest also that O is higher for many groups of drug
users. Detailed profiles of all groups of users are presented in A.
Roncero et al [47] highlighted the importance of the relationship between high N and the presence of
psychotic symptoms following cocaine-induced drug consumption. Vollrath & Torgersen [48] observed that
the personality traits of N, E, and C are highly correlated with hazardous health behaviours. A low score of C,
and high score of E, or a high score of N correlate strongly with multiple risky health behaviours. Formally,
this profile associated with risk can be described as (C⇓ AND E⇑) OR N⇑. Flory et al [49] found alcohol
use to be associated with lower A and C, and higher E. They also found that lower A and C, and higher O
are associated with marijuana use. Sutin et al [5] demonstrated that the relationship between low C and drug
consumption is moderated by poverty; low C is a stronger risk factor for illicit drug usage among those with
relatively higher socioeconomic status. They found that high N, and low A and C are associated with higher
risk of drug use (including cocaine, crack, morphine, codeine, and heroin). It should be mentioned that high
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N is positively associated with many other addictions like internet addiction, exercise addiction, compulsive
buying, and study addiction [50].
An individual’s personality profile contributes to becoming a drug user. Terracciano et al [51] demonstrated
that compared to ‘never smokers’, current cigarette smokers were lower on C and higher on N. They found
that the profiles for cocaine and heroin users scored very high on N, and very low on C whilst marijuana users
scored high on O but low on A, and C. Turiano et al [52] found a positive correlation between N and O, and
drug use, while increasing scores for C and A decreases risk of drug use. Previous studies demonstrated that
participants who use drugs, including alcohol and nicotine, have a strong positive correlation between A and C,
and a strong negative correlation for each of these factors with N [53, 54]. Three high-order personality traits
are proposed as endophenotypes for substance use disorders: Positive Emotionality, Negative Emotionality,
and Constraint [55].
The problem of risk evaluation for individuals is much more complex. This was explored very recently
by Yasnitskiy et al [56], Valeroa et al [80] and Bulut & Bucak [81]. Both individual and environmental
factors predict substance use, and different patterns of interaction among these factors may have different
implications [82]. Age is a very important attribute for diagnosis and prognosis of substance use disorders. In
particular, early adolescent onset of substance use is a robust predictor of future substance use disorders [83].
Valeroa et al [80] evaluated the individual risk of drug consumption for alcohol, cocaine, opiates, cannabis,
ecstasy, and amphetamines. Input data were collected using a Spanish version of the Zuckerman-Kuhlman
Personality Questionnaire (ZKPQ). Two samples were used in this study. The first one consisted of 336 drug
dependent psychiatric patients of one hospital. The second sample included 486 control individuals. The
authors used a decision tree as a tool to identify the most informative attributes. The sensitivity (proportion of
correctly identified positives) of 40% and specificity (proportion of correctly identified negatives) of 94% were
achieved for the training set. The main purpose of this research was to test if predicting drug consumption was
possible and to identify the most informative attributes using data mining methods. Decision tree methods
were applied to explore the differential role of personality profiles in drug consumer and control individuals.
The two personality factors, Neuroticism and anxiety and the ZKPQ’s Impulsivity, were found to be most
relevant for drug consumption prediction. The low sensitivity (40%) score means that such a decision tree
cannot be applied to real life situations.
Without focussing on specific addictions, Bulut & Bucak [81] estimated the proportion of teenagers who
exhibit a high risk of addiction. The attributes were collected by an original questionnaire, which included 25
questions. The form was filled in by 671 students. The first 20 questions asked about the teenagers’ financial
situation, temperament type, family and social relations, and cultural preferences. The last five questions were
completed by their teachers and concerned the grade point average of the student for the previous semester
according to a five-point grading system, whether the student had been given any disciplinary punishment so
far, if the student had alcohol problems, if the student smoked cigarettes or used tobacco products, and whether
the student misused substances. In Bulut et al’s study there were five risk classes as outputs. The authors
diagnosed teenagers’ risk of being a drug abuser using seven types of classification algorithms: k-nearest
neighbor, ID3 and C4.5 decision tree based algorithms, naı¨ve Bayes classifier, naı¨ve Bayes/decision trees
hybrid approach, one-attribute-rule, and projective adaptive resonance theory. The classification accuracy of
the best classifier was reported as 98%.
Yasnitskiy et al [56], attempted to evaluate the individual’s risk of illicit drug consumption and to
recommend the most efficient changes in the individual’s social environment to reduce this risk. The input
and output features were collected by an original questionnaire. The attributes consisted of: level of education,
having friends who use drugs, temperament type, number of children in the family, financial situation, levels of
alcohol and cigarette smoking consumption, family relations (cases of physical, emotional and psychological
abuse, level of trust and happiness in the family). There were 72 participants. A neural network model was
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used to evaluate the importance of attributes to diagnose the tendency towards drug addiction. A series of
virtual experiments was performed for several test patients (drug users) to evaluate how possible it is to
control the propensity for drug addiction. The most effective change of social environment features was
predicted for each person. The recommended changes depended on the personal profile, and significantly
varied for different participants. This approach produced individual bespoke advice to affect decreasing drug
dependence.
Profiles of drug users have some similarity for all drugs (for example, N⇑ and C⇓), but substance
abuse populations differ in details and severity of these deviations form the normal profile. This important
observation was done by Donovan et al. [57] in 1998. They used MMPI for personality description and
analysed groups of alcoholics, heroin, cocaine, and polydrug addicts by Discriminant Analysis. They identified
three functions in the MMPI data, which distinguished between the groups along important dimensions. These
functions are: Level of Disturbance, Mania versus Alienated Depression, and Odd Thinking and Introversion
versus Psychopathic Acting Out.
Two additional characteristics of personality are proven to be important for analysis of substance use,
Impulsivity (Imp) and Sensation-Seeking (SS).
Imp Impulsivity is defined as a tendency to act without adequate forethought;
SS Sensation-Seeking is defined by the search for experiences and feelings, that are varied, novel, complex
and intense, and by the readiness to take risks for the sake of such experiences.
It was shown that high SS is associated with increased risk of substance use [58–60].
Imp has been operationalised in many different ways [61]. It was demonstrated that substance use disorders
are strongly associated with high personality trait Imp scores on various measures [62, 63]. Moreover, Imp
score has significant impact on the treatment of substance use disorders: higher Imp implies lower success
rate [63]. It is possible that psychosocial and pharamacological treatments that may decrease Imp will improve
substance use treatment outcomes [63].
Impulsivity has been shown to predict aggression and heavy drinking [64]. Poor social problem solving has
been identified as a potential mediating variable between impulsivity and aggression. It is likely that the cog-
nitive and behavioural features of impulsivity militate against the acquisition of good social problem-solving
skills early in life and that these deficits persist into adulthood, increasing the likelihood of interpersonal
problems.
A model was proposed, which attributes substance use/misuse to four distinct personality factors: SS, Imp,
anxiety sensitivity (AS), and introversion/hopelessness (I/H). These four factors form a so-called Substance
Use Risk Profile Scale [65]. The model was tested on groups of cannabis users [65–67]. It was demonstrated
that SS was positively associated with expansion motives, Imp was associated with drug availability motives,
AS was associated with conformity motives and I/H was associated with coping motives for cannabis use [67].
Therefore, the authors of this model concluded that four personality risk factors in the model are associated
with distinct cannabis use motives.
The personality trait Imp and laboratory tests of neurobehavioral impulsivity measured different aspects of
general impulsivity phenomenon. Relationships between these two aspects are different in groups of heroin
users and amphetamines users (even the sign of correlations is different) [68]. Very recently, demographic,
personality (Imp, trait psychopathy, aggression, SS), psychiatric (attention deficit hyperactivity disorder,
conduct disorder, antisocial personality disorder, psychopathy, anxiety, depression), and neurocognitive
impulsivity measures (Delay Discounting, Go/No-Go, Stop Signal, Immediate Memory, Balloon Analogue
Risk, Cambridge Gambling, and Iowa Gambling tasks) are used as predictors in a machine-learning algorithm
to separate 39 amphetamine mono-dependent, 44 heroin mono-dependent, 58 polysubstance dependent, and
81 non-substance dependent individuals [69].
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Two integrative personality dimensions capture important risk factors for substance use diorder [70]:
• Internalizing relates to generalized psychological distress, refers to insufficient amounts of behavior and is
sensitive to a wide range of problems in living (associated with overcontrol of emotion, social withdrawal,
phobias, symptoms of depression, anxiety, somatic disorder, traumatic distress, suicide).
• Externalizing refers to acting-out problems that involve excess behavior and is often more directly
associated with behaviors that cause distress for others, and to self as a consequence (associated with
undercontrol of emotion, oppositional defiance, negativism, aggression, symptoms of attention deficit,
hyperactivity, conduct, and other impulse control disorders).
Empirical results suggested co-occurrence of internalizing and externalizing problems among substance
users [71]. Nevertheless, the externalizing dimension differentiated heroin users from alcohol, marijuana, and
cocaine users [72]. Internalizing and externalizing symptoms can be evaluated in FFM [73].
Correlations between drug consumption and gender, age, family income and geographical location was
studied in USA in a series of epidemiologic surveys (see [74]). For example, it was demonstrated that rates
of alcohol and cannabis abuse and dependence were greater among men than women. Nevertheless, the
gender differences reported in large-scale epidemiological studies, were not pronounced in some adolescent
samples [75].
In our study [76, 77] we tested associations with personality traits and biographical data (age, gender, and
education) for 18 different types of drugs separately, using the Revised NEO Five-Factor Inventory (NEO-
FFI-R) [16], the Barratt Impulsiveness Scale Version 11 (BIS-11) [84], and the Impulsivity Sensation-Seeking
Scale (ImpSS) [85] to assess Imp and SS respectively. For this analysis, we employed various methods of
statistics, data analysis and machine learning.
1.5 New dataset open for use
The database was collected by an anonymous online survey methodology by Elaine Fehrman, yielding
2051 respondents. In January 2011, the research proposal was approved by the University of Leicester
Forensic Psychology Ethical Advisory Group, and subsequently received strong support from the University
of Leicester School of Psychology Research Ethics Committee (PREC).
The database is available online [78, 79]. An online survey tool from Survey Gizmo [86, 87] was employed
to gather data which maximised anonymity; this was particularly relevant to canvassing respondents views,
given the sensitive nature of drug use. All participants were required to declare themselves at least 18 years of
age prior to giving informed consent.
The study recruited 2051 participants over a 12-month recruitment period. Of these persons, 166 did not
respond correctly to a validity check built into the middle of the scale, so were presumed to be inattentive to
the questions being asked. Nine of these were also found to have endorsed the use of a fictitious drug, which
was included precisely to identify respondents who overclaim, as have other studies of this kind [88]. This led
a useable sample of 1885 participants (male/female = 943/942). It was found to be biased when compared
with the general population, the comparison (see Chapter 3, Fig. 3.5) being based on the data published by
Egan et al. [17] and Costa & McCrae [16]. Such a bias is usual for clinical cohorts [51, 99] and ‘problematic’
or ‘pathological’ groups..
The sample recruited was highly educated, with just under two-thirds (59.5%) educated to, at least, degree
or professional certificate level: 14.4% (271) reported holding a professional certificate or diploma, 25.5%
(481) an undergraduate degree, 15% (284) a master’s degree, and 4.7% (89) a doctorate. Approximately
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26.8% (506) of the sample had received some college or university tuition although they did not hold any
certificates; lastly, 13.6% (257) had left school at the age of 18 or younger.
Twelve attributes are known for each respondent: personality measurements which include N, E, O, A,
and C scores from NEO-FFI-R, Impulsivity (Imp) from the BIS-11, Sensation Seeking (SS) from the ImpSS,
level of education (Edu.), age, gender, country of residence, and ethnicity. The data set contains information
on the consumption of 18 central nervous system psychoactive drugs including alcohol, amphetamines, amyl
nitrite, benzodiazepines, cannabis, chocolate, cocaine, caffeine, crack, ecstasy, heroin, ketamine, legal highs,
LSD, methadone, magic mushrooms (MMushrooms), nicotine, and Volatile Substance Abuse (VSA) i.e. glues,
gases, and aerosols. One fictitious drug (Semeron) was introduced to identify overclaimers. For each drug,
participants selected either: they never used this drug, used it over a decade ago, or in the last decade, year,
month, week, or day.
Participants were asked about various substances, which were classified as either central nervous system
depressants, stimulants, or hallucinogens. The depressant drugs comprised alcohol, amyl nitrite, benzodi-
azepines, tranquilizers, solvents and inhalants, and opiates such as heroin and methadone/prescribed opiates.
The stimulants consisted of amphetamines, nicotine, cocaine powder, crack cocaine, caffeine, and choco-
late. Although chocolate contains caffeine, data for chocolate was measured separately, given that it may
induce parallel psychopharmacological and behavioural effects in individuals congruent to other addictive
substances [98]. The hallucinogens included cannabis, ecstasy, ketamine, LSD, and magic mushrooms. Legal
highs such as mephedrone, salvia, and various legal smoking mixtures were also measured.
The objective of the study was to assess the potential effect of the FFM personality traits, Imp, SS, and
demographic data on drug consumption for different drugs, groups of drugs and for different definitions of drug
users. The study had two purposes: (i) to identify the association of personality profiles (i.e. FFM+Imp+SS)
with drug consumption and (ii) to predict the risk of drug consumption for each individual according to their
personality profile.
Participants were asked to indicate which ethnic category was broadly representative of their cultural
background. An overwhelming majority (91.2%; 1720) reported being White, (1.8%; 33) stated they were
Black, and (1.4%; 26) Asian. The remainder of the sample (5.6%; 106) described themselves as ‘Other’ or
‘Mixed’ categories. This small number of persons belonging to specific non-white ethnicities precluded any
analyses involving racial categories.
In order to assess the personality traits of the sample, the Revised NEO Five-Factor Inventory (NEO-FFI-R)
questionnaire was employed [11]. The NEO-FFI-R is a highly reliable measure of basic personality domains;
internal consistencies are 0.84 (N); 0.78 (E); 0.78 (O); 0.77 (A), and 0.75 (C) [89]. The scale is a 60-item
inventory comprised of five personality domains or factors. The NEO-FFI-R is a shortened version of the
Revised NEO-Personality Inventory (NEO-PI-R) [11]. The five factors are: N, E, O, A, and C with 12 items
per domain.
All of these domains are hierarchically defined by specific facets [90]. Egan et al. [17] observed that
the score for the O and E domains of the NEO-FFI instrument are less reliable than for N, A, and C. The
personality traits are not independent. They are correlated, with higher N being associated with lower E, lower
A and lower C, and higher E being associated with higher C (see Table 1.3 for more details).
In our study, participants were asked to read the 60 NEO-FFI-R statements and indicate on a five-point
Likert–type scale how much a given item applied to them (i.e. 0 = ‘Strongly Disagree’, 1 = ‘Disagree’, 2 =
‘Neutral’, 3 = ‘Agree’, to 4 = ‘Strongly Agree’).
The second measure used was the Barratt Impulsiveness Scale (BIS-11) [84]. BIS-11 is a 30-item self-report
questionnaire, which measures the behavioural construct of impulsiveness, and comprises three subscales:
motor impulsiveness, attentional impulsiveness, and non-planning. The ‘motor’ aspect reflects acting without
thinking, the ‘attentional’ component, poor concentration and thought intrusions, and the ‘non-planning’, a
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Table 1.3 Pearson’s correlation coefficients (PCC) between NEO-FFI trait scores for a large British sample, n = 1025 [17]; the
p-value is the probability of observing by chance the same or greater correlation coefficient if the data are uncorrelated
N E O A C
N −0.40** 0.07* −0.22** −0.36**
E −0.40** 0.16** 0.22** 0.30**
O 0.07* 0.16** 0.08* −0.15**
A −0.22** 0.22** 0.08* 0.13**
C −0.36** 0.30* −0.15** 0.13**
∗p < 0.02, **p < 0.001
lack of consideration for consequences [91]. The scale’s items are scored on a four-point Likert-type scale.
This study modified the response range to make it compatible with previous related studies [92]. A score of
five usually connotes the most impulsive response although some items are reverse-scored to prevent response
bias. Items are aggregated, and the higher the BIS-11 scores are, the higher the impulsivity level [93] is.
BIS-11 is regarded a reliable psychometric instrument with good test-retest reliability (Spearman’s rho is
equal to 0.83) and internal consistency (Cronbach’s alpha is equal to 0.83 [84, 91]).
The third measurement tool employed was the Impulsiveness Sensation-Seeking (ImpSS). Although the
ImpSS combines the traits of impulsivity and sensation-seeking, it is regarded as a measure of a general
sensation-seeking trait [85]. The scale consists of 19 statements in true-false format, comprising eight items
measuring impulsivity (Imp), and 11 items gauging Sensation-Seeking (SS). The ImpSS is considered a valid
and reliable measure of high risk behavioural correlates such as substance misuse [94].
It was recognised at the outset of this study that drug use research regularly (and spuriously) dichotomises
individuals as users or non-users, without due regard to their frequency or duration/desistance of drug use [95].
In this study, finer distinctions concerning the measurement of drug use have been deployed, due to the
potential for the existence of qualitative differences amongst individuals with varying usage levels. In relation
to each drug, respondents were asked to indicate if they never used this drug, used it over a decade ago, or in
the last decade, year, month, week, or day. This format captured the breadth of a drug-using career, and the
specific recency of use.
For decade based separation, we merged two isolated categories (‘Never used’ and ‘Used over a decade
ago’) into the class of non-users, and all other categories were merged to form the class of users. For year-
based classification we additionally merged the category ‘Used over a decade ago’ into the group of non-users
and placed four other categories (‘Used in last year-month-week-day’) into the group of users. We continued
separating into users and non-users depending on the timescale in this nested “Russian doll” style. We also
considered ‘month-based’ and ‘week-based’ user/non-user separations. Different categories of drug users are
depicted in Fig 1.2.
Analysis of the classes of drug users shows that part of the classes are nested: participants which belong
to the category ‘Used in last day’ also belong to the categories ‘Used in last week’, ‘Used in last month’,
‘Used in last year’ and ‘Used in last decade’. There are two special categories: ‘Never used’ and ‘Used over a
decade ago’ (see Fig 1.2). The data does not contain a definition of the users and non-users groups. Formally
only a participant in the class ‘Never used’ can be called a non-user, but a participant who used a drug more
than decade ago also cannot be considered a drug user for most applications. There are several possible ways
to discriminate participants into groups of users and non-users for binary classification:
1. Two isolated categories (‘Never used’ and ‘Used over a decade ago’) are placed into the class of non-users
with a green background in Fig 1.2, and all other categories into the class ‘users’ as the simplest version of
binary classification. This classification problem is called ‘decade-based’ user/non-user separation.
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Fig. 1.2 Categories of drug users. Categories with green background always correspond to drug non-users. Four different
definitions of drug users are presented.
2. The categories ‘Used in last decade’, ‘Used over a decade ago’ and ‘Never used’ are merged to form a
group of non-users and all other categories are placed into the group of users. This classification problem
is called ‘year-based’.
3. The categories ‘Used in last year’, ‘Used in last decade’, ‘Used over a decade ago’ and ‘Never used’ are
combined to form a group of non-users and all three other categories are placed into the group of users.
This classification problem is called ‘month-based’.
4. The categories ‘Used in last week’ and ‘Used in last month’ are merged to form a group of users and all
other categories are placed into the group of non-users. This classification problem is called ‘week-based’.
We began our analysis from the decade-based user/non-user separation because it is a relatively well-
balanced classification problem; that is, there are sufficiently many users in the united group ‘Used in last
decade-year-month-week’ for all drugs in the database. If the problem is not directly specified then it is the
decade-based classification problem. We also performed analysis for the year-, month-, and week-based
user/non-user separation. It is useful to group drugs with highly correlated usage for this purpose (see
Section 3.9).
The proportion of drug users among all participants is different for different drugs and for different
classification problems. The data set comprises 1,885 individuals without any missing data. Table 1.4 shows
the percentage of drug users for each drug and for each problem in the database. It is necessary to mention
that the sample is intentionally biased to a higher proportion of drug users. This means that for the general
population the proportion of illegal drug users is expected to be significantly lower [96]. A common problem
of online surveys is the unintentional biasing of samples [97]. We return to this problem in Chapter 3.
1.6 First results in brief
The first result is the production of the database, cleaned and published in open access [78, 79], and described
in this book. We are sure that our book does not exhaust all the important information which can be extracted
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Table 1.4 The number and fraction of drug users
Drug User definition based on
Decade Year Month Week
Alcohol 1817; 96.39% 1749; 92.79% 1551; 82.28% 1264; 67.06%
Amphetamines 679; 36.02% 436; 23.13% 238; 12.63% 163; 8.65%
Amyl nitrite 370; 19.63% 133; 7.06% 41; 2.18% 17; 0.90%
Benzodiazepines 769; 40.80% 535; 28.38% 299; 15.86% 179; 9.50%
Cannabis 1265; 67.11% 999; 53.00% 788; 41.80% 648; 34.38%
Chocolate 1850; 98.14% 1840; 97.61% 1786; 94.75% 1490; 79.05%
Cocaine 687; 36.45% 417; 22.12% 159; 8.44% 60; 3.18%
Caffeine 1848; 98.04% 1824; 96.76% 1764; 93.58% 1658; 87.96%
Crack 191; 10.13% 79; 4.19% 20; 1.06% 11; 0.58%
Ecstasy 751; 39.84% 517; 27.43% 240; 12.73% 84; 4.46%
Heroin 212; 11.25% 118; 6.26% 53; 2.81% 29; 1.54%
Ketamine 350; 18.57% 208; 11.03% 79; 4.19% 37; 1.96%
Legal highs 762; 40.42% 564; 29.92% 241; 12.79% 131; 6.95%
LSD 557; 29.55% 380; 20.16% 166; 8.81% 69; 3.66%
Methadone 417; 22.12% 320; 16.98% 171; 9.07% 121; 6.42%
MMushrooms 694; 36.82% 434; 23.02% 159; 8.44% 44; 2.33%
Nicotine 1264; 67.06% 1060; 56.23% 875; 46.42% 767; 40.69%
VSA 230; 12.20% 95; 5.04% 34; 1.80% 21; 1.11%
from this database, and will be happy if the database is used further in a variety of research and educational
projects.
The second result is the personality profiles calculated for users and non-users of 18 substances (and for
four definitions of users based on the recency of use). These profiles can be used in many research projects;
for example, for more detailed analysis of relations between the use of different drugs. The profiles, with 95%
confidence intervals and p-values for differences between users and non-users (probabilities to observe such
or greater difference by chance), are presented in the Appendix (Tables A.1, A.2).
In addition, the profile of users of all illicit drugs is calculated and presented in these tables. We have
conventionally called the following substances ‘illicit’: amphetamines, amyl nitrite, benzodiazepines, cannabis,
cocaine, caffeine, crack, ecstasy, heroin, ketamine, legal highs, LSD, methadone, magic mushrooms, and
VSA. The term ‘illicit’ is not fully precise because in some regions the recreational use of some of these
substances is decriminalized and in some countries alcohol, for example, is illicit. We use the term ‘illicit
drugs’ for brevity, while the exact definition of this group is just the list above.
Our study reveals that the personality profiles are strongly associated with group membership to the users
or non-users of the 18 drugs. For the analysis, we used the following subdivision of the sample T-score: the
interval 44-49 indicated a moderately low score, (−), the interval 49-51 indicated a neutral score (0), and the
interval 51-56 indicated a moderately high (+) score. We found that the N and O scores of drug users of all
18 drugs were moderately high (+) or neutral (0), except for crack usage for the week-based classification,
for which the O score was moderately low (−). The A and C scores were moderately low (−) or neutral (0)
for all groups of drug users and all user/non-user separations based on recency of use.
For most groups of illicit drug users the A and C scores were moderately low (−) with the exception of
two groups: the A score was neutral (0) in the year-based classification (‘used in last year’) for LSD users
and in the week-based classification (‘used in last week’) for LSD and magic mushrooms users.
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The A and C scores for groups of legal drugs users (i.e. alcohol, chocolate, caffeine, and nicotine)
were neutral (0), apart from nicotine users, whose C score was moderately low (−) for all categories of
user/non-user separation.
The impact of the E score was drug specific. For example, for the week-based user/non-user separation the
E scores were:
• moderately low (−) for amphetamines, amyl nitrite, benzodiazepines, heroin, ketamine, legal highs,
methadone, and crack;
• moderately high (+) for cocaine, ecstasy, LSD, magic mushrooms, and VSA;
• neutral (0) for alcohol, caffeine, chocolate, cannabis, and nicotine.
For more details see Section 3.5.
Usage of some drugs were correlated significantly. The structure of these correlations is analysed in Section
3.6. Two correlation measures were utilised: the Pearson’s Correlation Coefficient (PCC) and the Relative
Information Gain (RIG). We found three groups of drugs with highly correlated use (Section 3.9). The
central element was clearly identified for each group. These centres are: heroin, ecstasy, and benzodiazepines.
This means that drug consumption has a ‘modular structure’, which is made clear in the correlation graph.
The idea of merging correlated attributes into ‘modules’ referred to as correlation pleiades is popular in
biology [100–102].
The concept of correlation pleiades was introduced in biostatistics in 1931 [100]. They were used for
identification of a modular structure in evolutionary physiology [100–103]. According to Berg [102], correla-
tion pleiades are clusters of correlated traits. In our approach, we distinguished the core and the peripheral
elements of correlation pleiades and allowed different pleiades to have small intersections in their periphery.
‘Soft’ clustering algorithms relax the restriction that each data object is assigned to only one cluster (like
probabilistic [104] or fuzzy [105] clustering). See the book of R. Xu & D. Wunsch [106] for a modern review
of hard and soft clustering. We refer to [107] for a discussion of clustering in graphs with intersections.
The three groups of correlated drugs centered around heroin, ecstasy, and benzodiazepines were defined
for the decade-, year-, month-, and week-based classifications:
• The heroin pleiad includes crack, cocaine, methadone, and heroin;
• The ecstasy pleiad consists of amphetamines, cannabis, cocaine, ketamine, LSD, magic mushrooms, legal
highs, and ecstasy;
• The benzodiazepines pleiad contains methadone, amphetamines, cocaine, and benzodiazepines.
The topology of the correlation graph can help in analysis of mini-sequences of drug involvement. These
mini-sequences can be found in longitudinal studies [108]: cigarettes are a gateway to cannabis, and then to
hard drugs; and there is a synergistic effect of increasing involvement. Of course, correlation does not imply a
causal relationship, but use of the substances from one mini-sequence of involvement should be correlated.
Therefore, the correlation graph is a proper map for the study of the involvement routes, and synergistic and
reciprocal effects.
Analysis of the intersections between correlation pleiades of drugs leads to important questions and
hypotheses:
• Why is cocaine a peripheral member of all pleiades?
• Why does methadone belong to the periphery of both the heroin and benzodiazepines pleiades?
• Do these intersections reflect the structure of individual drug consumption and sequences of involvement,
or are they related to the structure of the groups of drug consumers?
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In this study, we evaluated the individual drug consumption risk separately, for each drug and pleiad of
drugs. We also analysed interrelations between the individual drug consumption risks for different drugs. We
applied several data mining approaches: decision tree, random forest, k-nearest neighbours, linear discriminant
analysis, Gaussian mixture, probability density function estimation, logistic regression and naı¨ve Bayes.
The quality of classification was surprisingly high (Section 3.8). We tested all of the classifiers by Leave-
One-Out Cross Validation. The best results, with sensitivity and specificity greater than 75%, were achieved
for cannabis, crack, ecstasy, legal highs, LSD, and VSA. Sensitivity and specificity greater than 70% were
achieved for the following drugs: amphetamines, amyl nitrite, benzodiazepines, chocolate, caffeine, heroin,
ketamine, methadone and nicotine. An exhaustive search was performed to select the most effective subset of
input features and data mining methods for each drug. The results of this analysis provide an answer to an
important question about the predictability of drug consumption risk on the basis of FFM+Imp+SS profile
and demographic data.
Users for each correlation pleiad of drugs are defined as users of any of the drugs from the pleiad. We solved
the classification problem for drug pleiades for the decade-, year-, month-, and week-based user/non-user
separations. The quality of classification is also high.
Simple Fisher’s linear discriminant classifiers have slightly worse performance than more advanced ma-
chine learning methods but are very robust, and give additional information. Coefficients of the discriminants
are presented in the Appendix for all user/non-user separation problems for every substance, group of illicit
substances, and three correlation pleiades. Stability of the discriminant models was tested in cross-validation.
Even a brief look at the linear discriminants reveals differences between drugs. For example, for month-based
user definition (‘used in last month’), the linear discriminants for heroin and cocaine users for seven variables
FFM+Imp+SS are (Table A.15):
heroin users −30.020+0.302N−0.409E+0.232O−0.499A−0.107C+0.345Imp+0.555SS > 0;
cocaine users −57.737+0.366N+0.148E+0.082O−0.370A−0.014C−0.001Imp+0.837SS > 0,
where the variables are represented by their T-scores (calculated for the database). These data, together with
the correlation tables (Tables A.3, A.4), give information about the importance of different variables for
user/non-user separation for different drugs.
We also studied the problem of separation of users of different drugs. For this purpose, we selected three
drugs: heroin, ecstasy, and benzodiazepines (the centres of the pleiades). The profiles of the users of these
drugs are different (see Fig. 3.21) (the confidence level below is 95%):
• The mean values in the groups of benzodiazepines and ecstasy users are statistically significantly different
for N (higher for benzodiazepines) and E (higher for ecstasy) for all definitions of users, for O (higher
for ecstasy) for all definitions of users excluding the year-based, and for SS (higher for ecstasy) for all
definitions excluding the month-based.
• The groups of benzodiazepines and heroin users are statistically significantly different for A (higher for
benzodiazepines) for all definitions of users, for Imp (higher for heroin) and SS (higher for heroin) for all
definitions of users excluding the week-based.
• Heroin and ecstasy are statistically significantly different for N (higher for heroin), E (higher for ecstasy)
and A (higher for ecstasy) for all definitions of users and for Imp (higher for heroin) for all definitions
excluding the week-based.
The creation of classifiers has provided the ability to evaluate the risk of drug consumption in relation
to individuals. The risk map is a useful tool for data visualisation and for the generation of hypotheses for
further study (see Chapter ‘Risk evaluation for the decade-based user/non-user separation’).
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In the next chapter, we briefly introduce the main methods used in the book, in Chapter 3 the results are
described in more detail, then after a brief Discussion and Summary, the main tables are presented in the
Appendix.
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Chapter 2
Methods of Data Analysis
This chapter presents a brief outline of the data analysic methods used in our work. We have tried to present
a comprehensive summary but the details of the algorithms, as well as many computational and statistical
estimates, remain beyond the current scope of this work. What lies herein cannot replace textbooks [1, 2], and
detailed handbooks like [3].
2.1 Preprocessing
Data should be preprocessed before application of any analytic techniques in order to solve any classification,
regression or other standard data analytic problem. Preprocessing is an important and time consuming step. It
includes dataset inspection (analysis of types of data, completeness, consistency, accuracy, believability, and
other crucial properties of a dataset), feature extraction from raw data, cleaning (managing of missed values,
noise and inconsistencies), feature selection and transformation (selection of necessary features, without loss
and redundancies, transformation to the most convenient scale and form), and dimensionality reduction. The
steps of feature selection and dimensionality reduction depend on the problem we aim to solve.
In our book we deal with data of the following types: numeric (quantitative) and categorical (with a finite
numbers of values). The categorical data belong to three subtypes: categorical ordinal (education level, for
example), categorical nominal (nation and race), and Boolean (for example, user/non-user of a drug).
2.1.1 Descriptive statistics: mean, variance, covariance, correlation, information gain
Given a sample of size N, consider N observations xi of a quantity X . The sample mean is defined to be
x¯ =
1
N
N
∑
i=1
xi.
The sample variance for the same sample is
23
24 2 Methods of Data Analysis
s2x =
1
N
N
∑
i=1
(xi− x¯)2.
For a vector variable the definitions of the sample mean and the sample variance are the same (the square of
the vector means the square of its Euclidean length).
If a sample point has two numerical attributes, xi and yi (i = 1, . . . ,N), then the sample covariance, sxy, and
Pearson Correlation Coefficient (PCC), rxy, are defined:
sxy =
1
N
N
∑
i=1
(xi− x¯)(yi− y¯); rxy = sxysxsy . (2.1)
The PCC measures how much of a linear connection between x and y exists. The linear approximation of y by
a linear function of x, which minimises the mean square error (simple linear regression), is
yˆ = y¯+
sy
sx
rxy(x− x¯). (2.2)
For several attributes, the sample covariance matrix S, with the diagonal sii = s2i , and the sample PCC matrix
with unit diagonal are used.
High correlations between the inputs and outputs are beneficial and allow researchers to create a good
predictive model. But the situation is different when the inputs for a regression or classification model are
highly correlated. This multicollinearity can cause some problems. Just as a trivial example we can take two
inputs, x and y, x≈ y (r ≈ 1). If the the coefficients of x and y in a regression model are a and b respectively,
then a+M and b−M are also approximate solutions for the regression problem, for possibly large values
of M. Thus, depending on the particular solution method, we might get large and oscillating solutions to
the regression problem. In this case we need to apply some procedure to constrain the sorts of solutions we
wish to allow. Such processes are often called regularisation processes. In the multidimensional case, tests
of multicollinearity are based on the analysis of efficient and stable invertibility of the correlation matrix.
Therefore, multidimensional multicollinearity is measured not by the values of PCCs but by the condition
number of the PCC matrix between input attributes, that is the ratio κ = λmax/λmin, where λmax and λmin
are the maximal and the minimal eigenvalues of this matrix [4]. (We recall that the correlation matrix is
symmetric and non-negative and its eigenvalues are real and non-negative numbers.) Collinearity with κ < 10
is considered as ‘modest’ collinearity; most methods work in this situation and only a few methods were
reported as having failed (like support vector machine, which we do not use) [5]. For higher κ , dimensionality
reduction seems to be unavoidable (the classical principal component analysis is the first choice, see below in
this chapter).
Relative Information Gain (RIG) is widely used in data mining to measure the dependence between
categorical attributes [6]. The greater the value of RIG is, the stronger the indicated correlation is. RIG is zero
for independent attributes, is not symmetric, and is a measure of mutual information. To construct RIG, we
start from the Shannon entropy. Consider a categorical attribute X with m values v1, . . . ,vm. Given sample
size N assume that the value X = vi appears in the sample ni times. The normalised frequency is fi = ni/N.
The sample Shannon entropy is
H(X) =−
m
∑
i=1
fi log2 fi.
In this formula it is assumed that 0 log0= 0 (by continuity). If any data point includes values of two categorical
attributes, X and Y , then for each value X = vi we calculate the conditional entropy H(Y |X = vi). For this
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purpose, we select a subsample, where X = vi, and calculate the entropy of Y in this subsample (if it is not
empty). The sample conditional entropy H(Y |X) is
H(Y |X) =
m
∑
i=1
fiH(Y |X = vi).
Information gain IG(Y |X) = H(Y )−H(Y |X) measures how much information about Y will be gained
from knowledge of X (on average, under given normalised frequencies of values X and Y ). Finally, the relative
information gain is RIG(Y |X) = IG(Y |X)/H(Y ). This measures the fraction of information about Y which
can be extracted from X (on average). It may be convenient to represent the formula for RIG more directly.
Consider two categorical attributes, X with values v1, . . . ,vm, and Y with values w1, . . . ,wk. Let the sample
have ni j cases with X = vi and Y = w j. The total number of cases is N = ∑i, j ni j. The normalised frequencies
are fi = ∑ j ni j/N, g j = ∑i ni j/N. The sample RIG is
RIG(Y |X) = ∑ j g j log2 g j−∑i
(
fi∑ j ni j log2 ni j
)
∑ j g j log2 g j
. (2.3)
Systematic comparison of the linear correlations provided by PCC, and the non-linear mutual information
approach discussed above was performed on genomic data [7].
2.1.2 Input feature normalization
Data centralization and normalization are convenient and, for some of the analysis methods, unavoidable.
The most popular normalization and centralization is given by the z-score. By definition, the z-score of an
observable attribute X is z = (x− µ)/σ , where µ it the expectation, and σ is the standard deviation of X .
However, the expectation and standard are calculated from a sample x, giving estimates x¯ ≈ µ and s ≈ σ .
Then we have
z =
x− x¯
s
.
The notion of T -score has two meanings, one in general statistics, the other in psychometrics. In our book
we use the psychometric definition:
T -score = 10z+50 = 10
x−µ
σ
+50, (2.4)
with an additional condition: T -score = 0 if the right hand side of (2.4) is negative, and T -score = 100, if
the right hand side of (2.4) exceeds 100. T -score returns results between 0 to 100 (most scores fall between
20 and 80 without any additional condition). The T -score of the expectation µ is 50, and the interval µ±σ
transforms into [40,60].
We meet problems in defining the population mean (the norm) µ and the standard deviation σ , which are
discussed in Chapter 3. For instance, what is ”normal” can depend on age, social group and other factors. Thus
the sense of an average becomes less clear. Additionally (see Table 3.12), the sample in our study deviates
from the population norm in the same direction as drug users deviate from the sample mean. However, the
deviations of the mean of users groups are different for different drugs. Therefore, the definition of T -score
we use in what follows is based on sample mean and standard deviation:
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T -scoresample = 10
x− x¯
s
+50. (2.5)
Usually, the T -score is categorized into five categories to summarise an individual’s personality score
concerning each factor: the interval 20-35 indicates very low scores; 35-45 low scores; 45-55 average scores;
55-65 high scores, and 65-80 indicates very high scores.
We study average T -scoresample for groups of users and non-users. The standard deviation of these mean
values decreases with the number m of cases in a group as 1/
√
m (due to the central limit theorem). To discuss
these mean profiles, we use a refined subdivision of the T -scoresample: the interval 44-49 indicates moderately
low (−) scores; 49-51 neutral (0) scores, and 51-56 indicates moderately high (+) scores.
The unification of the mean and standard deviation of the T-scoresample for all factors simplifies com-
parisons of users and non-users groups for each drug. A t-test is employed to estimate the significance of
the differences between the mean T-scoresample for groups of users and non-users for each FFM (NEO-FFI-
R)+Imp+SS factor and each drug (Tables A.1, A.2). In this t-test, a p-value is the probability of observing, by
chance, the same or a greater difference of mean. The analysis was performed using SAS 9.4.
2.2 Input feature transformation
2.2.1 Principal Component Analysis – PCA
Karl Pearson [8] invented PCA as a method for approximation of data sets by straight lines and lower-
dimensional planes (Fig. 2.1). The Unexplained Variance (UV) is the quadratic error of PCA, that is the
sum of the squared distances from the data points to the approximating low-dimensional plane or line. The
Explained Variance is the variance of the orthogonal projections of the data on the approximating line or plane.
The Fraction of Variance Unexplained (FVU) is the ratio of the unexplained sample variance to the total
sample variance. The Fraction of Variance Explained, otherwise known as the Coefficient of Determination
R2 is 1−FVU.
PCA is equivalent to spectral decomposition of the sample covariance matrix (or to the singular value
decomposition (SVD) of the data matrix). The eigenvalues λi of the sample covariance matrix are real and
non-negative. Let us order them by size in descending order: λ1 ≥ λ2 ≥ . . .≥ λn, (n is the dimension of the
data space) and choose a corresponding orthonormal basis of eigenvectors: w1,w2, . . . ,wn. These eigenvectors
are called the Principal Components (PC for short), and the best approximation of data by a k-dimensional
plane is given by the first k PCs via the formula
x− x¯≈
k
∑
i=1
wi(wi,x− x¯), (2.6)
where (wi,x) is the inner product. For this approximation, FVU= ∑ j>k λ j. Usually, PCA is applied after nor-
malization and centralization to z-scores. The sample covariance matrix for z− scores is the PCC (correlation)
matrix.
For applications, there exists a crucial question without a definite theoretical answer: how do we decide k?
That is, how many PCs should be used in our approximation? There are several popular heuristic rules for
component retention [20]. The most celebrated of them is Kaiser’s rule: retain PCs with λi above the average
value of λ [21, 22]. The trace of a matrix A is the sum of its diagonal elements, and we denote this by trA.
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We note that the average λ is 1n trQ =
1
n ∑i s
2
i , where Q is the sample covariance matrix, and s
2
i is the sample
variance of the ith attribute. For the PCC matrix, the average λ is 1 because rii = 1, and Kaiser’s rule is: retain
PCs with λ > 1.
Fig. 2.1 Pearson’s illustration of PCA definition. Pi are data points, pi are their distances to the approximating line. The best
approximation problem is UV= ∑i p2i → min
Various approaches to PCA were discussed in [9, 10]. There are several directions for generalisation
of PCA: nonlinear PCA [10–12], branching PCA [13, 14], nonlinear PCA with categorical variables [15].
Different norms for approximation errors have been employed instead of quadratic FVU [16–19].
2.2.2 Quantification of categorical input variables
It is convenient to code categorical variables by using real numbers. Such a coding allows us to use methods
developed for continuous data, to calculate PCCs, etc. There exists a universal method for quantification of
categorical variables by multidimensional vectors, the so-called ‘dummy coding’ . For a Boolean variable,
(with values ‘true’ or ‘false’) the real number 1 for true, and 0 for false, is returned. A categoric variable V
with values v1, . . . ,vm can be represented in dummy coding by a battery of m indicator Boolean variables
(B1, . . . ,Bm), where Bi = 1 if and only if X = vi. This is an m-dimensional vector with components 0 or
1, which are far from being independent (if one of them is 1 then all others are 0). Further dimensionality
reduction is desirable, by either linear or non-linear means. Such coding is systematically used in ANOVA
and ANCOVA models [2, 32].
In some cases, it is possible to quantify a categorical variable by using one numeric variable. Firstly, it
might be that ordinal features are ‘almost numeric’, and often have conventional numeric values assigned.
Secondly, if the set of numerical variables is sufficiently rich then it is possible to represent categories (even
nominal ones) via their average projections in the space of numerical variables (see Section 2.2.2.2 below).
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2.2.2.1 Ordinal feature quantification
Values of many categorical attributes are ordered linearly, by their nature: severity of a disease, quality
of a product, level of education, etc. For these attributes, we can assume that their values are obtained by
binning of a ‘latent’ numeric variable with a nice probability distribution. Usually, for this role of hypothetical
latent variable, the standard normal distribution is selected with zero mean and unit variance. Other ‘nice’
distributions might be selected for quantification, for example, the uniform distribution on [0,1]. The normal
distribution has density f and cumulative distribution function CDF) φ :
f (x) =
1√
2pi
e−
x2
2 ; φ(x) =
∫ x
−∞
f (x)dx.
Let V be a categoric ordinal variable with linearly ordered values v1 < v2 . . . < vm. Assume that there are
ni cases of category vi in the sample, and the corresponding frequency is pi = ni/N (i = 1, . . . ,m). To quantify
V , it is necessary to assign an interval [ti−1, ti] to each category vi (−∞= t0 < t1 < .. . < tm = ∞). A threshold
ti separates vi from vi+1 (i = 1, . . . ,m−1). A simple calculation gives (see Fig. 2.2)
ti = φ−1
(
i
∑
j=1
p j
)
, (2.7)
where φ−1 is the inverse function of φ .
Fig. 2.2 Quantification of an ordinal feature. Three thresholds, t1, t2, and t3 are found for three categories with normalised
frequencies p1, p2, and p3
After the thresholds ti are found, the numerical value should be selected for each category vi from the
interval [ti−1, ti]. A popular simple estimate is given by the value xi with average probability:
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xi = φ−1
(
i−1
∑
j=1
p j +
pi
2
)
. (2.8)
This value is the numeric substitution for the ordinal categoric value vi. This simple quantification method
allows a number of improvements, for instance, the values xi can be selected by the implicit maximum
likelihood method. The univariate determination of thresholds (2.7) can be generalised to the multivariate
selection of the thresholds under the assumption that the multidimensional latent variables are normally
distributed. These methods are part of a set of widely used techniques for dealing with latent continuous
variables, traditionally called ‘polychoric correlation’ [25, 26].
The matrix of polychoric coefficients can be used further to calculate PCs, etc. The technique of polychoric
correlation is based on the assumption that values of ordinal features result from the discretization of
continuous random values with fixed thresholds. A clear description of polychoric correlation coefficients,
including methods for their estimation is given in [27, 28]. The drawback with the multivariate selection of the
thresholds is in its dependence on pairs of correlated ordinal variables. If we have to analyse several dozens
of such variables then a univariate choice similar to (2.7) may be preferable. A critical inquiry into polychoric
and canonical correlation was published in [29]. In our work, we have used the univariate choice of thresholds
(2.7) and simple average probability values (2.7) for quantification of ordinal variables. Following this, we
have applied classical methods, and also machine learning algorithms, for data analysis.
We should ask the question: are FFM, Imp, and SS scores numerical or ordinal variables? Traditionally,
these scores are thought of as numerical but it is clear that this should be the case, especially if they were
obtained by short questionnaires and take a small number of values. We have taken an intermediate approach:
in the analysis of average personality profiles in groups of drug users and non-users, we have handled the
scores traditionally, as numeric variables, have evaluated p-values using the standard tests, calculated the
PCCs with estimation of their p-values and presented the results in Tables A.1, A.2, A.3, A.4. For application
of machine learning algorithms, we used the aforementioned procedure of quantification of ordinal features in
data preprocessing, including scores, and also of the nominal features using dummy coding or CatPCA from
Subsection 2.2.2.2. The raw database is published online in [30] and the database with quantified categorical
variables is published online in [31].
2.2.2.2 Nominal feature quantification
We cannot use the techniques described above to quantify nominal features such as gender, country of location,
and ethnicity, because the categories of these features are unordered. To quantify nominal features we have
used two methods and compare the results: universal dummy coding which tremendously increases dimension
of data, and nonlinear Categorical Principal Component Analysis (CatPCA) [15].
CatPCA can be applied if there exists a rich family of numerical inputs. This method combines classical
PCA with the idea of representation of the categories of a nominal feature by the centroids of examples
from these categories in the space of numerical features. CatPCA assumes that the latent variable behind the
nominal feature is correlated with the numerical input variables.
This procedure includes four steps (Algorithm 1).
The process of nominal feature quantification for the feature ‘country’ is depicted in Fig 2.3. In this figure,
the points corresponding to the UK category are located very far from all other points.
As an alternative variant of nominal feature quantification we have used dummy coding of nominal
variables: ‘country’ is transformed into seven binary features with values 1 (if ‘true’) or 0 (if ‘false’): UK,
Canada, USA, Other (country), Australia, Republic of Ireland and New Zealand; Ethnicity is transformed
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Algorithm 1 Nominal feature quantification
1: Exclude nominal features from the set of input features and calculate the PCs in the space of the numeric input features
which have been retained. To select informative PCs we use Kaiser’s rule [21, 22].
2: Calculate the projection Ci of the centroid of data points from each category vi on the selected PCs.
3: Consider these projections of centroids as a new dataset. Calculate the first PC of them, w.
4: The numerical value for each category is the projection of its centroid on this component: vi takes the numerical value of the
inner product (w,Ci).
Fig. 2.3 Quantification of the nominal feature ‘Country’. Centroids of groups from different countries projected on the plane of
the first two PCs of numerical input data. The line corresponds to the first PC of the set of centroids. It is worth mentioning that
this line is originally situated in the 9-dimensional space of the selected PCs of the numeric variables. In that 9-dimensional
space, the projections of the centroids on this line are orthogonal but this orthogonality may be lost in the two-dimensional
projection.
into seven binary features: Mixed-White/Asian, White, Other (ethnicity), Mixed-White/Black, Asian, Black
and Mixed-Black/Asian.
2.2.3 Input feature ranking
In this study, we have used three different techniques for input feature ranking. The first technique was
principal variables [33]. The idea is very simple. For each attribute xi calculate the linear regression line (2.2)
for predicting all other attributes. Evaluate UV, that is the sum of square errors of these predictions (for all
data points and all attributes). Select the attribute which gives the smallest FVU. This is the first principal
variable. Subtract the values predicted using the first principal variable from the data table. The new dataset
has one feature less (the values of the first principal variable become zero). Iterate the above approach. We can
calculate the fraction of variance explained by kth principal variable, and the cumulative fraction of variance
explained by the first k principal variables.
The second technique used was double Kaiser’s selection. Calculate PCs and select informative PCs, w j,
by Kaiser’s rule [21, 22]. Next apply the same idea to attribute selection. PCs are normalized vectors so that
the average of the square of their coordinates is 1/n. For each attribute find the maximal absolute value of
the corresponding coordinates in the informative PCs: γi = max j |w ji|. The ith attribute is called trivial if
γi ≤ 1/√n. If there are trivial attributes then the most trivial attribute is the attribute with minimal γi. We
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removed the most trivial attribute and repeated the procedure. This procedure stops if there are no trivial
attributes. This algorithm ranks attributes from the most trivial to the best.
The third technique utilised was sparse PCA [34]. In this study, we employed the simplest thresholding
sparse PCA. This method returns us a list of trivial (non-important) coordinates and the sparse PCs in the
space of important coordinates. The formal description is given in Algorithm 2.
Algorithm 2 Search of sparse PC
1: Set the number of attributes, n, the sample variance of the dataset, s2, and Kaiser’s threshold for the variance explained by a
component, h = s2/n.
2: Search for the usual first PC with the maximal variance λ explained by this PC. (The iterative algorithm gives the PCs in
descending order of λ .)
3: if λ < h then
4: All the informative PCs have been found. Remove the last PC and go to Step 10.
5: Find the PC coordinate with the minimal absolute value, |wmin|.
6: if |wmin|> 1/
√
n then
7: Go to Step 9. (All the attributes are non-trivial in this PC.)
8: Set the value of the coordinate with minimal size, found at Step 5, to zero. Calculate the first PC in the reduced space of
coordinates. Go to Step 5.
9: Subtract the projection onto the PC from the above PC reduction loop from the data (the dataset is redefined), and go to Step
2.
10: Search the attributes, which have zero coefficients in each of the PCs found by the previous selection process. These
attributes are trivial.
11: if there are trivial attributes then
12: Remove trivial attributes from the set of attributes and go to Step 1. (n and s2 should be redefined.)
13: else
14: Stop
2.3 Classification and risk evaluation
The main classification problem studied in this book is user/non-user classification for various substances
and recency of use. The inputs include age, gender, education, N, E, O, A, C, Imp., and SS quantified, by the
methods described in Sec. 2.2.2.
Several families of classification methods are applied to the solution of this problem. Most of the methods
are supplemented by risk evaluation tools.
2.3.1 Single attribute predictors
Solutions of a classification problem on the basis of one attribute are very attractive. It is nice to have one
measurement and a red threshold line: one class is situated below this line, another class is above. Of course,
such a simple rule is rarely reliable. Nevertheless, it is always a good idea to start from one-attribute classifiers
and to evaluate their capabilities. It will give use a good ‘bottom line’ for evaluation of more sophisticated
classifiers.
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Creation of one-attribute classifiers is very simple: create histograms of this attribute for both classes.
Traditionally, one class is called positive (users) and another is negative (non-users). For each threshold
(positive to one side, negative to another) several numbers can be evaluated easily: number of True Positive
(TP), True Negative (TN), False Positive (FP), and False Negative (FN) samples. Two important numbers help
us to evaluate the quality of a classifier: Sensitivity (or the true positive rate) Sn=TP/(TP+FN) and Specificity
(or the true negative rate) Sp=TN/(TN+FP). Sn is the fraction of correctly recognised samples of the positive
class and Sp is the fraction of correctly recognised samples of the negative class.
When we move threshold, Sn and Sp change in opposite directions. To represent the possible balance
between Sn and Sp, the Receiver Operating Characteristic (ROC) curve is used (Fig. 2.4), with the False
Positive Rate (1-Sp) on the abscissa, and the True Positive Rate (Sn) on the ordinate. The diagonal line
indicates what the balance is if we are classifying at random. Above the diagonal lines indicates a good
classifier, and below the line a bad classifier. Suppose we randomly select one positive case and one negative
case, that classification has positive cases above the threshold, and that the classification scores for these
cases are xpositive and xnegative respectively. Then, the Area Under the Curve (AUC) estimates the probability
xpositive > xnegative). The area between the ROC curve and the diagonal (shadowed on Fig. 2.4) is proportional
to the so-called Gini coefficient: Gini=2AUC-1. AUC is widely used in classification [35] despite the fact that
it is not a stable measure for small samples. Various alternatives have been proposed [36].
Fig. 2.4 ROC curve: dependence of True Positive Rate (Sn) on False Positive Rate (1-Sp). The AUC is 12 plus the area of the
shadowed region between the ROC curve and the diagonal.
A dimensionless variable z is convenient for representing the difference between two groups S1 and
S2, with the sample means of the attribute in the groups, x¯1, x¯2, and the sample standard deviations, s1,s2
respectively:
z =
|x¯1− x¯2|
s1+ s2
. (2.9)
This score measures how the variability between group means relates to the variability of the observations
within the groups. It is a useful measure of the separation of the two distributions [37]. It is calculated in the
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tables in Chapter 3 for each of seven psychological attributes and for two classes, users and non-users of illicit
drugs. The higher the score is, the better users are separated from non-users by the values of the attribute.
A simple motivation for this measure is that for the normal distributions inside groups the optimally
balanced separation of groups with given z has equal specificity and sensitivity P, where P = φ(z), recalling
that φ is the cumulative distribution function of the standard normal distribution (with µ = 0, σ = 1).
Tables 3.1, 3.3, 3.5, 3.7 demonstrate that P gives realistic estimate of the empirical Sn and Sp for the data
analysed.
The score z, its reciprocal z−1, and their multidimensional generalizations [37], are also widely used in
cluster analysis for the construction of criteria for the validity of clusters [39].
If we are not happy with the performance of one-attribute classifiers then it can be improved using many
approaches. Two of them are:
• Classification by combination of the existing one-attribute classifiers (with weights defined by their
individual performance);
• Combination of attributes to form a new multi-input discriminant function.
It is crucially important to note that when we extend the space of possible classification rules, then we add
new potential for overfitting and overoptimism. Special testing and validation procedures should be employed
to avoid potentially inaccurate and misleading results. (The critical review [40] is still relevant, especially
with respect to the new fashionable multidimensional machine learning methods).
2.3.2 Criterion for selecting the best method
A number of different criteria exist for the selection of the best classifier. If the cost of different misclassifica-
tions is specified then minimisation of the expected cost can be a reasonable criterion for selection. If the
costs of different misclassifications do not vary significantly then this approach leads to the minimisation of
the number of errors. In situations with significant class imbalance this minimization can lead to paradoxical
decisions, for example, to the selection of a trivial rule: everything is the dominating class. The class balance
in the database we use is strongly biased with respect to the general population. Therefore, we decided to
work with relative criteria, which provide balanced classification rules.
The criterion we used was to pick the method such that the minimum between sensitivity and specificity
was maximised: min{Sn,Sp}→max. If min{Sn,Sp} is the same for several classifiers, then we select from
these the classifier which maximises Sn+Sp. Classifiers with Sn or Sp less than 50% were not considered.
There are several approaches to test the quality of a classifier: usage of an isolated test set, n-fold cross
validation and Leave-One-Out Cross Validation (LOOCV) [41]. LOOCV is used for all tests in this study; we
exclude a sample from the classifier preparation, learn the classifier, and then test the result on the excluded
example. Specific problems with the estimation of classifier quality for techniques like decision tree and
random forest were considered in detail by Hastie et al. [3].
2.3.3 Linear Discriminant Analysis (LDA)
The first and the most famous tool of discriminant analysis is Fisher’s linear discriminant [38], where a new
attribute is constructed as a linear functional of the given attributes, with the best classification ability. It is
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possible to calculate the score (2.9) for values of any function. The linear function with the highest score is a
version of the Fisher’s linear discriminant.
We used Fisher’s linear discriminant for the binary version of the problem, to separate users from non-users
of each drug. We calculate the mean of the points in the ith class, x¯i, and empirical covariance matrix of the
ith class, Si, for both classes (i = 1,2). Then we calculate the discriminating direction as
ω = (S1+S2)−1 (x¯1− x¯2) . (2.10)
Each point is projected onto the discriminating direction by calculating the dot product (ω,xi). This projection
gives a new (combined) attribute. The optimal threshold to separate two classes is calculated.
In our study we have prepared linear discriminants for all possible selections of the subset of input
attributes, and selected the best set of inputs for each classification problem.
2.3.4 Logistic Regression (LR)
In the sequel we have implemented the weighted version of logistic regression [42]. This method can be used
for binary problems only, and is based on the following model assumption:
probability of the first class
probability of the second class
= exp(ω,x), (2.11)
where ω is the vector of regression coefficients and x is a data vector.
The maximum log likelihood estimate of the regression coefficients is used. This approach assumes that
the outcomes of different observations are independent and maximises the weighted sum of logarithms of
their probabilities. In order to prevent class imbalance difficulties, the weights of categories are defined. The
most common weight for the ith category is the inverse of the fraction of the ith category cases among all
cases. Logistic regression gives only one result because there is no option to customize the method except
by choice of the set of input features. We performed an exhaustive search for the best set of inputs for each
classification problem.
2.3.5 k Nearest Neighbours (kNN)
The basic concept of kNN is that the class of an object is the class of the majority of its k nearest neighbours
[43]. This algorithm is very sensitive to the definition of distance. There are several commonly used variants of
distance for kNN: Euclidean distance; Minkovsky distance; and distances calculated after some transformation
of the input space. In this study, we have used three distances: the Euclidean distance, the Fisher’s transformed
distance [38], and the adaptive distance [44]. Moreover, we have used a weighted voting procedure with
weighting of neighbours by one of the standard kernel functions [45].
The kNN algorithm is well-known [43]. The adaptive distance transformation algorithm is described
in [44]. kNN with Fisher’s transformed distance is less well-known. The following parameters are used: k is
the number of nearest neighbours, K is the kernel function, and k f ≥ k is the number of neighbours which are
used for the distance transformation. To define the risk of drug consumption we have to perform the steps
described in Algorithm 3.
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Algorithm 3 kNN with Fisher’s transformed distance
1: Find the k f nearest neighbours of the test point x.
2: Calculate the empirical covariance matrix of k f neighbours and Fisher’s discriminant direction.
3: Find the k nearest neighbours of the x using the distance along Fisher’s discriminant direction among the k f neighbours
found earlier.
4: Define the maximal distance d from x to the k neighbours.
5: Calculate the membership for each class C as a sum of the weights for y ∈C. The weight of y is the ratio K(‖x− y‖/d).
6: The drug consumption risk is defined as the ratio of the membership of the assigned class to the sum of memberships of all
classes.
The adaptive distance version implements the same algorithm but uses another transformation in Step 2,
and another distance in Step 3 [44]. The Euclidean distance version simply defines k f = k and omits Steps 2
and 3 of the algorithm. We have tested various versions of the kNN models for each drug, which differ by:
• The number of nearest neighbours, which varies between 1 and 30;
• The set of input features;
• One of the three distances: Euclidean distance, adaptive distance, and Fisher’s distance;
• The kernel function for adaptive distance transformation;
• The kernel functions for voting.
• The weight of class ‘users’ is varied between 0.01 and 5.0.
2.3.6 Decision Tree (DT)
The decision tree is one of the most popular methods of data analysis [46]. It was invented before the computer
era for clarification of complex diagnosis and decision making situations, in the form of a tree of simple
questions and decisions. We aim to solve the classification problem (user/non-user classification). For this
purpose, we consider a decision tree as a tool for combination of various classifiers. Each elementary classifier
can be thought of as a categorical variable X (symptom) with several nominal values v1, . . . ,vk. An elementary
branching divides the dataset (the root) into two subsets (the nodes, see Fig. 2.5). Perfect branching creates
0-1 frequencies, for example n11/N1 = n22/N2 = 1 and n12 = n21 = 0. Such a perfect situation (errorless
diagnosis by one feature) is not to be expected. However, we can find the elementary classifier, which results
in the closest to the perfect classification. Then we can then iterate, i.e., approach each node as a dataset and
try all possible elementary classifiers, etc., until we find a perfect solution, the solution cannot be improved,
or the number of examples in a node becomes too small (which will lead to overfitting).
There are many methods for developing a decision tree [47–53], which differ depending on the method
for selection of the best elementary classifier for branching (Fig. 2.5), and by the stopping criteria. We have
evaluated the best attributes for branching using one of the following ‘gain’ functions: RIG, Gini gain, and
DKM gain. They are defined in a similar way below.
Consider one node (the root, Fig. 2.5) with N cases and the binary classification problem. If the attribute X
has c possible categorical values v1, . . . ,vc then we consider branching into c nodes. We use the following
notation: Ni is the number of cases with X = vi (i = 1, . . . ,c), ni j (i = 1, . . . ,c, j = 1,2) is a number of cases
of class j with X = vi.
For a vector of normalised frequencies f = ( f1, . . . , fk) three concave (‘Base’) functions are defined:
• Entropy( f ) =−∑ki=1 fi log2 fi;
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Fig. 2.5 Elementary branching in a decision tree
• Gini( f ) = 1−∑ki=1 f 2i ;
• DKM( f ) = 2
√
f1 f2 (for k = 2).
The corresponding gain functions for branching are defined as
Gain = Base
(n1
N
,
n2
N
)
−
c
∑
i=1
Ni
N
Base
(
ni1
Ni
,
ni2
Ni
)
,
where Base( f ) is one of the functions Entropy, Gini, or DKM.
All of these Gain functions qualitatively measure the same thing: how far are distributions of nodes from
the initial distribution of the root, and how close they are to the perfect situation (when each node is strongly
biased to one of the classes).
For a variety of reasons one might want to weight classes differently, for instance, to reduce the impact
of classes with many outliers. We need to multiply class frequencies by weights and then to normalise by
dividing by the sum of weights.
The branching with maximal Gain is considered as the best for a given criterion function.
The set of elementary classifiers (attributes) may be large, and include all the one-attribute classifiers with
different thresholds, all linear discriminants, various non-linear discriminant functions, or other classifiers
like kNN, etc.
The specified minimal number of instances in a tree’s leaf is used as a criterion to stop node splitting; no
leaf of the tree can contain fewer than a specified number of instances.
We tested decision tree models, which differ by:
• The three split criterion (information gain, Gini gain or DKM gain);
• The use of the real-valued features in the splitting criteria separately, or in linear combination by Fisher’s
discriminant;
• The set of input features;
• The minimal number of instances in the leaf, which varied between 3 and 30;
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• Weight of class ‘users’ that is varied.
Direct exhaustive search of the best decision tree can lead to the overfitiing and ‘overoptimism’. Special
validation procedures are necessary. The standard LOOCV meets well-known problems [3] because the
topology of the tree may change in this procedure. Special notions of stability and structural stability are
needed. We return to this problem in more detail, after presentation of the classification results (Section 3.10).
2.3.7 Random Forest (RF)
Random forests were proposed by Breiman [54] for building a predictor ensemble with a set of decision
trees that grow in randomly selected subspaces of the data [59]. The random forests classification procedure
consists of a collection of tree structured classifiers h(x,Θk),k = 1, ..., where theΘk are independent identically
distributed random vectors and each tree casts a unit vote for the most popular class at input x [54].
In a random forest, each tree is constructed using a different bootstrap sample from the original data [3]. In
standard trees, each node is split using the best split among all variables. In a random forest, each node is
split using the best among a subset of predictors randomly chosen at that node [60].
Random forests try to improve on bagging by ‘de-correlating’ the trees. Each tree has the same expectation
[3]. The forest error rate depends on two things [54]. The first is the correlation between any two trees in the
forest. Increasing the correlation increases the forest error rate. The second is the strength of each individual
tree in the forest. A tree with a low error rate is a strong classifier. Increasing the strength of the individual
trees decreases the forest error rate. The random forest algorithm builds hundreds of decision trees and
combines them into a single model [61].
2.3.8 Gaussian Mixture (GM)
Gaussian mixture is a method of estimating probability under the assumption that each category of a target
feature has a multivariate normal distribution [55]. In each category we should estimate the empirical
covariance matrix and invert it. The primary probability of belonging to the ith category is:
pi(x) = p0i (2pi)
− k2 |Si|− 12 exp
[
−1
2
(x− x¯i)′S−1i (x− x¯i)
]
where p0i is a prior probability of the ith category, k is the dimension of the input space, x¯i is the mean
point of the ith category, x is the tested point, Si is the empirical covariance matrix of the ith category and |Si|
is its determinant. The final probability of belonging to the ith category is calculated as
p fi (x) = pi(x)/∑
j
p j(x).
The prior probabilities are estimated as the proportion of cases in the ith category. We also used s varied
multiplier to correct priors for the binary problem.
In the study, we tested Gaussian mixture models, which differ by the set of input features and corrections
applied to the prior probabilities.
38 2 Methods of Data Analysis
2.3.9 Probability Density Function Estimation (PDFE)
We have implemented the radial basis function method [56] for probability density function estimation [57].
The number of probability densities to estimate is equal to the number of categories of the target feature. Each
probability density function is estimated separately by using nonparametric techniques. The prior probabilities
are estimated from the database: pi = ni/N where ni is the number of cases in category i of the target feature,
and N is the total number of cases in the database.
We also use the database to define the k nearest neighbours of each data point. These k points are used to
estimate the radius of the neighbourhood of each point as a maximum of the distance from the data point to
each of its k nearest neighbours. The centre of one of the kernel functions is placed at the data point [45]. The
integral of any kernel function over the whole space is equal to one. The total probability of the ith category
is proportional to the integral of the sum of the kernel functions, which is equal to ni. The total probability
of each category has to be equal to the prior probability pi. Thus, the sum of the kernel functions has to be
divided by ni and multiplied by pi. This gives the probability density estimation for each category.
We have tested a number PDFE models, which differ by:
• The number of nearest neighbours (varied between 5 and 30);
• The set of the input features;
• The kernel function which was placed at each data point.
2.3.10 Naı¨ve Bayes (NB)
The NB approach is based on the simple assumption: attributes are independent. Under this assumption, we
can evaluate the distribution of the separate attributes and then produce a joint distribution function just as
a product of attributes’ distributions. Surprisingly, this approach performs satisfactorily in many real life
problems despite the obvious oversimplification. We have used the standard version of NB [58]. All attributes
which contain ≤20 different values were interpreted as categorical and the standard contingency tables
were calculated for such attributes. The contingency tables we calculated are used to estimate conditional
probabilities. Attributes which contain more than 20 different values were interpreted as continuous. The mean
and the variance were calculated for continuous attributes instead of the contingency tables. We calculated the
isolated mean and variance for each value of the output attribute. The conditional probability of a specified
outcome o and a specified value of the attribute x were evaluated as the value of the probability density
function for a normal distribution at point x with matched mean and variance, which were calculated for the
outcome o. This method has no customization options and was tested on different sets of input features. In the
study we tested 2,048 NB models per drug.
2.4 Visualisation on the non-linear PC canvas: Elastic maps
Elastic maps [13] provide a tool for nonlinear dimensionality reduction. By construction, they are a system
of elastic springs embedded in the data space. This system approximates a low-dimensional manifold, and
is a model of the principal manifold [11, 12]. The elastic coefficients of this system allow the switch from
completely unstructured k-means clustering (zero elasticity) to estimators approximating linear PCs (for high
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bending and low stretching modules). With certain intermediate values of the elasticity coefficients the system
effectively approximates non-linear principal manifolds. In this section we follow [10].
Let the data set be a set of vectors S in a finite-dimensional Euclidean space. The ‘elastic map’ is represented
by a set of nodes Wj (the ’elastic net’) in the same space, but not necessarily a subset of S. Each data point
s ∈ S has a ‘host node’, namely the node Wj closest to s (if there are several closest nodes then one takes the
node with the smallest index). The data set is divided in to classes
K j = {s |Wj is the host of s}.
The ‘approximation energy’ D is the distortion
D =
1
2
k
∑
j=1
∑
s∈K j
‖s−Wj‖2,
which is the energy of springs with unit elasticity connecting each data point with its host node.
On the set of nodes an additional structure is defined. Some pairs of nodes, (Wi,Wj), are connected by
‘elastic edges’. Denote this set of pairs E. Some triplets of nodes, (Wi,Wj,Wk), form ‘bending ribs’. Denote
this set of triplets G.
The stretching energy UE and the bending energy UG are
UE =
1
2
λ ∑
(Wi,W j)∈E
‖Wi−Wj‖2, UG = 12µ ∑
(Wi,W j ,Wl)∈G
‖Wi−2Wj +Wl‖2,
where λ and µ are the stretching and bending moduli respectively. The stretching energy is sometimes
referred to as the ‘membrane’ term, while the bending energy is referred to as the ‘thin plate’ term.
For example, on the 2D rectangular grid the elastic edges are just vertical and horizontal edges (pairs of
closest vertices) and the bending ribs are the vertical or horizontal triplets of consecutive (closest) vertices.
The total energy of the elastic map is thus U = D+UE +UG. The position of the nodes {Wj} is determined
by the mechanical equilibrium of the elastic map, i.e. its location is such that it minimizes the total energy U .
For a given splitting of the dataset S in to classes K j, minimization of the quadratic functional U is a linear
problem with the sparse matrix of coefficients. Therefore, similarly to PCA or k-means, a splitting method is
used:
• For given {Wj} find {K j};
• For given {K j} minimize U to find new {Wj};
• If no change, terminate.
This expectation-maximization algorithm guarantees a local minimum of U . To improve the approximation
various additional methods might be proposed, for example, the ”softening” strategy. This strategy starts with
a rigid grid (small length, small λ and large µ) and finishes with soft grids (small λ and µ). The training goes
in several epochs, each epoch with its own grid rigidness. Another adaptive strategy is the ‘growing net’: one
starts from a small number of nodes and gradually adds new nodes. Each epoch goes with its own number of
nodes.
The elastic map is a continuous manifold. It is constructed from the elastic net using some interpolation
procedure between nodes. For example, the simplest piecewise linear elastic map is build by triangulation and
a piecewise linear map. Data points are projected into the closest points of the elastic map [13].
The elastic map algorithm is extremely fast in the optimisation step due to the very simple form of the
smoothness penalty. In this book we have employed the original software libraries ViDaExpert freely available
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online [62]. This software allows the creation of an appropriate elastic manifold embedded in the dataspace
(Fig. 2.6a), and to color this map to visualise data density and distribution of all the attributes (Fig. 2.6).
An example of such work [12] is presented in Fig. 2.6 for breast cancer microarrays [63]. New open access
software for calculation of elastic graphs is available online in MatLab [64] and R [65].
Fig. 2.6 Visualization [12] of breast cancer dataset [63] using elastic maps: (a) configuration of nodes in the space of first
three PCs; (b) the distribution of points in the internal non-linear manifold coordinates together with an estimation of the
two-dimensional density of points. (A public domain illustration)
Elastic maps and software have been applied in various areas, from bioinformatics [12, 66] to political
sciences [67], financial analysis [68] and multiphase flows [69]. Examples of elastic maps for the drug
consumption database are presented in the next chapter.
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Chapter 3
Results of data analysis
3.1 Descriptive statistics and psychological profile of illicit drug users
The data set contains seven categories of drug users: ‘Never used’, ‘Used over a decade ago’, ‘Used in last
decade’, ‘Used in last year’, ‘Used in last month’, ‘Used in last week’, and ‘Used in last day’. A respondent
selected their category for every drug from the list. We formed four classification problems based on the
following classes (see Section ‘Drug use’ ): the decade-, year-, month-, and week-based user/non-user
separations.
We have identified the relationship between personality profiles (NEO-FFI-R) and drug consumption for
the decade-, year-, month-, and week-based classification problems. We have evaluated the risk of drug con-
sumption for each individual according to their personality profile. This evaluation was performed separately
for each drug for the decade-based user/non-user separation. We have also analysed the interrelations between
the individual drug consumption risks for different drugs. Part of these results has been presented in [1] (and
in more detail in the 2015 technical report [2]). In addition, in Section 3.9 we employ the notion of correlation
pleiades of drugs. We define three pleiades: heroin pleiad, ecstasy pleiad, and benzodiazepines pleiad, with
respect to the decade-, year-, month-, and week-based user/non-user separations. It is also important to
understand how the group of users of illicit drugs differs from the group of non-users.
The descriptive statistics for seven traits (FFM, Imp, and SS) are presented in Table 3.1: means, standard
deviations, and 95% confidence intervals for means for NEO-FFI-R for the full sample and for two subsamples:
non-users of illicit drugs and users of illicit drugs. We have conventionally called the following substances
‘illicit’: amphetamines, amyl nitrite, benzodiazepines, cannabis, cocaine, crack, ecstasy, heroin, ketamine,
legal highs, LSD, methadone, magic mushrooms (MMushrooms), and Volatile Substance Abuse (VSA).
A dimensionless variable z (see (2.9)), which measures how the variability between group relates to the
variability within the groups, is convenient for representing the difference between classes. For the normal
distributions inside groups the optimally balanced separation of groups with given z has equal specificity
and sensitivity P, where P = φ(z), and φ is the cumulative distribution function for the standard normal
distribution.
This is the first result: users of illicit drugs differ from non-users across all seven scales. The 95% CI
for means in these groups do not intersect. The most significant difference was found for SS, then for O,
for Imp and C, and for N. The smallest difference was found for E. Later we will demonstrate that E for
users of different drugs may deviate from E for non-users in a number of different ways. Moreover, the 95%
CIs for means of all three groups, total sample, users of illicit drugs and non-users of illicit drugs do not
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Table 3.1 Descriptive statistics: Means, 95% CIs for means, and standard deviations for the whole sample, for non-users of illicit
drugs and for users of illicit drugs (decade-based user definition). The dimensionless score z (2.9) for separation of users from
non-users of illicit drugs is presented as well as the sensitivity and specificity P of the best separation of normal distributions with
this z. Sensitivity (Sn) and Specificity (Sp) are calculated for all one-feature classifiers.Θ is the threshold for class separation:
one class is given by the inequality score≤Θ and another class by score>Θ .
Factors Total sample Non-users of illicit drugs Users of illicit drugs One feature classifier
Mean 95% CI SD Mean 95% CI SD Mean 95% CI SD z P(%) Θ Sn(%) Sp(%)
N 23.92 23.51, 24.33 9.14 21.00 20.29, 21.71 7.85 24.88 24.40, 25.37 9.32 0.226 59 22 60 58
E 27.58 27.27, 27.88 6.77 28.52 27.99, 29.04 5.73 27.27 26.90, 27.63 7.05 0.098 54 28 51 55
O 33.76 33.47, 34.06 6.58 30.22 29.67, 30.77 6.06 34.93 34.60, 35.26 6.32 0.381 65 32 63 67
A 30.87 30.58, 31.16 6.44 32.87 32.35, 33.38 5.65 30.21 29.87, 30.55 6.54 0.218 59 31 61 56
C 29.44 29.12, 29.75 6.97 32.89 32.39, 33.40 5.55 28.30 27.93, 28.66 7.01 0.366 64 31 65 65
Imp 3.80 3.70, 3.90 2.12 2.74 2.58, 2.90 1.74 4.15 4.04, 4.26 2.12 0.364 64 3 71 56
SS 5.56 5.44, 5.68 2.70 3.77 3.56, 3.98 2.32 6.15 6.02, 6.28 2.55 0.490 69 4 63 74
intersect for N, O, A, C, Imp and SS. Table 3.1 allows us to claim that the profile of users of illicit drugs has a
characteristic form:
N ⇑,O ⇑,A ⇓,C ⇓, Imp ⇑,SS ⇑ . (3.1)
The P column in Table 3.1 gives a simple estimate of the separability of users from non-users of illicit drugs
by a single trait. The best separation is given by the value of SS: estimated sensitivity and specificity are
69%. According to this estimate, SS for 69% of illicit drug users is higher then SS of 69% of non-users. Of
course, for more precise estimation methods the numbers will differ. We might also expect that the use of
several attributes and more sophisticated classification approaches would give better sensitivity and specificity.
Nevertheless, the P column gives us a good indication of the possible performance of classification.
Separation of classes “users of illicit drugs” and “non-users of illicit drugs” are presented in Tables 3.1–3.7,
whereΘ is the threshold of the separation: one class is given by the inequality score≤Θ and another class
by score>Θ . This convention, where to use strong inequality, is important because the values of scores are
integer. The histogram for separation by values of SS for the decade-based definition of users is presented in
Fig. 3.1.
Table 3.2 gives p values, i.e. the probabilities of finding the same or larger difference between mean values
of the traits between users of illicit drugs, non-users of illicit drugs, and the total sample. This table completely
supports the profile from (3.1).
Table 3.2 Significance of differences of means for total sample, users and nonusers of illicit drugs (p-values) for the decade-based
user definition.
Factors Total/User Total/Non-user User/Non-user
N 0.003 < 0.001 < 0.001
E 0.204 0.002 < 0.001
O < 0.001 < 0.001 < 0.001
A 0.004 < 0.001 < 0.001
C < 0.001 < 0.001 < 0.001
Imp < 0.001 < 0.001 < 0.001
SS < 0.001 < 0.001 < 0.001
There are both similarity and an important qualitative difference from the ‘dark triad’ of personality,
Machiavellianism, Narcissism and Psychopathy [5]. According to Table 1.2, the dark triad is associated with
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Fig. 3.1 The distributions of SS for users and non-users of illicit drugs (normalized to 100% in each group) for the decade-based
user/non-user separation. The optimal threshold isΘ = 4
N⇑, A⇓ and C⇓ and low (or neutral) O, whereas the profile (3.1) of the users of illicit drugs has the same N⇑,
A⇓ and C⇓ but high O⇑.
The descriptive tables for the year, month and week-based user definitions are similar (Tables 3.3–3.8).
Table 3.3 Descriptive statistics: Means, SDs, 95% CIs for means, for the sample and two groups: non-users of illicit drugs and
users of illicit drugs. Year-based classification.
Factors Total sample Non-users of illicit drugs Users of illicit drugs One feature classifier
Mean 95% CI SD Mean 95% CI SD Mean 95% CI SD z P(%) Θ Sn(%) Sp(%)
N 23.92 23.51, 24.33 9.14 22.26 21.66, 22.87 8.15 25.18 24.64, 25.73 9.51 0.165 57 35 60 56
E 27.58 27.27, 27.88 6.77 28.21 27.76, 28.65 6.01 27.17 26.76, 27.58 7.15 0.078 53 40 51 55
O 33.76 33.47, 34.06 6.58 30.89 30.44, 31.34 6.11 35.63 35.28, 35.98 6.14 0.387 65 45 63 67
A 30.87 30.58, 31.16 6.44 32.15 31.73, 32.57 5.71 29.96 29.58, 30.33 6.58 0.178 57 43 61 58
C 29.44 29.12, 29.75 6.97 31.96 31.51, 32.42 6.16 27.77 27.37, 28.18 7.03 0.318 62 42 65 63
Imp 3.80 3.70, 3.90 2.12 2.97 2.84, 3.11 1.84 4.32 4.20, 4.44 2.11 0.342 63 3 71 59
SS 5.56 5.44, 5.68 2.70 4.00 3.82, 4.19 2.46 6.50 6.36, 6.63 2.40 0.514 70 5 63 69
Table 3.4 p-values of significance of differences of means for total sample, non-users and users of illicit drugs. Year-based
classification
Factors Total/Users Total/Non-users Users/Non-users
N < 0.001 < 0.001 < 0.001
E 0.122 0.049 0.003
O < 0.001 < 0.001 < 0.001
A < 0.001 < 0.001 < 0.001
C < 0.001 < 0.001 < 0.001
Imp < 0.001 < 0.001 < 0.001
SS < 0.001 < 0.001 < 0.001
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Table 3.5 Descriptive statistics: Means, SDs, 95% CIs for means, for the sample and two groups: non-users of illicit drugs and
users of illicit drugs. Month-based classification
Factors Total sample Non-users of illicit drugs Users of illicit drugs One feature classifier
Mean 95% CI SD Mean 95% CI SD Mean 95% CI SD z P(%) Θ Sn(%) Sp(%)
N 23.92 23.51, 24.33 9.14 22.60 22.06, 23.14 8.22 25.13 24.53, 25.73 9.69 0.141 56 35 56 60
E 27.58 27.27, 27.88 6.77 28.27 27.89, 28.65 5.78 27.19 26.74, 27.64 7.27 0.083 53 39 56 51
O 33.76 33.47, 34.06 6.58 31.01 30.60, 31.43 6.24 36.04 35.67, 36.41 6.00 0.411 66 45 63 63
A 30.87 30.58, 31.16 6.44 31.82 31.43, 32.22 6.02 29.81 29.40, 30.22 6.65 0.159 56 43 56 61
C 29.44 29.12, 29.75 6.97 31.78 31.38, 32.17 5.97 27.50 27.06, 27.95 7.15 0.326 63 42 61 65
Imp 3.80 3.70, 3.90 2.12 3.04 2.91, 3.16 1.92 4.43 4.30, 4.56 2.08 0.348 64 3 64 71
SS 5.56 5.44, 5.68 2.70 4.15 3.99, 4.32 2.51 6.68 6.54, 6.83 2.35 0.521 70 5 67 63
Table 3.6 p-values of significance of differences of means for total sample,non-users and users of illicit drugs. Month-based
classification
Factors Total/Users Total/Non-users Users/Non-users
N 0.001 0.002 < 0.001
E 0.166 0.024 0.002
O < 0.001 < 0.001 < 0.001
A < 0.001 0.003 < 0.001
C < 0.001 < 0.001 < 0.001
Imp < 0.001 < 0.001 < 0.001
SS < 0.001 < 0.001 < 0.001
Table 3.7 Descriptive statistics: Means, SDs, 95% CIs for means, for the sample and two groups: non-users of illicit drugs and
users of illicit drugs. Week-based classification
Factors Total sample Non-users of illicit drugs Users of illicit drugs One feature classifier
Mean 95% CI SD Mean 95% CI SD Mean 95% CI SD z P(%) Θ Sn(%) Sp(%)
N 23.92 23.51, 24.33 9.14 22.79 22.27, 23.31 8.47 25.21 24.56, 25.86 9.72 0.133 55 35 55 60
E 27.58 27.27, 27.88 6.77 28.34 27.97, 28.71 5.96 27.09 26.60, 27.58 7.33 0.094 54 39 56 51
O 33.76 33.47, 34.06 6.58 31.18 30.78, 31.57 6.37 36.17 35.77, 36.57 5.99 0.404 66 46 66 63
A 30.87 30.58, 31.16 6.44 31.63 31.25, 32.01 6.18 29.80 29.35, 30.24 6.67 0.143 56 42 60 61
C 29.44 29.12, 29.75 6.97 31.57 31.20, 31.95 6.10 27.41 26.94, 27.89 7.10 0.315 62 41 64 65
Imp 3.80 3.70, 3.90 2.12 3.10 2.99, 3.22 1.94 4.45 4.31, 4.59 2.08 0.335 63 3 61 71
SS 5.56 5.44, 5.68 2.70 4.27 4.12, 4.43 2.52 6.73 6.58, 6.89 2.35 0.505 69 5 62 63
Table 3.8 P-values of significance of differences of means for total sample, non-users and users of illicit drugs. Week-based
classification
Factors Total/Users Total/Non-users Users/Non-users
N 0.001 0.011 < 0.001
E 0.100 0.016 0.001
O < 0.001 < 0.001 < 0.001
A < 0.001 0.018 < 0.001
C < 0.001 < 0.001 < 0.001
Imp < 0.001 < 0.001 < 0.001
SS < 0.001 < 0.001 < 0.001
Pearson’s correlation coefficient (PCC or r) is employed as a measure of the strength of a linear association
between two factors. PCC for all pairs of factors are presented in Table 3.9. Two pairs of factors do not have
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significant correlation: (1) N and O (r=0.017, p=0.471); (2) A and O (r=0.033, p=0.155). However, all other
pairs of personality factors are significantly correlated in the sample (compare to Table 1.3).
Table 3.9 PCC for NEO-FFI-R for raw data
Factors N E O A C
N -0.432* 0.017 -0.215* -0.398*
E -0.432* 0.236* 0.159* 0.318*
O 0.017 0.236* 0.033 -0.060**
A -0.215* 0.159* 0.033 0.249*
C -0.398* 0.318* -0.060** 0.249*
*p < 0.001; **p < 0.01.
Strictly speaking, the scores should be considered as ordinal features. Therefore, the polychoric correlation
coefficients (PoCC) should be used. Table 3.10 presents values of PoCCs between all of the psychological
traits we measured (compare to Tables 1.3 and 3.9). The corresponding p-values are presented in Table 3.1.
Table 3.10 Polychoric correlation coefficients (PoCC) of measured psychological traits (n=1,885).
N E O A C Imp SS
N −0.431* 0.010 −0.217* −0.391* 0.174* 0.080**
E −0.431* 0.245* 0.157* 0.308* 0.114* 0.210*
O 0.010 0.245* 0.039 −0.057*** 0.278* 0.422*
A −0.217* 0.157* 0.039 0.247* −0.230* −0.208*
C −0.391* 0.308* −0.057*** 0.247* −0.335* −0.229*
Imp 0.174* 0.114* 0.278* −0.230* −0.335* 0.623*
SS 0.080** 0.210* 0.422* −0.208* −0.229* 0.623*
*p < 0.0001, **p < 0.001, ***p < 0.02.
3.2 Distribution of number of drugs used
The diagrams in Fig. 3.2 show the graph of the number of users versus the number of illicit drugs used for the
decade-based (a) and month-based (b) user/non-user separations. In Fig. 3.2 a we can see that the distribution
of the number of users is bimodal with maxima at zero and seven drugs used. In Fig. 3.2 b the distribution of
the number of users of various numbers of illegal drugs during the last months looks like the exponential
distribution.
The distributions of the number of users for each drug are presented in Fig. 3.3 and Fig. 3.4. Most of the
distributions have an exponential-like shape, but several have bimodal distributions. The distributions of the
number of users for the three legal drugs have maximum at ‘Used in last day’ or ‘Used in last week’ (see
Fig. 3.3 a, e, and g). The distribution of the number of nicotine users (smokers) has three maxima: ‘Used
in last day’ for smokers, ‘Used in last decade’ for smokers who have quit smoking, and ‘Never used’ (see
Fig. 3.4 g). All distributions for illegal drug users have maximum in the category ‘Never used’. However, the
distribution of cannabis users has two maxima. The main maximum is in the category ‘Used in last day’, and
the second is in the category ‘Never used’ (see Fig. 3.3f).
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Fig. 3.2 The histograms of the number of users of illicit drugs (the number of users versus the number of illicit drugs used): (a)
for the decade-based user/non-user separation, and (b) for the month-based user/non-user separation
3.3 Sample mean and population norm
It may seem to be a good idea to use the T-scores with respect to the population norm. Caution is needed
however, since the mean values may depend on age and social group, so that the notion of ‘population norm’
is a complex hierarchical construct rather than a simple set of means.
Following [3] we include data about two groups. The first consists of high school students (n=1959) [6].
The age range is from 14 to 18 (M=16.5, S.D.=1.0 years); approximately two-thirds were girls. In Table 3.11,
we denote this group with the abbreviation HS.
The second sample consists of adults from the Baltimore Longitudinal Study of Aging (BLSA) [7]. BLSA
participants are generally healthy and well-educated men and women who have volunteered to return to the
Gerontology Research Center for periodic medical and psychosocial testing. The data was collected between
1991 and 2002, n=1,492 (695 men and 797 women) aged 19–93 (M=56.2, S.D.=17.0 years); 65.1% of the
sample was White, 27.6% Black, and 7.3% Other Race. In Table 3.11 we refer to this group as BLSA.
The third sample includes 1,025 participants (802 males and 221 females; two individuals did not provide
information on their gender) and combines data from several studies published between 1996–2000 [8]. This
cohort had a good range of skills, mental ability, and psychopathology, and aimed to be a representative
cross-section of British society. In Table 3.11, we use Brit to label this group.
For HS and BLSA data both NEO-FFI and NEO-FFI-R profiles are available. For Brit only the NEO-FFI
scores are available. For ease of comparison we include the Five Factor scores for our sample and for the
subsample of illicit drug users (Table 3.1) in Table 3.11.
The means of the NEO-FFI-R T-scores based on normative data are depicted in Fig. 3.5. For this example,
the ‘norm’ is taken from the BLSA group (NEO-FFI). It is obvious from this figure that Samp is significantly
biased when compared to the population (represented by the BLSA group). Such a bias is usual for clinical
cohorts, for example, the ‘problematic’ or ‘pathological’ groups [9], and the drug users [10, 11]. For the group
of non-users of illicit drugs the bias is much smaller.
It is important to observe that the mean values of scores for four factors in our sample, N, E, A, and C, are
between the mean scores for BLSA and HS. The mean O score in our sample is significantly higher.
The special role of “Openness to Experience” (O) for drug consumption has been observed by many
researchers. For example, in the paper “Undergraduate marijuana and drug use as related to openness to
experience” [12] we read: “Marijuana use, in the present sample of college students, was associated with
personality characteristics which many would tend to value (e.g., creativity). Open mindedness or ‘openness
to experience’ may account for our findings. People who are open to new experience become creative, try
marijuana, and, in general, experience more than people who have a less open life style. This accounts for
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Fig. 3.3 Distribution of drug usage: (a) Alcohol, (b) Amphetamines, (c) Amyl nitrite, (d) Benzodiazepines, (e) Cannabis, (f)
Chocolate, (g) Cocaine, (h) Caffeine, (i) Crack, and (j) Ecstasy
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Fig. 3.4 Distribution of drug usage: (a) Heroin, (b) Ketamine, (c) Legal highs, (d) LSD, (e) Methadone, (f) MMushrooms, (g)
Nicotine, and (h) VSA
our finding that the more a person uses marijuana, the more likely they are to try one or more other drugs.”
Non-users were characterised as “the typical non-creative, high authoritarian individuals.”
The high variability of means in the ‘normal’ groups has encouraged us to analyse the T-scores with
respect to the sample mean and to study the differences between users and non-users rather than deviation
from the norm. This analysis is presented in the next two sections.
3.4 Deviation of the groups of drug users from the sample mean 53
Table 3.11 Mean values of Five Factors for the three ‘normal’ samples and for our data.‘ N-u, Illicit’ stands for non-users of
illicit drugs with the decade-based definition of users (they either never used illicit drugs or used them more than a decade ago),
Samp stands for the total sample, ‘U, Illicit’ stands for users of illicit drugs for the decade-based definition of users; compare
with Table 3.1
N E O A C
Group Version Mean SD Mean SD Mean SD Mean SD Mean SD
BLSA NEO-FFI 15.77 7.47 28.50 6.26 29.32 6.11 33.39 4.98 33.48 6.36NEO-FFI-R 16.83 7.36 29.29 6.46 31.29 6.12 32.41 5.42 33.26 6.30
HS NEO-FFI 24.65 8.07 30.58 6.67 28.40 6.57 28.31 6.34 27.45 7.30NEO-FFI-R 25.08 7.95 31.80 6.94 31.18 6.96 28.09 6.93 27.00 7.40
Brit NEO-FFI 19.5 8.6 27.1 5.9 26.5 6.5 29.7 5.9 32.1 6.6
N-u, Illicit NEO-FFI-R 21.00 7.85 28.52 5.73 30.22 6.06 32.87 5.65 32.89 5.55
Samp NEO-FFI-R 23.92 9.14 27.58 6.77 33.76 6.58 30.87 6.44 29.44 6.97
U, Illicit NEO-FFI-R 24.88 9.32 27.27 7.05 34.93 6.32 30.21 6.54 28.30 7.01
Fig. 3.5 Mean T-score NEO-FFI-R for the total sample and for non-users of illicit drugs with respect to the BLSA mean as a
norm
3.4 Deviation of the groups of drug users from the sample mean
Tables A.1 and A.2 demonstrate the mean T-scoresample of five NEO-FFI-R factors, supplemented by Imp
and SSs for users and non-users, for each drug with respect to the decade-, year-, month-, and week-based
classification problems respectively (see Appendix A). Significant differences in personality factor scores
are observed between these groups. The hypothesis about the universal relationship between personality
profile and the risk of drug consumption can generally be described as in (3.1): an increase in scores of N, O,
Imp, and SS suggest an increase in the risk of use, whereas an increase in the scores of A and C results in a
decrease in the risk of use. Thus for each drug, drug users scored higher on N and O, and lower on A and C,
when compared to non-users of drugs. The influence of the score of E is drug specific (non-universal).
We now analyse the sign of T-scoresample for various drugs and the definitions of users (decade-, year-,
month- and week-based). We used a + sign for moderately high and high T-scoresample (T-scoresample > 55,
and a – sign for moderately low and low T-scoresample (T-scoresample < 45, and 0 for a score close to the mean
value 55≥T-scoresample ≥ 45. These signs reflect the distance from the group of users to the sample mean.
In the next section we analyse significance of deviations. There is a standard and well-known problem
with reporting of the values and significance of deviations: ‘significant’ does not mean ‘large’ and, conversely,
apparently large deviations could be insignificant. Everything is defined by interplay between the number
of elements in classes and the deviation value. Practically, significant but small deviations may be unstable:
after small change of conditions they may even change their sign. We consider the variability of the ‘normal’
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scores in Section 3.3. Insignificant but apparently large deviation may become significant for larger samples
or may vanish. Therefore, it is necessary to answer two questions: how large is the deviation (this section)
and how significant is it (next section)?
For a significant deviation of users from non-users we use the signs ⇑ and ⇓.
The inclusion of moderate subcategories of T-scoresample as suggested above enables us to separate the
drugs into five groups for the decade-based user/non-user separation. These are presented in Table 3.12. Each
group can be coded using the (N, E, O, A, C, Imp, SS) profile:
• The group with the profile (0,0,0,0,0,0,0) includes the users of three legal drugs: alcohol, chocolate and
caffeine;
• The group of drugs with the profile (0,0,+,−,−,+,+) includes the users of amyl nitrite, LSD, and magic
mushrooms;
• Nicotine users form their own group with the profile (0,0,+,0,−,+,+);
• The largest group of drugs with the profile (+,0,+,−,−,+,+) includes the users of amphetamines,
benzodiazepines, cannabis, cocaine, ecstasy, ketamine, and legal highs;
• Finally, the group with the profile (+,−,+,−,−,+,+) includes the users of crack, heroin, VSA and
methadone.
Table 3.12 Deviation of T-scoresample from the sample mean for various groups of users for the decade-based user/non-user
separation
Drug N E O A C Imp SS
Alcohol, Chocolate, Caffeine 0 0 0 0 0 0 0
Amyl nitrite, LSD, and MMushrooms 0 0 + − − + +
Nicotine 0 0 + 0 − + +
Amphetamines, Benzodiazepines, Cannabis,
Cocaine, Ecstasy, Ketamine, and Legal highs + 0 + − − + +
Crack, Heroin, VSA, and Methadone + − + − − + +
Ecstasy pleiad 0 0 + − − + +
Heroin pleiad, Benzodiazepines pleiad + 0 + − − + +
Illicit drugs + 0 + − − + +
For the year-based user/non-user classification, drugs are separated into eight groups as presented in
Table 3.13. Each group can be coded using the (N, E, O, A, C, Imp, SS) profile:
• The group with the profile (0,0,0,0,0,0,0) includes the users of three legal drugs alcohol, chocolate and
caffeine;
• The group of drugs with the profile (0,0,+,−,−,+,+) contains just the users of magic mushrooms;
• The LSD users also form their own group with the profile (0,0,+,0,−,+,+);
• The group with the profile (+,0,+,−,−,+,+) includes the users of amphetamines, amyl nitrite, cannabis,
cocaine, crack, legal highs and VSA;
• The group of drugs with the profile (+,−,+,−,−) includes the users of benzodiazepines, heroin, and
methadone;
• The ecstasy users form their own group with the profile (0,+,+,−,−,+,+);
• The ketamine users form their own group with the profile (+,+,+,−,−,+,+);
• The nicotine users form their own group with the profile (+,0,+,0,−,+,+).
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Similarly, the deviations of T-scoresample from the sample mean for the month-based user/non-user
classification and for the week-based user/non-user classification are described in Table 3.14 and Table 3.15
respectively.
Table 3.13 Deviation of T-scoresample from the sample mean for various groups of users for the year-based user/non-user
separation
Drug N E O A C Imp SS
Alcohol, Chocolate, Caffeine 0 0 0 0 0 0 0
MMushrooms 0 0 + − − + +
LSD 0 0 + 0 − + +
Amphetamines, Amyl nitrite, Cannabis,
Cocaine, Crack, Legal highs, and VSA + 0 + − − + +
Benzodiazepines, Heroin, and Methadone + − + − − + +
Ecstasy 0 + + − − + +
Ketamine + + + − − + +
Nicotine + 0 + 0 − + +
Heroin pleiad, Ecstasy pleiad, Benzodiazepines pleiad + 0 + − − + +
Illicit drugs + 0 + − − + +
Table 3.14 Deviation of T-scoresample from the sample mean for various groups of users for the month-based user/non-user
separation
Drug N E O A C Imp SS
Alcohol, Chocolate, Caffeine 0 0 0 0 0 0 0
Cannabis and MMushrooms 0 0 + − − + +
Nicotine + 0 + 0 − + +
Amphetamines, Ketamine, and Legal highs + 0 + − − + +
Benzodiazepines, Heroin, and Methadone + − + − − + +
Ecstasy and LSD 0 + + − − + +
Cocaine and VSA + + + − − + +
Amyl nitrite 0 0 0 − − + +
Crack + − 0 − − + +
Ecstasy pleiad 0 0 + − − + +
Heroin pleiad, Benzodiazepines pleiad + − + − − + +
Illicit drugs + 0 + − − + +
The personality profiles are strongly associated with membership of groups of the users and non-users
of the 18 drugs. We found that the N and O score of drug users of all 18 drugs are moderately high (+) or
neutral (0), and that the A and C scores of drug users are moderately low (−) or neutral (0). Detailed results
can be seen in Tables 3.13, 3.14, and 3.15.
The effect of the E score is drug specific. Drugs are divided into three groups with respect to the E score of
users (in the year-, month-, and week-based classification problems; see Tables 3.12, 3.13, 3.14 and 3.15. For
example, for the week-based user/non-user separation the E score is:
• Moderately low (−) in groups of users of amphetamines, amyl nitrite, benzodiazepines, heroin, ketamine,
legal highs, methadone, and crack;
• Moderately high (+) in groups of users of cocaine, ecstasy, LSD, magic mushrooms, and VSA;
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Table 3.15 Deviation of T-scoresample from the sample mean for various groups of users for the week-based user/non-user
separation
Drug N E O A C Imp SS
Alcohol, Chocolate, Caffeine 0 0 0 0 0 0 0
Cannabis 0 0 + − − + +
LSD and MMushrooms 0 + + 0 − + +
Ketamine 0 − + − − + +
Amphetamines, Benzodiazepines,
Heroin, Legal highs, and Methadone + − + − − + +
Ecstasy 0 + + − − + +
VSA 0 + + − 0 + +
Cocaine + + + − − + +
Nicotine + 0 + 0 − + +
Amyl nitrite 0 − 0 − − + +
Crack + − − − − + +
Heroin pleiad, Benzodiazepines pleiad + − + − − + +
Ecstasy pleiad 0 0 + − − + +
Illicit drugs + 0 + − − + +
• Neutral (0) in groups of users of alcohol, caffeine, chocolate, cannabis, and nicotine.
3.5 Significant differences between groups of drug users and non-users
Tables 3.16, 3.17, 3.18, and 3.19 (“user minus non-user profiles”) show where there are significant differences
between the means of the personality traits for the groups of users and non-users for the decade-, year-,
month-, and week-based classification problems respectively. Three significance level are used:
• 99% significance level (p-value is less than 0.01). Symbol ‘⇓ ’ corresponds to 99% significant difference
where the mean in users group is less than mean in non-users group and symbol ‘⇑’ corresponds to 99%
significant difference where the mean in users group is greater than the mean in non-users group.
• 98% significance level (p-value is less than 0.02). Symbol ‘↓ ’ corresponds to 98% significant difference
where the mean in users group is less than mean in non-users group and symbol ‘↑’ corresponds to 98%
significant difference where the mean in users group is greater than the mean in non-users group.
• 95% significance level (p-value is less than 0.05). Symbol ‘ ’ corresponds to 95% significant difference
where the mean in users group is less than mean in non-users group and symbol ‘’ corresponds to 95%
significant difference where the mean in users group is greater than the mean in non-users group.
Empty cells in the tables below correspond to insignificant differences.
For example for the decade-based user/non-user separation (see Table 3.16) chocolate does not have a
significant difference between users and non-users for any of the factors. Alcohol users and non-users only
have a 99% significant difference in the C , Imp, and SS scores, and 95% significant difference in the A score.
According to Table 3.12 all these deviations are small.
LSD and magic mushrooms for the decade-based user/non-user separation (see Table 3.16) have 99%
significant difference between users and non-users in the O, A, C, Imp, and SS scores and 95% significant
difference in the N score. According to Table 3.12 both for LSD and magic mushrooms the deviation in the N
score is small and all the deviations in the O, A, C, Imp, and SS scores are not small.
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In Table 3.16, benzodiazepines and methadone have 99% significant differences between users and
non-users in all seven scores. For methadone, all of these differences are not small (Table 3.12) and for
benzodiazepines the difference in the E score is small inspite of having 99% significance.
The significance of the differences of the means for groups of users and non-users for the year, month,
and week-based user definition is presented in Tables 3.17–3.19. We hope that the previous descriptions of
where the significant differences lie are enough for the reader to interpret this table. It is useful to consider
significance of differences together with their value (Tables 3.13– 3.15). Additional information about these
differences could be extracted from the detailed Tables A.1, A.2 in the Appendix.
Table 3.16 Significant differences of means for groups of users and non-users for the decade-based user/non-user separation.
Drug N E O A C Imp SS
Chocolate
Alcohol  ⇓ ⇑ ⇑
Amyl nitrite ⇑ ⇓ ⇓ ⇑ ⇑
Caffeine  ⇑ ↓ ↑ ⇑
LSD, MMushrooms  ⇑ ⇓ ⇓ ⇑ ⇑
Amphetamine, Cocaine, Crack, Ecstasy, Ketamine, Legal highs, Nicotine, VSA ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Cannabis, Heroin ⇑  ⇑ ⇓ ⇓ ⇑ ⇑
Benzodiazepines, Methadone ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Benzodiazepines pleiad, Heroin pleiad ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Ecstasy pleiad ⇑  ⇑ ⇓ ⇓ ⇑ ⇑
Illicit drugs ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Table 3.17 Significant differences of means for groups of users and non-users for the year-based user/non-user separation.
Drug N E O A C Imp SS
Chocolate
Alcohol ⇑
Amyl nitrite ↑ ⇓ ⇓ ⇑ ⇑
LSD ⇑  ⇓ ⇑ ⇑
MMushrooms ⇑ ⇓ ⇓ ⇑ ⇑
Caffeine ↑   ⇑ ⇑
Ecstasy ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Ketamine ↑ ⇑ ⇓ ⇓ ⇑ ⇑
VSA ⇑ ⇑ ↓ ⇓ ⇑ ⇑
Amphetamine, Cannabis, Crack, Legal highs, Nicotine ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Cocaine ⇑  ⇑ ⇓ ⇓ ⇑ ⇑
Heroin ⇑ ↓ ⇑ ⇓ ⇓ ⇑ ⇑
Benzodiazepines, Methadone ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Heroin pleiad ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Benzodiazepines pleiad, Ecstasy pleiad ⇑  ⇑ ⇓ ⇓ ⇑ ⇑
Illicit drugs ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Mean values of Five Factor scores for groups of drug users and non-users for the decade-based user/non-
user separation are depicted in Fig. 3.6. Some similarities and differences between users of different drugs are
obvious from this figure: compare, for example, profiles of ecstasy users and heroin users, which are very
different to profiles for nicotine and cannabis users, which are qualitatively similar (but with larger deviations
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Table 3.18 Significant differences of means for groups of users and non-users for the month-based user/non-user separation.
Drug N E O A C Imp SS
Chocolate
Amyl nitrite ↓  ↑ ⇑
LSD, MMushrooms ⇑ ⇓ ⇑ ⇑
VSA ⇑  ⇑ ⇑
Ketamine ⇑  ⇓ ⇑ ⇑
Caffeine ⇑ ⇑ ⇑
Alcohol ⇑  ⇑
Ecstasy ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Crack ⇑   ↑ ⇑
Amphetamine, Cannabis, Cocaine, Legal highs, Nicotine ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Heroin ⇑ ↓ ⇓ ⇓ ⇑ ⇑
Benzodiazepines, Methadone ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Ecstasy pleiad, Heroin pleiad ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Benzodiazepines pleiad ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Illicit drugs ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Table 3.19 Significant differences of means for groups of users and non-users for the week-based user/non-user separation.
Drug N E O A C Imp SS
Chocolate ↓
Crack   ⇑
Amyl nitrite    ⇑
Ketamine ↑ ↓ ↓ ↑ ⇑
VSA ⇑ ⇑ ⇑
LSD ⇑ ⇓  ⇑
Cannabis ⇑ ⇓ ⇓ ⇑ ⇑
MMushrooms  ⇑ ⇑ ⇑
Caffeine ↑ 
Ecstasy ↑ ⇑ ⇓ ⇑ ⇑
Alcohol ⇑ ⇑
Cocaine ↑ ⇓ ⇓ ⇑ ⇑
Amphetamine, Nicotine ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Heroin ⇑  ⇓ ⇓ ⇑ ⇑
Methadone ⇑ ⇓  ⇓ ⇓ ⇑ ⇑
Benzodiazepines, Legal highs ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Ecstasy pleiad ⇑ ⇑ ⇓ ⇓ ⇑ ⇑
Benzodiazepines pleiad, Heroin pleiad ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
Illicit drugs ⇑ ⇓ ⇑ ⇓ ⇓ ⇑ ⇑
of cannabis users profiles from the sample mean). Mean values of all seven factor scores for groups of drug
users and non-users for all definitions of users are presented in Tables A.1 and A.2.
3.6 Correlation between usage of different drugs
Usage of each drug is a binary variable (users or non-users) for all versions of user definition. Tables A.3
and A.4 contain PCCs, which are computed for each pair of the 153 (=18 times 17 divided by 2) potential
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Fig. 3.6 Average personality profiles for the month-based user/non-user separation. T-scores with respect to the population
norm mean for Ecstasy, Heroin, Benzodiazepines, VSA, Nicotine, Cannabis, Cocaine, and the whole group of Illicit drugs
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drug usages for the decade- and year-based user/non-user separations respectively (see Appendix A.2). The
majority of the PCCs are significant, since the sample size is 1,885.
The correlation in 124 pairs of drug usages from a totality of 153 pairs have, for the decade-based
classification problem, p-values less than 0.01 (p-value is the probability of observing by chance the same or
greater correlation coefficient for uncorrelated variables). It is necessary to employ a multi-testing approach
when testing 153 pairs of drug usages in order to estimate the significance of the correlation [13]. We apply
the most conservative technique, the Bonferroni correction, and used the Benjamini-Hochberg (BH) step-up
procedure [13] to control the False Discovery Rate (FDR) in order to estimate the genuine significance of
these correlations. There are 115 significant correlation coefficients with Bonferroni corrected p-value 0.001.
The BH step-up procedure with threshold of FDR equal to 0.01 defines 127 significant correlation coefficients.
However, a significant correlation does not necessarily imply a strong association or causality. For example,
the correlation coefficient for alcohol usage and amyl nitrate usage is significant (i.e. the p-value is equal
to 0.0013) but the value of this coefficient is equal to 0.074, and thus cannot be considered as an important
association. We consider correlations with absolute values of PCC |r| ≥ 0.4. Fig. 3.7 sets out all significant
identified correlations greater than 0.4. In this study, for the decade-based classification problem, we consider
the correlation as weak if |r|< 0.4, medium if 0.45 > |r| ≥ 0.4, strong if 0.5 > |r| ≥ 0.45, and very strong if
|r| ≥ 0.5.
Fig. 3.7 Strong drug usage correlations:(a) for the decade-based classification problem, and (b) for the year-based classification
problem
The correlation coefficient is high for each pair from the group: amphetamines, cannabis, cocaine, ecstasy,
ketamine, legal highs, LSD, and magic mushrooms, excluding correlations between cannabis and ketamine
usage (r=0.302) and between legal highs and ketamine usage (r=0.393) (Fig. 3.7a). Crack, benzodiazepines,
heroin, methadone, and nicotine usages are correlated with one, two, or three other drugs usage (see Fig. 3.7a).
Amyl nitrite, chocolate, caffeine and VSA usage are uncorrelated or weakly correlated with usage of any
other drug.
The structure of correlations of the year-based user/non-user separation is approximately the same as
for the decade-based classification problem (see Fig. 3.7). We consider correlations with absolute values of
PCC |r| ≥ 0.35 for the year-based classification. Fig. 3.7B sets out all identified significant correlations with
|r|> 0.35. The correlation can be interpreted as weak if |r|< 0.35; medium if 0.40 > |r| ≥ 0.35; strong if
0.5 > |r| ≥ 0.40; and very strong if |r| ≥ 0.5. On base of this similarity of correlation structures we define
pleiades for three central drugs: heroin, ecstasy, and benzodiazepines (as described in the Section 3.9).
3.7 Ranking of input features 61
Relative Information Gain (RIG) is widely used in data mining to measure the dependence between
categorical attributes (2.3). For example, the value of RIG for Drug 1 usage from usage of Drug 2 is equal
to a fraction of uncertainty (entropy) in drug 1 usage, which can be removed if the value of drug 2 usage is
known. The significance of RIG for binary random variables is the same as for PCC. The majority of RIGs
are statistically significant, but have small values. Fig. 3.8 presents all pairs with RIG >0.15.
Fig. 3.8 Pairs of drug usages with high RIG: ((a) approximately symmetric RIG and (b) significantly asymmetric RIG. In Figure
(b), the arrow from cocaine usage to heroin usage, for example, means that knowledge of cocaine usage can decrease uncertainty
in knowledge about heroin usage
Fig. 3.8a shows ‘approximately symmetric’ RIGs. Here, we call RIG(X |Y ) approximately symmetric if
|RIG(X |Y )−RIG(Y |X)|
min(RIG(X |Y ),RIG(Y |X)) < 0.2.
RIG is approximately symmetric for each pair from the following group: amphetamines, cannabis, cocaine,
ecstasy, legal highs, LSD and magic mushrooms. This group is the same as in Fig. 3.7 (except ketamine).
Fig. 3.8b shows asymmetric RIGs. Asymmetric RIGs illustrate a markedly different pattern to that of Fig. 3.7.
3.7 Ranking of input features
It should be stressed that the five factors (FFM), Imp, and SS are all correlated. To identify the most informative
features we applied the methods which are described in Section 2.2.3. The results of the principal variables
calculation are given in Table 3.20 for CatPCA quantification, and in Table 3.21 for the dummy coding of
nominal features. Tables 3.20 and 3.21 contain lists of attributes in order from best to worst. The results of the
Double Kaiser ranking are shown in the same tables.
The results of application of sparse PCA are shown in Tables 3.22 and 3.23. As a result of feature selection
we can exclude ethnicity from further consideration. There is a more intriguing effect regarding country of
location. Only two countries are informative (in our sample): the UK and the USA. Furthermore, inclusion
of country in the personality measures does not add much to the prediction of drug usage. To understand
the reasons for these two countries’ importance in the prediction of drug consumption we compare the
statistics for the subsamples: UK - non-UK and USA - non-USA. We calculated the p-value for coincidence of
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Table 3.20 The results of feature ranking. Data include country of residence and ethnicity quantified by CatPCA. FVE is the
fraction of explained variance. Gndr stays for gender. CFVE is the cumulative FVE. The least informative features are located
towards the bottom of the table.
Principal variable ranking Double Kaiser’s ranking
Attribute FVE CFVE
SS 0.192 0.192 E
N 0.153 0.345 C
A 0.106 0.451 SS
Edu 0.104 0.555 N
O 0.092 0.647 Imp
C 0.088 0.735 O
E 0.076 0.811 A
Age 0.073 0.884 Age
Imp 0.055 0.939 Edu
Country 0.037 0.976 Country
Gndr 0.021 0.997 Gndr
Ethnicity 0.003 1.000 Ethnicity
Table 3.21 The results of feature ranking. Data include dummy coded country of residence and ethnicity. FVE is the fraction of
explained variance. CFVE is the cumulative FVE. The least informative features are lower located.
Principal variable ranking Double Kaiser’s ranking
Attribute FVE CFVE
SS 0.186 0.186 E
N 0.149 0.335 C
A 0.103 0.438 SS
Edu 0.101 0.539 N
O 0.089 0.627 Imp
C 0.086 0.714 O
E 0.074 0.787 A
Age 0.071 0.858 Age
Imp 0.053 0.911 Edu
UK 0.027 0.938 UK
Gndr 0.020 0.959 USA
USA 0.013 0.972 Gndr
White 0.010 0.982 Other (country)
Other (country) 0.005 0.988 White
Canada 0.004 0.991 Other (ethnicity)
Other (ethnicity) 0.003 0.994 Canada
Black 0.002 0.995 Asian
Australia 0.002 0.997 Mixed-White/Black
Asian 0.001 0.998 Australia
Mixed-WhiteBlack 0.001 0.999 Black
Republic of Ireland 0.000 1.000 Mixed-White/Asian
Mixed-WhiteAsian 0.000 1.000 Republic of Ireland
New Zealand 0.000 1.000 New Zealand
Mixed-BlackAsian 0.000 1.000 Mixed-Black/Asian
distribution of personality measurements in each subsample. We obtained the same results for both divisions
into subsamples: all input features have significantly different distributions with a 99.9% confidence level
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for UK and non-UK subsamples and likewise for USA – non-USA subsamples. This means that the UK and
non-UK samples are biased, and similarly for the USA and non-USA samples.
Our goal is to predict the risk of drug consumption for an individual. This means that we have to consider
individual specific factors. Occupation within a specific country can be thought of as an important risk factor,
but we do not have enough data for countries other than the UK and the USA because of the composition of
the dataset: participants from the UK (1,044; 55.4%), the USA (557; 29.5%), Canada (87; 4.6%), Australia
(54; 2.9%), New Zealand (5; 0.3%) and Ireland (20; 1.1%). A total of 118 (6.3%) came from a diversity
of other countries, none of whom individually formed as much as 1% of the sample, or did not declare the
country of location. Thus we exclude the ‘country’ feature from further study. As a result, we continue with
the 10 input features: Age, Edu, N, E, O, A, C, Imp, SS, and Gndr.
Table 3.22 The result of sparse PCA feature ranking. Data include country of residence and ethnicity quantified by CatPCA.
Step # of components Removed attributes
1 5 Gndr and Ethnicity
2 4
No removed attributes. The retained set of attributes: Age, Edu,
N, E, O, A, C, Imp, SS, and country
Table 3.23 The result of sparse PCA feature ranking. Data include dummy coded country of residence and ethnicity.
Step # of components Removed attributes
1 8
Canada, Other (country), Australia, Republic of Ireland,
New Zealand, Mixed-White/Asian, White, Other (ethnicity),
Mixed-White/Black, Asian, Black and Mixed-Black/Asian
2 5 Gndrr, UK and USA
3 4
No removed attributes. The retained set of attributes: Age,
Edu, N, E, O, A, C, Imp, and SS
3.8 Selection of the best classifiers for the decade-based classification problem
The first step for risk evaluation is the construction of classifiers. We have tested the eight methods described
in the ‘Risk evaluation methods’ Section and selected the best one. The results of classifier selection are
presented in Table 3.24. This table shows that for all drugs except alcohol, cocaine and magic mushrooms,
the sensitivity and specificity are greater than 70%, which is an unexpectedly high accuracy.
Recall that we have 10 input features: Age, Edu, N, E, O, A, C, Imp, SS, and Gndr; each of which is
an important predictor for at least five drugs. However, there is no single most effective classifier which
uses all input features. The maximal number of attributes used is 6 out of 10 and the minimal number is 2.
In Section 2.3.2 the best method is defined as the method which maximises the value of the minimum of
sensitivity and specificity. If the minimum of sensitivity and specificity is the same for several classifiers then
the classifier with the maximal sum of the sensitivity and specificity is selected from these. Table 3.24 shows
the different sets of attributes which are used in the best user/non-user classifier for each different drug.
The use of a feature in the best classifier can be interpreted as ‘ranking by fact’. We note that this ranking
by fact is very different from the other rankings presented in Tables 3.20 and 3.22. For example, in Tables 3.20
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Table 3.24 The best results of the drug users classifiers (decade-based definition of users). Symbol ‘X’ means the used input
feature. Results are calculated by LOOCV.
Target feature Classifier Age Edu N E O A C Imp SS Gndr Sn Sp Sum
(%) (%) (%)
Alcohol LDA X X X X X 75.34 63.24 138.58
Amphetamines DT X X X X X X 81.30 71.48 152.77
Amyl nitrite DT X X X X 73.51 87.86 161.37
Benzodiazepines DT X X X X X X 70.87 71.51 142.38
Cannabis DT X X X X X X 79.29 80.00 159.29
Chocolate kNN X X X X 72.43 71.43 143.86
Cocaine DT X X X X X 68.27 83.06 151.32
Caffeine kNN X X X X X 70.51 72.97 143.48
Crack DT X X 80.63 78.57 159.20
Ecstasy DT X X X 76.17 77.16 153.33
Heroin DT X X X 82.55 72.98 155.53
Ketamine DT X X X X X 72.29 80.98 153.26
Legal highs DT X X X X X X 79.53 82.37 161.90
LSD DT X X X X X X 85.46 77.56 163.02
Methadone DT X X X X X 79.14 72.48 151.62
MMushrooms DT X X 65.56 94.79 160.36
Nicotine DT X X X X 71.28 79.07 150.35
VSA DT X X X X X X 83.48 77.64 161.12
and 3.22 we see that Age is not one of the most informative measures, but it is used in the best classifiers
for 14 of the drugs. The second most used input feature is Gndr, which is regarded as non-informative by
Sparse PCA (Table 3.22) and as one of the least informative by other methods (Table 3.20). This means that
consumption of these 10 drugs is Gndr dependent.
We have found some unexpected outcomes. For example, in the dataset the fraction of females who are
alcohol users is greater than that fraction of males (Fig. 3.9) but a greater proportion of males consume
caffeine drinks (for example, coffee) (Fig. 3.10). The fraction of males who do not eat chocolate is greater
than for females (Fig. 3.11). The conditional distributions for nicotine show the fraction of males who smoke
is higher (Fig. 3.12).
Fig. 3.9 Conditional distribution for Gndr and alcohol
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Fig. 3.10 Conditional distribution for Gndr and caffeine
Fig. 3.11 Conditional distribution for Gndr and chocolate
The next most informative input features are E and SS which are used in the best classifiers for nine drugs.
Features O, C, and Imp are used in the best classifiers for eight drugs. Features N and A are used in the
best classifiers for six drugs. Thus, personality factors are associated with drug use and each one impacts on
specific drugs. Finally, Edu is used in the best classifiers for five drugs (see Table 3.24).
To predict the usage of most drugs DT is the best classifier (see Table 3.24). LDA is the best classifier
for alcohol use with five input features, and has sensitivity 75.34% and specificity 63.24%. kNN is the best
classifier for chocolate and caffeine users. These kNN classifiers use four features for chocolate and five
features for caffeine.
The drugs can be separated into disjoint groups by the number of attributes used for the best classifiers:
• The group of classifiers with two input features contains classifiers for two drugs: crack and magic
mushrooms. Both classifiers for this group use the E score.
• The group of classifiers with three input features includes classifiers for two drugs: ecstasy and heroin.
Both classifiers in this group use Age and Gndr and do not use any NEO-FFI factors.
• The group of classifiers with four input features includes classifiers for three drugs: amyl nitrite, chocolate,
and nicotine. All classifiers for this group use the C score.
66 3 Results of data analysis
Fig. 3.12 Conditional distribution for Gndr and nicotine
• The group of classifiers with five input features includes classifiers for five drugs: alcohol, cocaine, caffeine,
ketamine, and methadone. All classifiers for this group use Age.
• The group of classifiers with six input features includes classifiers for six drug users: amphetamines,
benzodiazepines, cannabis, legal highs, LSD, and VSA. All classifiers for this group use Age.
It is important to stress that the attributes which are not used in the best classifiers are not non-informative.
For example, for ecstasy consumption the best classifier is based on Age, SS, and Gndr and has sensitivity
76.17% and specificity 77.16%. There exists a DT for usage of the same drug based on Age, Edu, O, C, and
SS, with sensitivity 77.23% and specificity 75.22%; a DT based on Age, Edu, E, O, and A, with sensitivity
73.24% and specificity 78.22%; a LR classifier based on Age, Edu, O, C, Imp, SS, and Gndr, with sensitivity
74.83% and specificity 74.52%; a kNN classifier based on Age, Edu, N, E, O, C, Imp, SS, and Gndr, with
sensitivity 75.63% and specificity 75.75%. This means that for the risk evaluation of ecstasy usage all input
attributes are informative but the required information can be extracted from a smaller subset of the attributes.
The results presented in Table 3.24 were calculated by LOOCV. It should be stressed that different methods
of testing give rise to different values for sensitivity and specificity. Common methods include calculation of
test set errors (the holdout method), k-fold cross-validation, testing on the entire sample (if it is sufficiently
large, the so-called ‘naı¨ve’ method), random sampling, and many others. For example, a DT formed for the
entire sample can have a sensitivity and specificity different from LOOCV [15]. For illustration, consider the
DT for ecstasy, depicted in Fig. 3.13. It has sensitivity 78.56% and specificity 71.16%, calculated using the
whole sample. The results of LOOCV for a tree with the same choices are given in Table 3.24: sensitivity
76.17% and specificity 77.16%.
The role of SS is very important for most of the party drugs. In particular, the risk of ecstasy consumption
can be evaluated with high accuracy on the basis of Age, Gndr and SS (see Table 3.24, Fig. 3.13, and 3.27),
and does not need the personality traits from the FFM.
3.9 Correlation pleiades of drugs
Consider correlations between drug usage for the year- and decade-based definitions (Fig. 3.7). It can be seen
from Fig. 3.7 that the structure of these correlations for the year- and decade-based definitions of drug users is
approximately the same. We have found three groups of strongly correlated drugs, each containing several
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Fig. 3.13 Decision tree for ecstasy. Input features are: Age, SS, and Gndr. Non-terminal nodes are depicted with dashed border.
Values of Age, SS, and Gndr are calculated by quantification procedures described in Section 2.2.2. The weight of each case of
users class is 1.15 and of non-users class is 1. In column ‘Weighted’ normalizing weights are presented (the weight of each class
is divided by sum of weights)
drugs which are pairwise strongly correlated. This means that drug consumption has a ‘modular structure’,
and we have identified three modules:
• Crack, cocaine, methadone, and heroin;
• Amphetamines, cannabis, cocaine, ketamine, LSD, magic mushrooms, legal highs, and ecstasy;
• Methadone, amphetamines, cocaine and benzodiazepines.
This modular structure has a clear representation in the correlation graph, Fig. 3.7.
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The idea of merging correlated attributes into ‘modules’ is popular in biology These modules are called
correlation pleiades [16–18]. This concept was introduced in biostatistics in 1931 [16]. Correlation pleiades
were used in evolutionary physiology for the identification of modular structures in a variety of contexts [16–
19]. Berg [18] presented correlation data from three unspecialized and three specialized pollination species,
and proposed that correlation pleiades are clusters of correlated traits. This means that, in the standard
approach to clustering, the pleiades do not intersect. The classical clustering methods are referred to as ‘hard’
or ‘crisp’ clustering, meaning that each data object is assigned to only one cluster. This restriction is relaxed
for fuzzy [20] and probabilistic clustering [21]. Such approaches are useful when the clusters are not well
separated.
In our study, correlation pleiades are appropriate since the drugs can be grouped in clusters with highly
correlated use (see Fig. 3.7a and b):
• The Heroin pleiad (heroinPl) includes crack, cocaine, methadone, and heroin;
• The Ecstasy pleiad (ecstasyPl) includes amphetamines, cannabis, cocaine, ketamine, LSD, magic mush-
rooms, legal highs, and ecstasy;
• The Benzodiazepines pleiad (benzoPl) includes methadone, amphetamines, cocaine, and benzodiazepines.
These correlation pleiades include 12 drugs (Fig. 3.14). Additionally, we can consider the ‘smoking
couple’, the highly correlated pair cannabis–nicotine. Other drugs do not have strong symmetric correlations.
There exists an asymmetric correlation link from ecstasy to amyl nitrite (Fig. 3.8). Therefore, amyl nitrite can
be considered as a peripheral element of the ecstasy pleiad.
Fig. 3.14 Correlation pleiades for drug use (in a circle, in a triangle and in a rectangle). Additionally, a highly correlated
‘smoking couple’, cannabis and nicotine, is separated by an ellipse. E stands for ecstasy, H for heroin, B for benzodiazepines, and
MM for magic mushrooms. Other drugs are denoted by the first two letters of their names. Edges represent correlations
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Fuzzy and probabilistic clustering may help to reveal more sophisticated relationships between objects
and clusters. For example, analysis of the intersections between correlation pleiades of drugs can generate
important questions and hypotheses:
• Which patterns of behaviour are reflected by the existence of pleiades? (For example, is the ecstasyPl just
the group of party drugs united by habits of use?)
• Why is cocaine a peripheral member of all pleiades?
• Why does methadone belong to the periphery of both the heroin and benzodiazepines pleiades?
• Why do amphetamines belong to the periphery of both the ecstasy and benzodiazepines pleiades?
• Do these intersections reflect the structure of individual drug consumption or the structure of the groups of
drug consumers?
We have defined groups of users and non-users for each pleiad. A group of users for a pleiad includes the
users of any individual drug from the pleiad (see Table 3.25). A group of non-users contains all participants
which are not included in the group of users. Table 3.25 shows the total number of users and their percentages
in the database for three pleiades and for each user definition of (the decade-, year-, month-, or week-based
user/non-user separation).
The class imbalance problem is well known [15]. Users form a small fraction of the dataset (significantly
less than half) for most drugs (see Table 1.4). The classes of users and non-users are more balanced for
pleiades of drugs than for individual drugs (compare Tables 3.25 and 1.4). Table 3.25 shows that the number
of drug users in the database for all three pleiades are more balanced (closer to 50%) than the number of users
of the corresponding individual drug (Table 1.4). For example, for the year-based classification problem the
number of benzoPl users is 830 (44.03%), while the number of benzodiazepine users is 535 (28.38%) and the
number of heroinPl users is 585 (31.03%), while the number of heroin users is 118 (6.26%).
Table 3.25 Number of drug users for pleiades in the database
Pleiad User definition based on
Decade Year Month Week
HeroinPl 832 (44.14%) 585 (31.03%) 309 (16.39%) 184 (9.76%)
EcstasyPl 1317 (69.87%) 1089 (57.77%) 921 (48.86%) 792 (42.02%)
BenzoPl 1089 (57.77%) 830 (44.03%) 528 (28.01%) 363 (19.26%)
The introduction of moderate subcategories of T-scoresample for pleiades of drugs enables us to separate
the pleiades of drugs into two groups for the decade-, month-, and week-based user/non-user separation. For
year-based user/non-user separation there is only one group with profile (+,0,+,−,−), and includes the
users of heroinPl, ecstasyPl and benzoPl.
For the decade-based classification problem, the group with the profile (+,0,+,−,−) includes the users
of heroinPl and benzoPl. The group with the profile (0,0,+,−,−) includes the users of EcstasyPl.
For the month- and week-based classification problem, the group with the profile (+,−,+,−,−) includes
the users of heroinPl and benzoPl. The group with the profile (0,0,+,−,−) includes the users of EcstasyPl.
The personality profiles for pleiades of drugs are qualitatively similar but some differences should be
mentioned: the N level for EcstasyPl users is lower than for HeroinPl users, whereas levels of E and A are
higher for EcstasyPl users (see Fig. 3.15).
We have applied the eight methods described in Section ‘Risk evaluation methods’ and selected the best
one for each pleiad for the decade-, year-, month-, and week-based classification problems. The results of
classifier selection are depicted in Table 3.27. The quality of classification is high.
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Table 3.26 Statistically significant differences of means for groups of users and non-users for each pleiad for decade- year-,
month-, and week-based classification problem. The symbol ‘⇓ ’corresponds to a significant difference where the mean in the
users group is less than the mean in the non-users group, and the symbol ‘⇑’ corresponds to a significant difference where the
mean in the users group is greater than the mean in the non-users group. Empty cells corresponds to insignificant differences.
The difference is considered to be significant if the p-value is less than 0.01)
Pleiades od drugs N E O A C
The decade-based user/non-user separation
HeroinPl, EcstasyPl, BenzoPl ⇑ ⇑ ⇓ ⇓
The year-based user/non-user separation
HeroinPl, EcstasyPl, BenzoPl ⇑ ⇑ ⇓ ⇓
The month-based user/non-user separation
HeroinPl, EcstasyPl ⇑ ⇑ ⇓ ⇓
BenzoPl ⇑ ⇓ ⇑ ⇓ ⇓
The week-based user/non-user separation
HeroinPl, BenzoPl ⇑ ⇓ ⇑ ⇓ ⇓
EcstasyPl ⇑ ⇑ ⇓ ⇓
The classification results are excellent for each pleiad for the decade-, year-, month, and week-based
problems. We can compare the classifiers for one pleiad and for different problems (see Table 3.27). For
example:
• The best classifier for ecstasyPl for the year-based user/non-user separation is a DT with seven attributes
and has sensitivity 80.65% and specificity 80.72%;
• The best classifier for heroinPl for the month-based user/non-user separation is a DT with five attributes
and has sensitivity 74.18% and specificity 74.11%;
• The best classifier for benzoPl for the week-based user/non-user separation is a DT with five attributes and
has sensitivity 75.10% and specificity 75.76%.
Table 3.27 The best results for classifiers of the pleiad users. Symbol ‘X’ means input feature used in the best classifier.
Sensitivity (Sn) and Specificity (Sp) were calculated by LOOCV.
Pleiades Classifier Age Edu N E O A C Imp SS Gndr # Sn Sp Sum
of drugs (%) (%) (%)
The decade-based user/non-user separation
HeroinPl DT X X X X 4 71.23 78.85 150.07
EcstasyPl DT X X X X X X 6 80.63 79.80 160.44
BenzoPl DT X X X X X 5 73.37 72.45 145.82
The year-based user/non user-separation
HeroinPl DT X X X X 4 73.69 71.80 145.49
EcstasyPl DT X X X X X X X 7 80.65 80.72 161.37
BenzoPl DT X X X X 4 73.93 73.98 147.91
The month-based user/non user-separation
HeroinPl DT X X X X X 5 74.18 74.11 148.29
EcstasyPl PDFE X X X X X X X X 8 79.34 79.50 158.83
BenzoPl DT X X X X 4 73.18 73.11 146.28
The week-based user/non user-separation
HeroinPl DT X X X X X X X X 8 75.84 73.91 149.75
EcstasyPl LR X X X X X X X X 8 77.68 77.78 155.45
BenzoPl DT X X X X X 5 75.10 75.76 150.86
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Fig. 3.15 Average personality profiles for drug pleiades for the month- and week-based user/non-user separation (T-scoresample
with respect to the sample means)
Comparison of Tables 3.24 and 3.27 shows that the best classifiers for the ecstasy and benzodiazepines
pleiades are more accurate than the best classifiers for the consumption of the ‘central’ drugs of the pleiades,
ecstasy and benzodiazepines respectively, even for the decade-based user definition. Classifiers for heroinPl
may have slightly worse accuracy but these classifiers are more robust because they solve classification
problems which have more balanced classes. All other classifiers for pleiades of drugs are more robust too for
the same reasons, for all pleiades and definitions of users.
Tables 3.24 and 3.27 for the decade-based user definition show that most of the classifiers for pleiades use
more input features than the classifiers for individual drugs. We can see from these tables that the accuracies
of the classifiers for pleiades and for individual drugs do not differ drastically, but the use of a greater number
of input features suggests more robust classifiers.
It is important to remark that pleiades are usually assumed to be disjoint. We have considered pleiades
which are named by the central drug and the peripheral drugs can be shared. For example, the heroin and
ecstasy pleiades have cocaine as an intersection. This approach corresponds to the concept of ‘soft clustering’.
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3.10 Overoptimism problem
The best machine learning methods selected give impressive solutions for the user/non-user classification
problems. Nevertheless, the procedure of selection has used the same data as the training process: we have
tested each method by LOOCV. Such an approach could produce so-called overoptimism: the cross-validation
errors of the best method on the same set, which was used for the method selection, may be underestimated.
To demonstrate that the data of Tables 3.24 and 3.27 are valid for generalisation errors and samples we have
never seen before, we may need additional validation on a large hold out sample, which was not compromised
by its usage in the method selection. We do not have an additional large sample and splitting the existing
sample into a training set (for training and cross-validation in method selection) and a validation set (for
validation of the best method) will decrease the statistic power of analysis [22].
Following [24], high performance on the test sample does not guarantee high performance on future
samples, things do change and there is always a chance that a variable and its relationships will be different in
future samples. Selection of the best models and best sets of ‘dominant variables’ can damage robustness of
the model to future variations.
The idea of stability of the model can significantly help in the testiong of classifiers [23]. In the process of
cross-validation we can test additionally stability of the model and answer the questions:
• How many examples change their class in cross-validation (we can calculate the number for each transition
between classes: class A→ class B, etc.). This is classification stability.
• How many qualitatively different models (for example, decision trees with different structure) were
generated in cross-validation. This is structural stability.
We can also extract the set of examples with unstable classification and study this set separately.
Hand [25] clearly demonstrated that ‘simple methods typically yield performance almost as good as more
sophisticated methods, to the extent that the difference in performance may be swamped by other sources of
uncertainty that generally are not considered in the classical supervised classification paradigm.’
Therefore, let us consider the results of the best methods (Tables 3.24 and 3.27) as an upper border of the
possible classifier performance and apply the simple linear discriminant method. This method is robust and
leaves no space for overoptimism if the samples are sufficiently large and there is no multicollinearity. We
have also analysed the classification stability of the linear discriminant in cross-validation.
Multicollinearity means strong linear dependence between input attributes. This makes the model very
sensitive to fluctuations in data is an important source of instability of classifiers. The standard measure of
multicollinearity is the condition number of the correlation matrix, that is the ratio κ = λmax/λmin, where λmax
and λmin are the maximal and the minimal eigenvalues of this matrix. Collinearity with κ < 10 is considerated
as ‘modest’ collinearity [26].
Eigenvalues of the correlation matrix between the seven psychological traits are:
λi = 2.267,1.809,0.887,0.678,0.548,0.468,0.342; κ = λmax/λmin = 6.628.
Eigenvalues of the correlation matrix between the ten attributes (quantified) including the seven psychological
traits, Age, Edu and Gndr are:
λi = 2.595,1.867,1.111,0.980,0.814,0.757,0.599,0.524,0.427,0.327; κ = λmax/λmin = 7.945.
We can see that there is no strong multicollinearity despite the existence of significant and not small
correlations between psychological traits (see Tables 3.9 and 3.10). Three correlation coefficients, between
the N and E scores, between the O and SS scores and between the Imp and SS scores exceed 0.4 in
3.11 User/non-user classification by linear discriminant for ecstasy and heroin 73
absolute value. Absolute values of correlation coefficients above 0.4 are sometimes interpreted as indicating
a multicollinearity problem. This heuristic rule is not rigorous but existence of such correlations rises a
suspicion of multicollinearity and it is necessary to apply a stronger test. We have calculated the condition
number and it is sufficiently low to exclude strong multicollinearity. In the next section we have demonstrated
that Fisher’s linear discriminant is sufficiently robust and works stably for these values of κ in our database.
3.11 User/non-user classification by linear discriminant for ecstasy and heroin
Fisher [4] defined the linear discriminant (LD) as a linear function of attributes, for which the ratio of the
difference between classes to the standard deviation within classes is maximal (see, for example, the score
2.9). We have used the classical formula for the LD direction (2.10). The selection threshold (intercept)Θ is
defined by the balance condition Sn=Sp.
Linear discriminants separate users from non-users by linear inequalities:
D(z) =Θ +∑cizi > 0 (3.2)
for users and ≤ 0 for non-users, whereΘ are the thresholds (intercepts), zi are the attributes, and ci are the
coefficients.
Tables A.5-A.8 in the Appendix contain the coefficients ci of the linear discriminants for user/nonuser
separation in 10-dimensional space (7 psychological attributes, Age, Edu, and Gndr). The attributes in these
tables are quantified and transformed to z-scores with zero mean and unit variance (positive values of the Gndr
z-score corresponds to female). The last rows of the tables include the standard deviation of the coefficients
in LOOCV. For the 7-dimensional space of psychological attributes (T-scores), the coefficients of linear
discriminants are presented in Tables A.13-A.16.
Performance of linear discriminants in user/non-user separation is evaluated by several methods (Tables
A.9–A.12 for the 10-dimensional data space and Tables A.17–A.20 for the 7-dimensional space of T-scores of
psychological attributes). First of all, we have calculated the linear discriminant using the whole sample (see
Tables A.5–A.8) and find all of their errors. For each solution of the classification problem we have several
numbers, P (positive), the number of samples recognised as positive, and N (negative), the number of samples
recognised as negative. P+N is the total number of samples. P=TP+FP (True Positive plus False Positive)
and N=TN+FN (True Negative plus False Negative). Sensitivity is Sn=TP/(TP+FN)×100% and Specificity is
Sp=TN/(TN+FP)×100%. Accuracy is Acc=(TP+TN)/(P+N)×100%.
We have calculated these performance indicators for the total sample and for the LOOCV procedure.
In LOOCV the linear discriminant is calculated for the set of all samples excluding the example left out
for testing. The test was performed for all samples with the corresponding redefining of Sn, Sp, and Acc.
In LOOCV the linear discriminants are calculated for each test example. Each of these discriminants is a
separate classification model. Stability of classification can be measured by the number of examples which
change their class at least once. We have taken the basis model for the total sample and found how many TP
examples of this model became FN examples of a LOOCV model at least once. This number measured in %
of TP+FP of the basic model is TP→FN. Analogously, we have defined FP→TN, TN→FP, and FN→TP. The
last two numbers are measured in % of TN+FN of the basic model.
In this section we have analysed performance of linear discriminants for two drugs, ecstasy and heroin.
They are typical (and central) elements of two pleiades, groups of drugs with correlated drug usage. The
differences between them might tell us a story about different types of drug users.
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Table 3.28 Coefficients of the linear discriminant for the ecstasy user/non-user separation and decade-, year-, month-, and
week-based definition of users (10 attributes)
Period Θ Age Edu N E O A C Imp SS Gndr
Decade -0.171 -0.631 -0.188 0.053 0.018 0.351 -0.065 -0.210 -0.088 0.559 -0.265
Year -0.464 -0.782 -0.101 -0.015 0.099 0.238 -0.025 -0.173 -0.004 0.453 -0.275
Month -0.633 -0.820 0.047 -0.139 0.093 0.284 -0.123 -0.165 -0.028 0.328 -0.257
Week -0.779 -0.697 0.077 -0.115 0.161 0.545 -0.093 -0.252 0.217 0.230 -0.022
SD ≤ 0.018 ≤ 0.002 ≤ 0.003 ≤ 0.004 ≤ 0.004 ≤ 0.003 ≤ 0.003 ≤ 0.003 ≤ 0.004 ≤ 0.005 ≤ 0.003
Table 3.29 Performance and stability of the linear discriminant for the ecstasy user/non-user separation and decade-, year-,
month-, and week-based definition of users (10 attributes). All indicators are in %.
Total sample LOOCV Stability indicators
Period Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Decade 74.4 74.7 74.6 74.2 74.3 74.2 0.3 0.7 0.5 0.4
Year 75.4 75.7 75.6 75.0 75.6 75.4 0.2 0.6 0.8 0.3
Month 72.5 72.4 72.4 71.3 72.3 72.1 1.7 1.3 1.2 1.2
Week 72.6 71.5 71.5 67.9 71.4 71.2 3.6 8.3 2.4 5.3
Table 3.30 Coefficients of the linear discriminant for the heroin user/non-user separation and decade-, year-, month-, and
week-based definition of users (10 attributes)
Period Θ Age Edu N E O A C Imp SS Gndr
Decade -0.615 -0.210 -0.370 0.413 -0.211 0.477 -0.265 -0.029 0.222 0.381 -0.332
Year -0.849 -0.584 -0.168 0.352 -0.252 0.222 -0.275 0.014 0.216 0.359 -0.378
Month -1.037 -0.560 -0.371 0.181 -0.350 0.159 -0.397 0.016 0.368 0.154 -0.226
Week -1.096 -0.386 -0.077 0.467 -0.255 0.184 -0.412 0.013 0.437 -0.077 -0.400
SD ≤ 0.005 ≤ 0.004 ≤ 0.004 ≤ 0.004 ≤ 0.004 ≤ 0.004 ≤ 0.004 ≤ 0.004 ≤ 0.005 ≤ 0.006 ≤ 0.003
Table 3.31 Performance and stability of the linear discriminant for the heroin user/non-user separation and decade-, year-,
month-, and week-based definition of users (10 attributes). All indicators are in %.
Total sample LOOCV Stability indicators
Period Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Decade 70.8 69.9 70.0 68.4 69.8 69.7 2.8 6.1 1.3 2.2
Year 73.7 73.7 73.7 70.3 73.6 73.4 2.5 2.5 2.1 2.3
Month 79.2 77.6 77.7 69.8 77.5 77.2 9.4 7.5 3.2 3.8
Week 79.3 80.1 80.1 65.5 80.0 79.8 6.9 6.9 4.6 4.8
Coefficients of LD can be used for indication of how a change in an attribute value will affect the value
of D(z) under the condition that the values of all other attributes do not change. It is possible to change one
attribute without changing other attributes because there is no strong multicollinearity. The most interesting
in this ranking for the Tables 3.28 and 3.30 is the essential difference between ranking for ecstasy and for
heroin user/non-user discriminants.
Comparison of Tables 3.28 and 3.30 immediately gives a result. The coefficients of LD for ecstasy and
heroin have significant differences: for ecstasy, the effect of Imp is less than for heroin (and can even have
different sign), whereas the effect of SS is bigger for ecstasy. For ecstasy, the coefficients of A have smaller
values than the coefficients of C. For heroin the situation is opposite: C has much smaller coefficient than A
(and can even have the opposite sign). Also, coefficients of N for ecstasy are smaller than for heroin and can
have different sign. Edu has negative coefficients for heroin with bigger values (it ‘prevents’ usage of heroin),
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whereas for ecstasy the influence of Edu is smaller and can have opposite signs (for week- and month-based
definition of usage). Coefficients of E are positive for the ecstasy user/non-user separation and negative for the
heroin user/non-user separation. Age has large negative coefficients both for ecstasy and heroin but for ecstasy
they are 1.5–2 times bigger. For example, for the month-based definition of users the ranking of variables is:
• For ecstasy: Age⇓ , SS⇑, O⇑, Gndr⇓ , C⇓, N⇓, A⇓, E⇑, Edu⇑, Imp⇓;
• For heroin: Age⇓, A⇓, Edu⇓, Imp⇑, E⇓, Gndr⇓ , N⇑, O⇑, SS⇑, C⇑.
The arrows ⇑ ⇓ here indicates the sign of the effect of the attribute in the user/non-user separation (and not the
shift of the mean as it was in previous sections): for positive coefficients it is ⇑ and for negative coefficients it
is ⇓. The difference between heroin and ecstasy discriminants is impressive. The most important five attributes
for ecstasy user/non-user discrimination have only one attribute in common with the top five attributes of
heroin user/non-user discrimination (Age). We invite the reader to pay attention to the different signs of
coefficients of some of the attributes for the ecstasy and heroin linear user/non-user discrimination in this case:
C, N, E, and Imp. For most of these attributes, the traditional expectation is well-known: C⇓, N⇑, Imp⇑ (at
least, for illegal drugs). The values of the coefficients with unexpected signs are relatively small, the attributes
with these values are ranked as less important, but the expectation is not met in any case: we can state that it
is a wrong assumption that high N and Imp are predictors for ecstasy use, and it is also wrong that low C is a
predictor for heroin use.
If we do not use Age, Edu, and Gndr, then the difference of the predictors persists (Tables 3.32 and 3.33):
for ecstasy LD the most important attribute becomes SS, then O and C. The attributes Imp, A, N, and E have
smaller coefficients, and for Imp, E, and N the sign of the coefficients depends on recency of usage. For
heroin C seems to be less important than other attributes.
The ranking of these seven psychological attributes for the same month-based user/non-user discrimination
looks similar:
• For ecstasy: SS⇑, O⇑, C⇓, N⇓, A⇓, Imp⇓, E⇑;
• For heroin: SS⇑, A⇓ , E⇓ , Imp⇑, N⇑, O⇑, C⇓ .
The reader should note the opposite signs of N, E, and Imp for the ecstasy and heroin user/non-user
discriminants in this case. The only big jump from the 10-attribute ranking is the change of rank of SS for
heroin user/non-user discrimination. We believe that this is because of large negative correlations between SS
and Age, which is important for classification but not available in the seven-attribute model. Again, the upper
four variables for ecstasy user/non-user discrimination have only one attribute in common with the top four
attributes of heroin user/non-user discrimination (SS).
Table 3.32 Coefficients of the linear discriminant for ecstasy user/non-user separation, for the decade-, year-, month-, and
week-based definition of users (7 attributes).
Period Θ N E O A C Imp SS
Decade -35.896 0.045 -0.017 0.407 -0.085 -0.342 -0.156 0.827
Year -42.579 -0.019 0.078 0.373 -0.045 -0.356 -0.096 0.846
Month -27.572 -0.169 0.101 0.462 -0.191 -0.354 -0.139 0.752
Week -60.127 -0.095 0.168 0.695 -0.128 -0.355 0.242 0.528
SD ≤ 0.565 ≤ 0.004 ≤ 0.005 ≤ 0.004 ≤ 0.004 ≤ 0.004 ≤ 0.005 ≤ 0.006
Employment of simple LDA demonstrates that users of ecstasy and heroin differ significantly, and users of
different groups of drugs should be studied separately. The hypothesis that drug usage is associated with N⇑,
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Table 3.33 Coefficients of the linear discriminant for heroin user/non-user separation, for the decade-, year-, month-, and
week-based definition of users (7 attributes).
Period Θ N E O A C Imp SS
Decade -55.851 0.381 -0.283 0.526 -0.322 -0.124 0.249 0.563
Year -44.733 0.361 -0.327 0.368 -0.397 -0.108 0.218 0.641
Month -30.020 0.302 -0.409 0.232 -0.499 -0.107 0.345 0.555
Week -37.099 0.548 -0.325 0.265 -0.547 -0.069 0.389 0.261
SD ≤ 0.523 ≤ 0.004 ≤ 0.004 ≤ 0.005 ≤ 0.004 ≤ 0.005 ≤ 0.006 ≤ 0.007
A⇓, and C⇓ seems plausible at first glance, but appears to be an oversimplification. Such an analysis, and an
even more detailed consideration using all definitions of drug use, is possible for every pair of drugs (and
for four groups of drugs) on the basis of the linear discriminant coefficients presented in Tables A.5-A.8 and
A.13-A.16.
The difference between linear discriminant directions can be evaluated by measuring the angles between
them. For each drug, we calculate the angles between linear discriminant directions for all definition of users
and the direction for the decade-based definition of users. These angles are significantly smaller than the
angles between the linear discriminant directions for the same recency of use and different drugs (Fig. 3.16).
Fig. 3.16 Angles between directions of linear discriminants for user/non-user classification for ecstasy and heroin. Two types
of angles are presented: between the discriminant directions for all periods and the discriminant vector for the decade-based
definitions of users for both drugs, and angles between directions of linear discriminants for ecstasy and heroin (and the same
periods). For convenience, both cosines of angles (a, b) and angles in degrees (c, d) are presented
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3.12 Separation of heroin users from ecstasy users: what is the difference?
In this section we continue the story about the differences between heroin and ecstasy use. The first simple
question is: what is the intersections between the sets of users of these drugs? The answer is illustrated by
Fig. 3.17. It is obvious from the figure that for recent users the proportion of simultaneous use of heroin
and ecstasy is smaller. We hypothesize that people who used drugs more than a month or year ago, but not
recently, just tried various drugs, whereas recent users prefer more specific drugs. Fig. 3.17 is an argument in
favour of this hypothesis.
Fig. 3.17 Venn diagrams of relations between ecstasy and heroin use for decade-, year-, month-, and week-based definitions of
users
For each recency of use, there are six important sets: users of ecstasy, users of heroin, users of ecstasy OR
heroin (the union), users of ecstasy AND heroin (the intersection), users of ecstasy NOT heroin (users of
ecstasy only, the difference: users of ecstasy \ users of heroin), and users of heroin NOT ecstasy (users of
heroin only, the difference: users of heroin \ users of ecstasy).
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The intersection of heroin and ecstasy users is sometimes large, so the discrimination task is a non-standard
classification. At least, the standard TPR (Sn) and TNR (Sp) do not make much sense. Let us consider a
binary classification rule which separates all users of ecstasy OR heroin into two classes: E and H. We will
consider an example from the set of users of heroin OR ecstasy to be FE (‘false ecstasy’) if it is a non-user of
ecstasy classified as a user of ecstasy (or, which is the same, a user of heroin but NOT ecstasy classified as
a user of ecstasy). Analogously, an example is considered as FH (‘false heroin’) if it is non-user of heroin
classified as a user of heroin. In the Tables 3.34 we use an unusual measures of classification accuracy: True
Ecstasy Rate (TER) (correctly recognised fraction of users of ecstasy NOT heroin) and True Heroin Rate
(THR) (correctly recognised fraction of users of heroin NOT ecstasy). We do not identify the case when a
user of both drugs is recognised as a user of one them as an error:
TER =
# correctly recognised users of ecstasy NOT heroin
# users of ecstasy NOT heroin
;
THR =
# correctly recognised users of heroin NOT ecstasy
# users of heroin NOT ecstasy
.
The descriptive statistics for seven traits (FFM, Imp, and SS) are presented in Table 3.34 (compare to Table
3.1). We can see that for ecstasy – heroin discrimination the best classifier with one attribute is N. Moreover,
differences between means of ecstasy users and heroin users are statistically significant with confidence level
99% for N and A, for all definitions of users, for Imp for decade-based and month-based definitions, and for
E for all definitions excluding the decade-based one. This difference is obvious in the graphs of mean values
of N, E, A, and Imp for ecstasy and heroin users shown in Fig. 3.19.
We have employed LDA for separation of ecstasy users from heroin users. We have applied the formula
(2.10) for the linear discriminant direction with covariance matrices for ecstasy users and heroin users
calculated for the month-based definition of users. The intercept Θ was calculated for the most balanced
separation measured by TER and THR.
The ranking of attributes for the month-based ecstasy users / heroin users separation, based on the size of
the coefficients of the linear discriminant, is:
N, E, A, Imp, SS, C, O (7 attributes).
It is important to note that the values of the coefficients of N, E, A, and Imp do not differ much and for SS, C,
and O the coefficients are much smaller.
For 10 attributes the ranking by the linear discriminant coefficients is:
Edu, Imp, A, N, E, C, Gndr, SS, O, Age.
Again, for the leading group of attributes, Edu, Imp, A, N, and E, the coefficients decay slowly, and for the
other attributes are much smaller. These observations, together with analysis of attribute means (Fig. 3.19),
convinces us that the main and statistically significant differences between ecstasy users and heroin users are
in Edu, Imp, A, N, and E.
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Table 3.34 Means and standard deviations for users of ecstasy, users of heroin, and users of ecstasy OR heroin (E OR H users).
The dimensionless z-score (2.9) for separation of ecstasy users from heroin users is given as well as P = φ(z) (%), TER (%), and
THR (%). The H-E p-value is the probability of observing by chance the same or greater difference.
Factors Ecstasy users Heroin users E OR H users H-E One feature classifier
Mean SD Mean SD Mean SD p-value z P Θ TER THR
Decade-based user definition
N 25.06 9.20 28.06 8.89 25.26 9.23 < 0.001 0.154 56 27 65 61
E 27.91 7.12 26.48 7.37 27.76 7.14 0.012 0.088 54 27 57 60
O 36.14 6.02 36.55 5.86 36.07 6.02 0.366 0.041 52 35 55 55
A 29.88 6.61 27.98 7.28 29.77 6.67 0.001 0.128 55 28 62 58
C 27.50 6.87 26.52 7.00 27.45 6.87 0.071 0.067 53 27 53 55
Imp 4.45 2.06 5.02 2.06 4.44 2.06 < 0.001 0.139 56 4 48 58
SS 6.90 2.23 7.18 2.34 6.86 2.26 0.117 0.070 53 6 59 50
Year-based user definition
N 24.57 9.46 28.83 8.76 25.02 9.47 < 0.001 0.209 58 27 64 62
E 28.60 7.12 26.01 7.46 28.20 7.29 0.001 0.148 56 27 62 66
O 36.46 6.00 36.03 5.97 36.46 5.98 0.483 0.035 51 36 54 53
A 29.93 6.74 27.25 7.49 29.68 6.86 < 0.001 0.170 57 28 61 57
C 27.36 6.88 26.27 7.38 27.26 6.91 0.145 0.069 53 26 54 55
Imp 4.59 2.04 5.08 2.01 4.62 2.05 0.020 0.113 54 4 55 51
SS 7.14 2.15 7.29 2.36 7.15 2.18 0.525 0.031 51 7 55 50
Month-based user definition
N 23.50 9.73 30.04 8.76 24.32 9.80 < 0.001 0.308 62 27 68 66
E 29.09 7.53 24.58 8.65 28.43 7.89 0.001 0.233 59 27 64 65
O 36.66 6.12 35.40 6.82 36.55 6.14 0.217 0.089 54 36 55 54
A 29.64 6.82 25.83 7.42 29.27 6.81 0.001 0.242 60 28 59 57
C 27.54 7.20 24.81 7.60 27.19 7.31 0.020 0.159 56 26 58 59
Imp 4.53 2.07 5.30 1.89 4.63 2.07 0.010 0.170 57 4 65 52
SS 7.08 2.14 7.53 2.31 7.12 2.18 0.198 0.092 54 7 59 52
Week-based user definition
N 24.18 9.66 31.83 6.76 26.12 9.67 < 0.001 0.348 64 28 67 68
E 29.86 8.29 24.03 8.84 28.25 8.81 0.003 0.239 59 25 73 70
O 37.81 6.06 35.34 7.62 37.12 6.55 0.122 0.125 55 36 55 59
A 29.94 6.48 25.38 5.46 28.81 6.57 0.001 0.285 61 27 62 59
C 27.33 7.07 24.59 7.49 26.57 7.22 0.091 0.135 55 25 59 56
Imp 5.01 2.17 5.24 1.79 5.06 2.06 0.576 0.046 52 5 46 56
SS 7.33 2.19 7.28 2.45 7.30 2.25 0.911 0.005 50 7 57 48
Table 3.35 Coefficients of the linear discriminant for separation of ecstasy users from heroin users for the month-based definition
of users (7 attributes). TER=70.5% THR=73.0% (the sample of ecstasy AND heroin users); TER=69.6% THR=62.2% (LOOCV).
Θ N E O A C Imp SS
Coefficients 29.896 -0.541 0.476 -0.050 0.469 -0.136 -0.441 -0.214
SD of coefficients 1.331 0.012 0.010 0.013 0.008 0.011 0.015 0.018
Table 3.36 Coefficients of the linear discriminant for separation of ecstasy users from heroin users for the month-based
definition of users (10 attributes). TER=75.0% THR=73.0% (the sample of ecstasy AND heroin users); TER=71.6% THR=64.9%
(LOOCV).
Θ Age Edu N E O A C Imp SS Gndr
Coefficients 0.915 0.011 0.534 -0.401 0.379 -0.039 0.411 -0.176 -0.417 -0.092 0.166
SD of coefficients 0.023 0.015 0.010 0.011 0.010 0.010 0.008 0.009 0.012 0.014 0.011
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Fig. 3.18 Distribution of ecstasy (NOT heroin) users, heroin (NOT ecstasy) users, and heroin AND ecstasy users in various age
and education groups
3.13 Significant difference between benzodiazepines, ecstasy, and heroin
Analysis of differences between various groups of drug users can be extended to all pairs of drugs. Let us
add for investigation the centre of third pleiad, benzodiazepines. The relations between groups of users of
benzodiazepines, ecstasy and heroin is shown in Fig. 3.20.
In Fig. 3.21 the mean values of personality traits N, E, O, A, Imp, SS are given with 95% CI for groups of
benzodiazepines, ecstasy, and heroin users, and different recency of use. (C is not given because the difference
in C between different groups of drug users is insignificant.)
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Fig. 3.19 Mean values with their 95% confidence intervals for significantly different psychological traits of ecstasy and heroin
users: (a) N, (b) E, (c) A, (d) Imp
Table 3.37 p-values of differences of mean values for benzodiazepines (benzos), ecstasy and heroin for all definitions of users.
Factors Benzos and ecstasy Benzos and heroin Ecstasy and heroin
Decade Year Month Week Decade Year Month Week Decade Year Month Week
N 0.003 <0.001 <0.001 <0.001 0.021 0.088 0.322 0.188 <0.001 <0.001 <0.001 <0.001
E 0.007 <0.001 <0.001 <0.001 0.443 0.275 0.189 0.590 0.012 0.001 0.001 0.003
O 0.045 0.058 0.035 0.002 0.024 0.629 0.898 0.921 0.366 0.483 0.217 0.122
A 0.697 0.128 0.141 0.150 0.002 0.007 0.010 0.006 0.001 <0.001 0.001 0.001
C 0.439 0.943 0.412 0.557 0.021 0.135 0.052 0.146 0.071 0.145 0.020 0.091
Imp 0.315 0.520 0.457 0.172 <0.001 0.007 0.028 0.099 <0.001 0.020 0.010 0.576
SS <0.001 0.001 0.081 0.009 <0.001 0.011 0.025 0.139 0.117 0.525 0.198 0.911
We can see from Table 3.37 that mean values in the groups of benzodiazepines and ecstasy users are
statistically significantly different with confidence level 95% for N (higher for benzodiazepines) and E (higher
for ecstasy) for all definition of users, for O (higher for ecstasy) for all definitions of users excluding the
year-based, and for SS (higher for ecstasy) for all definitions excluding the month-based. Benzodiazepines
and heroin are statistically significantly different with confidence level 95% for A for all definition of users,
for Imp (higher for heroin) and SS (higher for heroin) for all definitions of users excluding the week-based.
Heroin and ecstasy are statistically significantly different with confidence level 95% for N (higher for heroin),
E (higher for ecstasy) and A (higher for ecstasy) for all definition of users, and for Imp (higher for heroin) for
all definitions excluding the week-based.
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Fig. 3.20 Venn diagrams of relations between benzodiazepines, ecstasy and heroin use for (a) decade-, (b) year-, (c) month-, and
(d) week-based definitions of users.
3.14 A tree of linear discriminants: no essential improvements
Performance of simple LDA is not much worse than the quality of the best selected classifiers (see Table
3.24). Moreover, straightforward attempts to improve performance by creation of a simple decision tree, or
simple kNN classifiers, fail. In Fig. 3.22 a two-level decision tree with a hierarchy of linear discriminants is
presented. The PCA visualisation demonstrates that after application of the first linear discriminant, there
remains a typical ‘flies-and-mosquito’ mixture without any apparent user – non-user separation in the groups.
(Principal components were recalculated for each node.) Use of kNN classifiers does not give any essential
improvement over LDA either (Table 3.39).
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Fig. 3.21 Mean values with their 95% confidence intervals for significantly different psychological traits of benzodiazepines,
ecstasy and heroin users: (a) N, (b) E, (c) O, (d) A, (e) Imp, and (f) SS.
Table 3.38 The numbers of false positive (FP) and false negative (FN) errors for ecstasy user/non-user decision tree classifiers
(decade-based definition of users) with linear discriminant at each node, and with four different criteria of threshold selection:
Accuracy, Sp+Sn, Balance (Sn=Sp), and Information Gain (IG).
Accuracy Sp+Sn Balanced IG
Level FP FN FP FN FP FN FP FN
1 232 224 330 155 287 192 401 130
2 232 224 330 155 287 192 401 130
3 232 224 210 250 189 287 251 220
4 238 203 268 190 268 179 251 220
5 228 169 218 206 189 240 210 253
6 173 177 203 160 177 171 242 201
7 156 185 121 186 168 173 193 198
Table 3.39 Performance of kNN user/non-user classifiers for ecstasy (decade-based definition of users) for different k and for
the standard Euclidean distance.
k 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Sp (%) 59.7 70.5 65.5 72.0 68.3 65.2 70.5 66.9 71.2 68.9 66.4 70.2 67.5 70.4 68.6
Sn (%) 81.9 72.8 80.2 72.2 78.3 81.5 75.8 78.8 74.7 77.8 80.2 77.5 80.0 76.0 79.5
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Fig. 3.22 A two-level classification tree for ecstasy users and non-users (decade-based definition of users) with linear discriminant
classifiers at the nodes. A data cloud is visualised by projection onto the plane of the two first principal components for the root
and the nodes of the first levels (above nodes). Users are represented by blue (light) circles, non-users by red (dark) circles. The
ROC curves for the linear discriminants at each branching node are below the nodes
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3.15 Visualisation on non-linear PCA canvas
Principal components provide us with a canvas for convenient visualisation of the data distribution (see Fig.
3.22). This works well if the data are distributed near a low-dimensional plane. Manifold learning methods,
using non-linear PCA, generalise this idea to data approximation by smooth non-linear manifolds of small
dimension [27]. These methods allow us to approximate data more successfully, and to find in non-linear
two-dimensional visual data maps effects which can only be captured in higher-dimensional linear principal
components [28].
In a series of works, the metaphor of elastic membrane and plate was used to construct one-, two- and
three-dimensional principal manifold approximations for various data topologies [28]. The error of mean-
squared distance approximation, combined with the elastic energy of the membrane, serves as a functional to
be optimised.
We have generated an elastic map for the whole dataset in the 10-dimensional space of quantified attributes
(Fig. 3.24). Neither three-dimensional PCA view and the elastic map view reveal any significantly non-linear,
non-ellipsoidal peculiarities in data distribution. In Figs. 3.24 – 3.25 the attributes are visualised.
We can see that the attributes Imp, SS, and O generate similar colorings, which are opposite to the coloring
for Age. It should be mentioned that this similarity suggests strong correlations of attributes on the two-
dimensional map but does not imply strong correlations in the higher-dimensional data space. Analogously,
attributes N, A, C, and Edu have similar coloring on the map with N opposite to other three attribute colorings
(Fig. 3.25a-d). The colorings for E and Gndr differ from all others, and are independent on the map (Fig.
3.25e,f). Linear discriminant separation of drug users from non-users is visualised on the elastic map in Fig.
3.26. Of course, on the non-linear canvas the linear discriminant is represented by a curve, not a straight line.
The quality of the linear discriminant separation is visibly high.
3.16 Risk maps
For every set of attributes, we can evaluate the conditional probability density to be a drug user for each value
of the attributes. Visualisation of the conditional density of drug use can be thought of as a risk map [29, 30].
Let us recall that the probability of being a drug user in the data base is higher than in the populations. In
application of the risk maps to real cases, risk evaluation should be renormalised to the population a priori
probability of drug use. These maps can be used without such a renormalisation if we consider, not the
absolute risk, but the relative risk for comparison of different values of attributes.
In Fig. 3.27 we have presented the simplest risk maps produced by the bi-Gaussian approximation of
the probability density: the densities of users and of non-users of a specific drug were approximated by
two-dimensional Gaussian distributions, and then the conditional probability density ρu of drug use has been
evaluated:
ρu =
nuN(µu,Su)
nuN(µu,Su)+nn−uN(µn−u,Sn−u)
,
where nu and nn−u are the number of users and non-users of the drug respectively, Su and Sn−u are the empiric
covariance matrices of the users and non-users respectively, and N(µ,Σ) is the normal distribution with mean
µ and covariance matrix Σ . For the user/non-user separation this approximation corresponds to so-called
quadratic discriminant analysis [31].
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Fig. 3.23 Elastic maps and density visualisation for the database of drug users: (a) Visualisation of the density of the data cloud
on the elastic map presented in the internal coordinates, (b)-(d) Elastic map embedded in the 3-dimensional principal component
space with various points of view. Data points are in black
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Fig. 3.24 Visualisation of various functions on the elastic map (internal coordinates): (a) Age, (b) Imp, (c) SS, (d) O (Age and
attributes apparently correlated with Age on the maps)
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Fig. 3.25 Visualisation of various functions on the elastic map (internal coordinates): (a) N, (b) A, (c) C, (d) Edu, (e) E, (f) Gndr
90 3 Results of data analysis
(a)
Fig. 3.26 Visualisation of linear discriminant classifiers on the non-linear PCA elastic map canvas:( a) Ecstasy, (b) Heroin, (c)
Benzodiazepines, (d) The group of ‘Illicit drugs’. White squares – users, black squares – non-users. Light (red) background –
LDA predicts users, dark (blue) background – LDA predicts non-users
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Fig. 3.27 Simplest examples of risk maps of: ecstasy consumption for female (a) and male (b), heroin consumption for female
(c) and male (d), and benzodiazepines consumption for female (e) and male (f)

Summary
What have all of these data tables told us? We have asked whether or not a psychological predisposition to
drug consumption exists. Now, we can formulate the answer in brief:
• There is a significant difference in the psychological profiles of drug users and non-users.
• The psychological predisposition to using different drugs may be different.
• Machine learning algorithms can solve the user/non-user classification problem for many drugs with im-
pressive sensitivity and specificity. Therefore, the question of predictability of the risk of drug consumption
on the basis of personality traits and simple demographic attributes is answered in the affirmative.
• Simple robust Fisher’s linear discriminants are successfully employed for this classification.
• We describe the groups of drugs which have correlated use (correlation pleiades) and we can collect users
of these groups of drugs together for the purpose of analysis.
• Mean profiles of users of different drugs are different. (This is explicitly proved for benzodiazepines,
ecstasy, and heroin; this is obvious from the attached tables for many more pairs of substances.)
Our study demonstrates strong correlations between personality profiles and the risk of drug use. This
result partially supports observations from the previous research [1–8]. For example, individuals involved in
the use of ‘heavy’ drugs like heroin and methadone are more likely to have higher scores for N, and lower
scores for A and C . In addition, they have significantly higher O, and so the typical profile is N⇑, O⇑, A⇓,
and C⇓. The profile is different for recent users (within the last year) of ‘party drugs’ like ecstasy, LSD, and
amyl nitrite. For them, N is not high, and the typical profile is O⇑, A⇓, and C⇓.
We have analysed, in full detail, the average differences in the groups of drug users and non-users for 18
drugs (Tables 3.12, 3.13, 3.14, and 3.15). In addition to this analysis, we have achieved a much more detailed
understanding of the relationship between personality traits, demographic data, and the use of individual
drugs or drug clusters by an individual subject.
The database we analysed contains 1,885 participants and 12 features (input attributes). These features
include the five personality traits (NEO-FFI-R); impulsivity (BIS-11), sensation-seeking (ImpSS), level
of education, age, gender, country of residence, and ethnicity. The data set includes information on the
consumption of 18 central nervous system psychoactive drugs: alcohol, amphetamines, amyl nitrite, ben-
zodiazepines, cannabis, chocolate, cocaine, caffeine, crack, ecstasy, heroin, ketamine, legal highs, LSD,
methadone, mushrooms, nicotine, as well as VSA (output attributes).
In our analysis we used three different techniques for ranking features. After input feature ranking we
excluded ethnicity and country of residence since the dataset has not enough data for most of the ethnicities
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and countries to prove the value of this information. As a result, 10 input features remained: age, Edu., N, E,
O, A, C, Imp, SS, and gender. Our aim was to predict the risk of drug consumption for an individual.
All input features are ordinal or nominal. To apply data mining methods which were developed for
continuous input features we applied the CatPCA technique to quantify the data.
We used four different definitions of drug users based on the recency of the last consumption of the drug:
the decade-based, year-based, month-based and week-based user/non-user separation (Fig. 1.2).
Our findings have allowed us to draw a number of important conclusions about the associations between
personality traits and drug use. All five personality factors are relevant traits to be taken into account when
assessing the risk of an individual consuming drugs.
The mean scores for the groups of users of all 18 drugs are high or neutral for N and O, and moderately
low for A and C. The only exception is for crack usage for the week-based classification problem, which has
a moderately low (−) O score (see Table 3.15). Users of legal drugs (alcohol, chocolate, and caffeine) have
neutral A and C scores, and nicotine users have moderately low (−) C score. For LSD users in the year-based
classification problem and for LSD and magic mushrooms users in the week-based classification problem, the
A score is neutral.
The impact of the E score was found to be drug specific. For example, for the decade-based user/non-user
definition the E score is negatively correlated with the consumption of crack, heroin, VSA, and methadone
(the E score is (−) for their users). It has no predictive value for other drugs for the decade-based classification
(the E score for users was (0)), whereas in the year-, month-, and week-based classification problems all three
possible values of E score were observed (see Tables 3.12, 3.13, 3.14 and 3.15).
We confirm the findings of previous researchers that higher scores for N and O, and lower scores for C and
A, lead to increased risk of drug use [12]. The O score is marked by curiosity and open-mindedness (and
correlated with intelligence), and it is therefore understandable why higher O may be sometimes be associated
with drug use [13]. Flory et al. [4] found marijuana use to be associated with lower A and C, and higher
O. These findings have been partially confirmed by our study. Our results improve the understanding of the
pathways leading to drug consumption. In particular, these pathways should form paths in the correlation
pleiades of drugs.
Our study has demonstrated that different attributes are important for different drugs. The detailed profiles
for users and non-users of all drugs, and groups of drugs, are collected in Tables A.1, A.2 Using these tables
we can compare, discuss, and verify almost all results and hypotheses concerning the psychological profiles
of drug users. For example:
1. In the paper [5] significant differences in the NEO-PI-R mean profiles of current cocaine/heroin users and
non-users was found: for users, N⇑ and C⇓. In our table, for the month-based user definition (Table A.2),
the mean profiles for cocaine users differ from non-users but the differences in A and O are also significant
(p≤ 0.001): N⇑, O⇑, A⇓, and C⇓. For heroin, our table gives the result N⇑, E⇓, A⇓, and C⇓. The mean
heroin user profile differs significantly from the profile for cocaine users: heroin users are significantly less
extroverted than non-users, whereas the E-score for cocaine users is found to be slightly higher than for
non-users (p = 0.129). Joining heroin users and cocaine users in one category concealed the deviations in
E-score. The mean O-score of heroin users is higher than for non-users but not significantly higher (the
empirical value of the O-score for heroin users is approximately the same as for cocaine users but the
significance is different because of the different sample sizes).
2. Again in [5] and in [9] significant deviations of NEO-PI-R mean profiles for current cannabis users, from
the means for non-users, are given as O⇑, A⇓, and C⇓. We additionally see in Table A.2 that we have N⇑.
The differences in the empirical value of N-scores between cannabis users and non-users are approximately
the same in our tables as in [5] (≈ 1), but the sample sizes are different and therefore, the statistical
significance differs.
Summary 95
3. In [4] a strong difference in N between cannabis users and non-users is proposed, and no significant
differences in E and O. This result strongly contradicts our observations, as well those of other earlier
works [5, 10], which report a high difference in O and no (or more modest) difference in N.
4. Combinations of high and low scores in three NEO-FFI personality dimensions, neuroticism (N), extraver-
sion (E), and conscientiousness (C), result in eight different personality types. Smoking, consumption of
alcohol and drugs, and risky sexual behaviour were studied in a sample of 683 university students in [3].
Two types, E⇑, C⇓ (Impulsives, Hedonists) and N⇑, C⇓ (Insecures) were particularly inclined to engage
in multiple, risky health behaviours, whereas the type with E⇓, C⇑ (Sceptics, Brooders) abstained from
risky behaviour. Let us look at our data with the month-based user definition (Table A.2).
• Users of amphetamines, benzodiazepines, cannabis, cocaine, crack, heroin, legal highs, and nicotine
belong to the type N⇑, C⇓ (Insecures) and do not belong to the type E⇑, C⇓ (Impulsives, Hedonists).
• Users of ecstasy and LSD belong to the type E⇑, C⇓ and do not belong to the type N⇑ , C⇓.
• Users of methadone belong to both types (the intersection).
• It is worth mentioning that users of VSA do not belong to these types but have significant deviations in
O⇑ and in A⇓ (insufficient significance of deviation in N and C may be caused by the small sample
size with VSA).
• Users of magic mushrooms have significant deviations in O⇑ and in C⇓ but do not belong to both types
(insignificance of deviation of E⇑ may be caused by the small number of magic mushroom users).
• Users of ketamine also have the profile O⇑ and in C⇓ (insignificance of deviation of N⇑ may be caused
by the sample size).
• Users of amyl nitrite have profile A⇓, C⇓.
• The profile with C⇑ does not exist among user profiles.
The hypothesis we make above about types of risky behaviour is partially supported by the data. Moreover,
we suggest that the type E⇑, C⇓ (Impulsives, Hedonists) is more typical among ecstasy and LSD consumers,
whereas the type N⇑, A⇓ is more expected among heroin users. Detailed comparison of ecstasy and heroin
users demonstrates that they are significantly different. Heroin users have higher N, and lower E and A.
We also suggest that a high O-score is typical for many drug users (besides users of heroin, crack, and
amyl nitrite) and therefore the O score cannot be excluded from the typology of risky behaviour. Moreover,
very low A⇓ is typical for VSA users. This is especially interesting because low A is the main significant
predictor of violence in FFM and is central to the dark behaviours [11]. These comments may help in the
further development of the typology of risky behaviour.
We tested eight types of classifiers for each drug for the decade-based user definition. Leave one out
cross-validation (LOOCV) was used to evaluate sensitivity and specificity. In this study we select as the
best, the classification method which provides the maximal value of the least of sensitivity and specificity.
If there is a tie on this basis, as there is in two cases, the method with maximal sum of the sensitivity and
specificity is selected as the best. There were classifiers with sensitivity and specificity greater than 70%
for the decade-based user/non-user separation for all drugs except magic mushrooms, alcohol, and cocaine
(Table 3.24). This accuracy was unexpectedly high for this type of problem. The poorest result was obtained
for the prediction of alcohol consumption.
The best set of input features was defined for each drug (Table 3.24). An exhaustive search was performed
to select the most effective subset of input features, and the best data mining methods to classify users and
non-users for each drug. There were 10 input features. Each of them is an important factor for risk evaluation
for the use of some drugs. However, there was no single most effective classifier using all input features. The
maximal number of attributes used in the best classifiers is six (out of 10) and the minimal number is two.
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Table 3.24 shows the best sets of attributes for user/non-user classification for different drugs and for the
decade-based classification problem. This table, together with its analogues for pleiades of drugs and all
decade-year-month-week classification problems (Table 3.27), are important outputs of the analysis.
The decision tree (DT) for crack consumption used only two features, E and C, and provided sensitivity of
80.63%, and specificity of 78.57%. The DT for VSA used age, Edu., E, A, C, and SS, and provided sensitivity
83.48% and specificity 77.64% (Table 3.24).
Age was employed in the best classifiers for 14 drugs for the decade-based classification problem, and so
was a very widely used feature. Gender was used in the best methods for 10 drugs. We found some unexpected
outcomes. For example, the fraction of females which are alcohol users is greater than the fraction of males
but a majority of males consume caffeine (coffee).
Most of the features which are not used in the best classifiers are redundant but not uninformative. For
example, the best classifier for ecstasy consumption used age, SS, and gender, and had sensitivity 76.17% and
specificity 77.1 6%. There is another DT which utilizes age, Edu., O, C, and SS with sensitivity 77.23% and
specificity 75.22%; a DT with inputs age, Edu., E, O, and A, with sensitivity 73.24% and specificity 78.22%,
and an advanced kNN classifier with inputs age, Edu., N, E, O, C, Imp., SS, and gender, with sensitivity
75.63% and specificity 75.75%. This means that for evaluating the risk of ecstasy usage all input attributes
are informative but the required information can be extracted from a subset of attributes.
We have demonstrated that there are three groups of drugs with strongly correlated consumption. That is,
drug usage has a ‘modular structure’. The idea of merging correlated attributes into ‘modules’ is popular in
biology. These modules are called the ‘correlation pleiades’ [14–16] (see Section ‘Pleiades of drugs’). The
modular structure contains three modules: the heroin pleiad, ecstasy pleiad, and benzodiazepines pleiad:
• The Heroin pleiad (heroinPl) includes crack, cocaine, methadone, and heroin.
• The Ecstasy pleiad (ecstasyPl) includes amphetamines, cannabis, cocaine, ketamine, LSD, magic mush-
rooms, legal highs, and ecstasy.
• The Benzodiazepines pleiad (benzoPl) contains methadone, amphetamines, and cocaine.
The modular structure is well represented in the correlation graph Fig 3.7. We define groups of users and
non-users for each pleiad. In most of the databases the classes of users and non-users for most of the individual
drugs are imbalanced (see Table 1.4), but merging the users of all drugs into one class ‘drug users’ does not
seem to be the best solution because of physiological, psychological, and cultural differences in the usage of
different drugs. We propose instead to use correlation pleiades for the analysis of drug usage as a solution
to the class imbalance problem because for all three pleiades the classes of users and non-users are better
balanced (Table 3.25), and the consumption of different drugs from the same pleiad is correlated.
We have applied the eight methods described in the ‘Risk evaluation methods’ Section and selected the
best one for each problem for each of the pleiades. The results of the classifier selection are presented in
Table 3.27 and the quality of the classification is high. The majority of the best classifiers for pleiades of
drugs has a better accuracy than the classifiers for individual drug usage (see Tables 3.24 and 3.27). The
best classifiers for pleiades of drugs use more input features than the best classifiers for the corresponding
individual drugs. The classification problems for pleiades of drugs are more balanced. Therefore, we expect
that the classifiers for pleiades are more robust than the classifiers for individual drugs.
The user/non-user classifiers can also be used for the formation of risk maps. Risk maps are useful tools
for the visualisation of data and for generating hypotheses about the problem under consideration.
The limitations of the proposed analysis are obvious:
• Collection of data through the Internet with elements of the snowball technology (existing participants
recruit future participants from amongst their acquaintances) created a biased sample.
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• Our definitions of ‘substance use’ do not assume any form of dependence, and are much more inclusive and
wider than the definition of substance dependence disorder [17]. Therefore, for example, the majority of
participants were considered as users of alcohol and caffeine. For these substances, non-users form special
categories of interest. Similar differences in definitions are common problems. For example, standard
epidemiological surveys often use data from official records with unavoidable potential biases, whereas
personal interviews give qualitatively different information.
Now, after we finished this book, we see that our analysis is not exhaustive and we are ready to restart.
Many questions should be answered. Some of them require just an extension of our analysis: for example,
analyse differences between heroin and cocaine users or between cannabis and nicotine users. Some questions
are qualitatively different. For example, we considered groups of substance users but did not consider groups
of poly drug users separately. Nevertheless, these groups are not small (Figs. 3.17, 3.20) and require special
attention because of synergistic effects between different drugs. In a comparative analysis of ecstasy and
heroin users we have to create classifiers for three groups: users of heroin but not ecstasy, users of ecstasy but
not heroin, and users of ecstasy and heroin. For three drugs (Fig. 3.20) we have to analyse seven groups. Such
expansion of the data analysis will increase the research report enormously and will, perhaps, require a book
which is three times longer.
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Discussion
These results are important as they examine the question of the relationship between drug use and personality
comprehensively and engage in the challenge of untangling correlated personality traits (the FFM, impul-
sivity, and sensation-seeking [1]), and clusters of substance misuse (the correlation pleiades). The work
acknowledged the breadth of a common behaviour which may be transient and leave no impact, or may
significantly harm an individual. We examined drug use behaviour comprehensively in terms of the many
kinds of substances that may be used (from the legal and anodyne, to the deeply harmful), as well as the
possibility of behavioural over-claiming. Through inclusion of different timescales we were able to explore
persistence of use, perhaps related to trends and fashions (e.g. the greater use of LSD in the 1960s and 1970s,
the rise of ecstasy in the 1980s, some people being one-off experimenters with recreational drugs, and others
using such substances on a daily basis).
We defined substance use in terms of behaviour rather than legality, as legislation in the field is variable.
Our data were gathered before legal highs emerged as a health concern [2] so we did not differentiate, for
example, synthetic cannabinoids and cathinone-based stimulants; these substances have since been widely
made illegal. We were nevertheless able to accurately classify users of these substances (reciprocally, our
data were gathered before cannabis decriminalisation in parts of North America, but again, we were able to
accurately classify cannabis users). We included control participants who had never used these substances,
those who had used them in the distant past, up to and including persons who had used the drug in the past
day, avoiding the Procrustean data-gathering and classifying methods which may prevent an accurate picture
of drug use behaviour and risk [3]. Such rich data and the complex methods used for analysis necessitated a
large and substantial sample.
The study was atheoretical regarding the morality of the behaviour, and did not medicalise or pathologise
participants, optimising engagement by persons with heterogeneous drug-use histories. Our study used a
rigorous range of data-mining methods beyond those typically used in studies examining the association of
drug use and personality in the psychological and psychiatric literature, revealing that decision tree methods
were most commonly effective for classifying drug users. We found that high N, low A, and low C are the most
common personality correlates of drug use, these traits being sometimes seen, in combination, as an indication
of higher-order stability and behavioural conformity, and, inverted, are associated with externalisation of
distress [4–6]. Deviation from this rule (N⇑, A⇓, C⇓) for some drugs is also interesting. LSD use correlates
with high O and low C (and does not correlate significantly with high N, at least, for recent LSD users). High
O is correlated with the use of many drugs. Nevertheless, there exist significant differences between profiles
of different drugs. We analysed this difference in detail for benzodiazepines, ecstasy, and heroin. This may be
important for risk assessment and treatment planning.
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Low stability is also a marker of negative urgency [7] whereby people act rashly when distressed. Our
research points to the importance of individuals acquiring emotional self-management skills preceding distress
as a means to reduce self-medicating drug-using behaviour, and the risk to health that injudicious or chronic
drug use may cause.
In this book we have hopefully demonstrated how to use data analytic methods for investigating a
fascinating data set, and found some really interesting patterns in users of different drugs. Of course we have
not discovered all of the information that is hiding in the data. We invite other interested parties, be they
undergraduate, post graduate, or full time researcher, to join in with us in exploring this data to uncover more
interesting relationships, which may help various agencies to manage the challenges associated with drug use.
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Appendix A
Main tables
A.1 Psychological profiles of drug users and non-users
Mean for groups of users and non-users. In this Appendix, we present mean T-scoresample (2.5) for groups of
users and non-users for decade, year, month, and week based user definitions respectively. Column p-value
assesses the significance of differences of mean scores for groups of users and non-users: it is the probability
of observing by chance the same or greater differences for mean scores if both groups have the same mean.
Rows ‘#’ contain number of users and non-users for the drugs. These tables include all information about five
factor personality profiles for various definitions of users of 18 drugs, and four groups of drugs:
• The heroin pleiad: crack, cocaine, methadone, and heroin;
• The ecstasy pleiad: amphetamines, cannabis, cocaine, ketamine, LSD, magic mushrooms, legal highs, and
ecstasy;
• The benzodiazepines pleiad includes methadone, amphetamines, cocaine, and benzodiazepines.
• The union of these three pleiades and Volatile Substance Abuse (VSA): amphetamines, amyl nitrite,
benzodiazepines, cannabis, cocaine, crack, ecstasy, heroin, ketamine, legal highs, LSD, methadone, magic
mushrooms (MMushrooms), and VSA, which we call for short ‘illicit drugs’ (with some abuse of language).
Table A.1: Mean T-scoresample (MT) and 95% CI for it for groups of users and non-
users with decade and year based definitions of users
Factor Decade based Year based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Alcohol
# 1817 68 1749 136
N 50.07 49.61, 50.53 48.12 45.70, 50.54 0.119 49.96 49.49, 50.43 50.55 48.87, 52.23 0.501
E 50.00 49.54, 50.46 50.00 47.63, 52.36 0.997 50.12 49.64, 50.59 48.52 46.89, 50.14 0.064
O 50.04 49.58, 50.50 48.86 46.51, 51.22 0.331 50.07 49.60, 50.54 49.11 47.46, 50.76 0.271
A 49.91 49.45, 50.37 52.49 50.24, 54.74 0.028 49.95 49.48, 50.42 50.70 49.03, 52.37 0.392
C 49.88 49.42, 50.34 53.28 51.01, 55.54 0.004 49.94 49.47, 50.41 50.73 49.03, 52.44 0.378
Imp 50.14 49.68, 50.60 46.23 44.09, 48.37 0.001 50.08 49.61, 50.55 48.96 47.31, 50.62 0.203
SS 50.19 49.74, 50.65 44.81 42.57, 47.06 < 0.001 50.24 49.77, 50.71 46.91 45.24, 48.58 < 0.001
Continued on the next page
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Table A.1. Continued
Factor Decade based Year based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Amphetamines
# 679 1206 436 1449
N 51.64 50.88, 52.39 49.08 48.52, 49.64 < 0.001 52.40 51.43, 53.36 49.28 48.77, 49.78 < 0.001
E 49.65 48.84, 50.47 50.20 49.66, 50.73 0.274 49.48 48.45, 50.50 50.16 49.66, 50.66 0.243
O 53.05 52.34, 53.76 48.28 47.72, 48.84 < 0.001 53.83 52.92, 54.74 48.85 48.34, 49.35 < 0.001
A 48.37 47.58, 49.16 50.92 50.37, 51.46 < 0.001 47.47 46.45, 48.48 50.76 50.27, 51.26 < 0.001
C 46.97 46.21, 47.73 51.71 51.17, 52.25 < 0.001 45.91 44.94, 46.88 51.23 50.74, 51.72 < 0.001
Imp 53.49 52.76, 54.22 48.04 47.49, 48.58 < 0.001 54.93 54.02, 55.84 48.52 48.02, 49.01 < 0.001
SS 54.76 54.12, 55.40 47.32 46.77, 47.87 < 0.001 55.79 55.01, 56.56 48.26 47.75, 48.76 < 0.001
Amyl nitrite
# 370 1515 133 1752
N 50.72 49.72, 51.73 49.82 49.32, 50.33 0.118 51.57 49.85, 53.29 49.88 49.41, 50.35 0.063
E 50.89 49.87, 51.91 49.78 49.28, 50.29 0.055 50.25 48.44, 52.06 49.98 49.51, 50.45 0.778
O 51.45 50.48, 52.42 49.65 49.14, 50.15 0.001 51.97 50.36, 53.59 49.85 49.38, 50.32 0.014
A 48.65 47.62, 49.69 50.33 49.83, 50.83 0.004 46.35 44.64, 48.07 50.28 49.81, 50.74 < 0.001
C 48.01 47.02, 48.99 50.49 49.98, 50.99 < 0.001 46.92 45.25, 48.60 50.23 49.77, 50.70 < 0.001
Imp 52.20 51.23, 53.18 49.46 48.96, 49.97 < 0.001 52.39 50.71, 54.08 49.82 49.35, 50.29 0.004
SS 53.89 53.02, 54.77 49.05 48.54, 49.56 < 0.001 55.06 53.67, 56.44 49.62 49.15, 50.09 < 0.001
Benzodiazepines
# 769 1116 535 1350
N 52.77 52.06, 53.48 48.09 47.53, 48.65 < 0.001 53.69 52.84, 54.54 48.54 48.03, 49.05 < 0.001
E 49.02 48.27, 49.78 50.67 50.12, 51.23 0.001 48.91 47.97, 49.85 50.43 49.92, 50.94 0.005
O 52.64 51.96, 53.33 48.18 47.60, 48.76 < 0.001 53.00 52.17, 53.83 48.81 48.28, 49.34 < 0.001
A 48.26 47.52, 49.01 51.20 50.64, 51.75 < 0.001 47.55 46.64, 48.46 50.97 50.46, 51.48 < 0.001
C 47.62 46.90, 48.33 51.64 51.08, 52.21 < 0.001 47.07 46.19, 47.94 51.16 50.65, 51.68 < 0.001
Imp 52.53 51.82, 53.24 48.25 47.69, 48.82 < 0.001 53.35 52.52, 54.19 48.67 48.15, 49.19 < 0.001
SS 52.98 52.30, 53.65 47.95 47.37, 48.52 < 0.001 54.10 53.32, 54.87 48.38 47.85, 48.90 < 0.001
Cannabis
# 1265 620 999 886
N 51.02 50.46, 51.58 47.92 47.19, 48.65 < 0.001 51.10 50.46, 51.74 48.76 48.14, 49.38 < 0.001
E 49.69 49.12, 50.27 50.63 49.91, 51.34 0.045 49.73 49.08, 50.39 50.30 49.69, 50.91 0.217
O 52.47 51.96, 52.99 44.95 44.20, 45.70 < 0.001 53.68 53.13, 54.23 45.85 45.22, 46.48 < 0.001
A 48.81 48.25, 49.37 52.42 51.69, 53.15 < 0.001 48.77 48.13, 49.40 51.39 50.76, 52.02 < 0.001
C 48.08 47.53, 48.63 53.92 53.22, 54.61 < 0.001 47.33 46.70, 47.95 53.02 52.42, 53.62 < 0.001
Imp 52.05 51.50, 52.61 45.81 45.13, 46.49 < 0.001 52.74 52.13, 53.36 46.91 46.30, 47.51 < 0.001
SS 52.95 52.44, 53.45 43.99 43.28, 44.70 < 0.001 54.29 53.76, 54.81 45.17 44.55, 45.79 < 0.001
Chocolate
# 1850 35 1840 45
N 50.00 49.54, 50.45 50.21 46.31, 54.11 0.912 50.01 49.56, 50.47 49.45 46.05, 52.86 0.744
E 49.99 49.53, 50.44 50.75 47.67, 53.84 0.621 49.99 49.53, 50.45 50.49 47.75, 53.24 0.716
O 50.05 49.59, 50.51 47.41 44.43, 50.38 0.083 50.04 49.58, 50.50 48.27 45.59, 50.94 0.194
A 50.03 49.57, 50.48 48.61 44.55, 52.67 0.486 50.02 49.56, 50.48 49.17 45.72, 52.62 0.626
C 49.97 49.52, 50.43 51.55 47.83, 55.27 0.399 49.97 49.51, 50.42 51.41 47.81, 55.01 0.425
Imp 49.98 49.53, 50.44 50.81 47.30, 54.31 0.640 49.98 49.52, 50.43 50.94 47.98, 53.90 0.520
SS 50.01 49.55, 50.46 49.51 45.65, 53.37 0.796 50.00 49.54, 50.45 50.06 46.84, 53.29 0.968
Continued on the next page
A.1 Psychological profiles of drug users and non-users 103
Table A.1. Continued
Factor Decade based Year based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Cocaine
# 687 1198 417 1468
N 51.78 51.02, 52.54 48.98 48.42, 49.53 < 0.001 52.16 51.19, 53.13 49.39 48.88, 49.89 < 0.001
E 50.27 49.49, 51.05 49.84 49.29, 50.40 0.381 50.93 49.88, 51.98 49.74 49.24, 50.23 0.044
O 52.58 51.88, 53.29 48.52 47.95, 49.09 < 0.001 52.79 51.87, 53.71 49.21 48.70, 49.72 < 0.001
A 47.69 46.91, 48.47 51.33 50.79, 51.86 < 0.001 46.84 45.81, 47.86 50.90 50.41, 51.39 < 0.001
C 47.41 46.68, 48.14 51.48 50.93, 52.04 < 0.001 46.81 45.86, 47.76 50.91 50.40, 51.41 < 0.001
Imp 53.29 52.54, 54.03 48.12 47.57, 48.66 < 0.001 54.29 53.33, 55.25 48.78 48.29, 49.28 < 0.001
SS 54.40 53.75, 55.06 47.47 46.92, 48.03 < 0.001 55.63 54.81, 56.45 48.40 47.90, 48.90 < 0.001
Caffeine
# 1848 37 1824 61
N 50.00 49.54, 50.45 50.06 46.57, 53.54 0.974 49.99 49.53, 50.45 50.36 47.75, 52.96 0.783
E 50.07 49.61, 50.52 46.67 43.77, 49.58 0.025 50.10 49.64, 50.56 46.92 44.34, 49.50 0.018
O 50.11 49.65, 50.56 44.65 41.70, 47.61 0.001 50.10 49.64, 50.56 47.07 44.45, 49.69 0.026
A 49.98 49.52, 50.44 51.05 47.67, 54.42 0.529 49.96 49.50, 50.42 51.15 48.61, 53.69 0.360
C 49.93 49.47, 50.39 53.56 50.75, 56.37 0.014 49.91 49.45, 50.37 52.78 50.14, 55.43 0.036
Imp 50.08 49.62, 50.53 46.10 43.15, 49.05 0.010 50.13 49.67, 50.59 46.23 43.95, 48.51 0.001
SS 50.12 49.66, 50.57 44.21 41.16, 47.27 < 0.001 50.18 49.72, 50.63 44.70 42.22, 47.18 < 0.001
Crack
# 191 1694 79 1806
N 53.00 51.56, 54.43 49.66 49.19, 50.14 < 0.001 54.06 51.77, 56.35 49.82 49.36, 50.28 0.001
E 48.74 47.28, 50.20 50.14 49.67, 50.62 0.073 49.24 47.20, 51.28 50.03 49.57, 50.50 0.455
O 52.92 51.61, 54.22 49.67 49.19, 50.15 < 0.001 52.90 50.72, 55.08 49.87 49.41, 50.33 0.008
A 47.00 45.44, 48.55 50.34 49.87, 50.81 < 0.001 46.65 44.18, 49.12 50.15 49.69, 50.60 0.007
C 46.14 44.65, 47.63 50.44 49.97, 50.90 < 0.001 45.08 42.92, 47.25 50.22 49.76, 50.67 < 0.001
Imp 55.48 54.12, 56.85 49.38 48.91, 49.85 < 0.001 56.55 54.62, 58.48 49.71 49.25, 50.17 < 0.001
SS 55.43 54.26, 56.61 49.39 48.91, 49.86 < 0.001 56.56 54.89, 58.22 49.71 49.25, 50.17 < 0.001
Ecstasy
# 751 1134 517 1368
N 51.24 50.52, 51.96 49.18 48.60, 49.75 < 0.001 50.71 49.82, 51.61 49.73 49.21, 50.25 0.062
E 50.49 49.74, 51.24 49.68 49.11, 50.24 0.089 51.51 50.60, 52.42 49.43 48.91, 49.95 < 0.001
O 53.61 52.95, 54.26 47.61 47.04, 48.18 < 0.001 54.10 53.32, 54.89 48.45 47.93, 48.97 < 0.001
A 48.47 47.73, 49.20 51.01 50.45, 51.58 < 0.001 48.55 47.64, 49.45 50.55 50.03, 51.07 < 0.001
C 47.22 46.52, 47.93 51.84 51.28, 52.40 < 0.001 47.02 46.17, 47.87 51.13 50.61, 51.65 < 0.001
Imp 53.04 52.35, 53.74 47.98 47.42, 48.55 < 0.001 53.74 52.91, 54.57 48.59 48.07, 49.11 < 0.001
SS 54.97 54.37, 55.56 46.71 46.15, 47.27 < 0.001 55.85 55.16, 56.53 47.79 47.27, 48.31 < 0.001
Heroin
# 212 1673 118 1767
N 54.53 53.21, 55.85 49.43 48.95, 49.90 < 0.001 55.37 53.62, 57.12 49.64 49.18, 50.10 < 0.001
E 48.38 46.90, 49.85 50.21 49.73, 50.68 0.021 47.69 45.68, 49.69 50.15 49.69, 50.62 0.019
O 54.24 53.03, 55.45 49.46 48.98, 49.94 < 0.001 53.45 51.80, 55.11 49.77 49.30, 50.24 < 0.001
A 45.51 43.98, 47.04 50.57 50.10, 51.03 < 0.001 44.38 42.26, 46.50 50.38 49.92, 50.83 < 0.001
C 45.81 44.45, 47.17 50.53 50.06, 51.00 < 0.001 45.46 43.52, 47.39 50.30 49.84, 50.76 < 0.001
Imp 55.74 54.43, 57.06 49.27 48.80, 49.74 < 0.001 56.01 54.29, 57.74 49.60 49.14, 50.06 < 0.001
SS 56.02 54.84, 57.20 49.24 48.76, 49.71 < 0.001 56.41 54.81, 58.00 49.57 49.11, 50.04 < 0.001
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Table A.1. Continued
Factor Decade based Year based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Ketamine
# 350 1535 208 1677
N 51.35 50.34, 52.36 49.69 49.19, 50.20 0.004 51.52 50.20, 52.84 49.81 49.33, 50.29 0.017
E 50.31 49.19, 51.43 49.93 49.44, 50.42 0.542 51.02 49.48, 52.57 49.87 49.40, 50.34 0.162
O 53.85 52.88, 54.82 49.12 48.62, 49.62 < 0.001 54.18 52.88, 55.48 49.48 49.01, 49.96 < 0.001
A 47.78 46.64, 48.91 50.51 50.02, 51.00 < 0.001 47.90 46.42, 49.38 50.26 49.79, 50.73 0.003
C 46.79 45.74, 47.85 50.73 50.24, 51.22 < 0.001 46.34 44.91, 47.76 50.45 49.98, 50.93 < 0.001
Imp 53.81 52.77, 54.85 49.13 48.64, 49.62 < 0.001 54.18 52.83, 55.53 49.48 49.01, 49.96 < 0.001
SS 55.25 54.40, 56.11 48.80 48.30, 49.30 < 0.001 55.93 54.83, 57.02 49.26 48.79, 49.74 < 0.001
Legal highs
# 762 1123 564 1321
N 51.43 50.71, 52.16 49.03 48.45, 49.60 < 0.001 51.27 50.41, 52.12 49.46 48.93, 49.99 < 0.001
E 49.66 48.89, 50.42 50.23 49.68, 50.79 0.228 50.02 49.11, 50.92 49.99 49.48, 50.51 0.966
O 54.29 53.67, 54.91 47.09 46.52, 47.66 < 0.001 54.49 53.76, 55.22 48.08 47.55, 48.62 < 0.001
A 48.59 47.84, 49.34 50.96 50.40, 51.51 < 0.001 48.10 47.23, 48.96 50.81 50.29, 51.34 < 0.001
C 46.92 46.20, 47.65 52.09 51.54, 52.63 < 0.001 46.56 45.71, 47.41 51.47 50.95, 51.98 < 0.001
Imp 53.19 52.49, 53.89 47.83 47.28, 48.39 < 0.001 53.82 53.00, 54.63 48.37 47.85, 48.89 < 0.001
SS 55.14 54.55, 55.72 46.51 45.95, 47.08 < 0.001 56.00 55.35, 56.64 47.44 46.92, 47.97 < 0.001
LSD
# 557 1328 380 1505
N 50.80 49.98, 51.62 49.66 49.12, 50.20 0.023 49.98 48.97, 50.99 50.00 49.50, 50.51 0.969
E 50.01 49.11, 50.92 49.99 49.48, 50.51 0.971 50.72 49.63, 51.81 49.82 49.32, 50.31 0.140
O 55.23 54.52, 55.93 47.81 47.28, 48.33 < 0.001 56.29 55.48, 57.10 48.41 47.91, 48.91 < 0.001
A 48.40 47.53, 49.28 50.67 50.15, 51.19 < 0.001 49.05 47.98, 50.12 50.24 49.74, 50.74 0.048
C 47.46 46.64, 48.29 51.06 50.53, 51.59 < 0.001 47.74 46.71, 48.77 50.57 50.07, 51.07 < 0.001
Imp 53.47 52.69, 54.25 48.54 48.01, 49.08 < 0.001 53.50 52.56, 54.43 49.12 48.61, 49.62 < 0.001
SS 55.62 54.95, 56.30 47.64 47.11, 48.17 < 0.001 56.34 55.56, 57.12 48.40 47.90, 48.90 < 0.001
Methadone
# 417 1468 320 1565
N 53.33 52.38, 54.28 49.05 48.55, 49.56 < 0.001 53.74 52.65, 54.84 49.23 48.75, 49.72 < 0.001
E 47.93 46.85, 49.01 50.59 50.10, 51.08 < 0.001 47.75 46.47, 49.03 50.46 49.99, 50.94 < 0.001
O 53.78 52.87, 54.68 48.93 48.42, 49.43 < 0.001 53.81 52.76, 54.86 49.22 48.73, 49.71 < 0.001
A 47.06 46.03, 48.09 50.84 50.34, 51.33 < 0.001 46.53 45.33, 47.73 50.71 50.23, 51.19 < 0.001
C 46.16 45.17, 47.15 51.09 50.60, 51.58 < 0.001 46.01 44.87, 47.15 50.82 50.33, 51.30 < 0.001
Imp 53.64 52.70, 54.59 48.97 48.46, 49.47 < 0.001 53.77 52.67, 54.87 49.23 48.74, 49.72 < 0.001
SS 54.45 53.56, 55.33 48.74 48.23, 49.24 < 0.001 54.73 53.73, 55.74 49.03 48.54, 49.52 < 0.001
Magic mushrooms
# 694 1191 434 1451
N 50.66 49.91, 51.40 49.62 49.05, 50.19 0.029 50.33 49.40, 51.26 49.90 49.38, 50.42 0.431
E 50.10 49.29, 50.90 49.94 49.40, 50.49 0.758 50.71 49.66, 51.76 49.79 49.29, 50.28 0.118
O 54.34 53.70, 54.99 47.47 46.91, 48.03 < 0.001 55.72 54.95, 56.48 48.29 47.78, 48.80 < 0.001
A 48.52 47.75, 49.30 50.86 50.31, 51.41 < 0.001 48.51 47.48, 49.53 50.45 49.95, 50.95 0.001
C 47.46 46.73, 48.20 51.48 50.92, 52.04 < 0.001 47.30 46.36, 48.24 50.81 50.30, 51.32 < 0.001
Imp 53.24 52.53, 53.95 48.11 47.55, 48.67 < 0.001 53.74 52.86, 54.63 48.88 48.37, 49.39 < 0.001
SS 54.78 54.18, 55.39 47.21 46.65, 47.78 < 0.001 55.92 55.19, 56.64 48.23 47.72, 48.74 < 0.001
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Table A.1. Continued
Factor Decade based Year based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Nicotine
# 1264 621 1060 825
N 50.90 50.35, 51.45 48.16 47.40, 48.93 < 0.001 51.16 50.55, 51.76 48.52 47.85, 49.18 < 0.001
E 49.91 49.35, 50.48 50.18 49.43, 50.93 0.582 49.80 49.17, 50.42 50.26 49.61, 50.91 0.309
O 51.46 50.91, 52.00 47.04 46.28, 47.79 < 0.001 51.91 51.31, 52.51 47.55 46.90, 48.20 < 0.001
A 49.18 48.63, 49.73 51.67 50.90, 52.44 < 0.001 49.04 48.42, 49.65 51.24 50.58, 51.90 < 0.001
C 48.58 48.02, 49.14 52.89 52.17, 53.61 < 0.001 47.98 47.38, 48.57 52.60 51.95, 53.25 < 0.001
Imp 51.53 50.97, 52.09 46.89 46.17, 47.60 < 0.001 52.08 51.46, 52.69 47.33 46.71, 47.95 < 0.001
SS 52.13 51.60, 52.67 45.66 44.93, 46.39 < 0.001 52.83 52.26, 53.41 46.36 45.72, 47.00 < 0.001
VSA
# 230 1655 95 1790
N 52.80 51.49, 54.12 49.61 49.13, 50.09 < 0.001 53.81 51.67, 55.95 49.80 49.34, 50.26 < 0.001
E 48.91 47.41, 50.41 50.15 49.68, 50.62 0.122 49.55 47.32, 51.79 50.02 49.56, 50.48 0.683
O 54.21 53.01, 55.40 49.42 48.93, 49.90 < 0.001 53.59 51.58, 55.60 49.81 49.35, 50.27 < 0.001
A 47.28 45.90, 48.67 50.38 49.90, 50.85 < 0.001 47.48 45.35, 49.61 50.13 49.67, 50.60 0.017
C 45.13 43.79, 46.47 50.68 50.21, 51.15 < 0.001 45.31 43.18, 47.44 50.25 49.79, 50.71 < 0.001
Imp 55.10 53.90, 56.30 49.29 48.81, 49.77 < 0.001 54.61 52.73, 56.49 49.76 49.29, 50.22 < 0.001
SS 56.76 55.73, 57.78 49.06 48.58, 49.54 < 0.001 56.24 54.48, 57.99 49.67 49.21, 50.13 < 0.001
Heroin pleiad
# 832 1053 585 1300
N 51.65 50.96, 52.35 48.70 48.11, 49.28 < 0.001 52.24 51.41, 53.07 48.99 48.46, 49.52 < 0.001
E 49.70 48.98, 50.41 50.24 49.66, 50.82 0.246 49.59 48.68, 50.49 50.19 49.67, 50.70 0.260
O 52.75 52.11, 53.39 47.83 47.23, 48.43 < 0.001 53.02 52.25, 53.79 48.64 48.10, 49.18 < 0.001
A 47.91 47.20, 48.62 51.65 51.08, 52.21 < 0.001 47.10 46.24, 47.97 51.30 50.79, 51.81 < 0.001
C 47.37 46.69, 48.05 52.08 51.50, 52.65 < 0.001 46.72 45.91, 47.53 51.47 50.95, 52.00 < 0.001
Imp 52.93 52.26, 53.60 47.68 47.11, 48.26 < 0.001 53.75 52.94, 54.56 48.31 47.79, 48.83 < 0.001
SS 54.00 53.39, 54.60 46.84 46.26, 47.43 < 0.001 54.87 54.16, 55.59 47.81 47.28, 48.34 < 0.001
Ecstasy pleiad
# 1317 568 1089 796
N 51.00 50.44, 51.55 47.68 46.94, 48.42 < 0.001 51.16 50.54, 51.78 48.41 47.77, 49.05 < 0.001
E 49.69 49.13, 50.26 50.71 49.98, 51.44 0.031 49.59 48.96, 50.22 50.56 49.93, 51.20 0.033
O 52.31 51.81, 52.82 44.64 43.86, 45.42 < 0.001 53.32 52.78, 53.85 45.46 44.81, 46.12 < 0.001
A 48.75 48.20, 49.30 52.89 52.15, 53.64 < 0.001 48.55 47.95, 49.16 51.98 51.33, 52.63 < 0.001
C 48.10 47.56, 48.64 54.40 53.70, 55.10 < 0.001 47.43 46.83, 48.02 53.52 52.91, 54.13 < 0.001
Imp 51.98 51.44, 52.52 45.41 44.72, 46.11 < 0.001 52.70 52.11, 53.29 46.31 45.69, 46.92 < 0.001
SS 52.83 52.34, 53.33 43.43 42.71, 44.14 < 0.001 54.00 53.49, 54.51 44.53 43.89, 45.17 < 0.001
Benzodiazepines pleiad
# 1089 796 830 1055
N 51.55 50.94, 52.15 47.88 47.23, 48.54 < 0.001 52.23 51.53, 52.93 48.25 47.68, 48.82 < 0.001
E 49.63 49.01, 50.25 50.51 49.85, 51.16 0.057 49.45 48.71, 50.18 50.43 49.87, 51.00 0.037
O 52.28 51.70, 52.85 46.89 46.22, 47.55 < 0.001 52.86 52.20, 53.51 47.75 47.16, 48.34 < 0.001
A 48.57 47.96, 49.18 51.96 51.31, 52.60 < 0.001 47.88 47.16, 48.59 51.67 51.11, 52.23 < 0.001
C 47.90 47.30, 48.50 52.87 52.23, 53.51 < 0.001 47.21 46.51, 47.90 52.20 51.64, 52.76 < 0.001
Imp 52.16 51.56, 52.75 47.05 46.40, 47.69 < 0.001 53.09 52.41, 53.76 47.57 47.00, 48.14 < 0.001
SS 53.00 52.44, 53.55 45.90 45.24, 46.55 < 0.001 54.13 53.52, 54.74 46.75 46.17, 47.33 < 0.001
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Table A.1. Continued
Factor Decade based Year based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Illicit drugs
# 1418 467 1179 706
N 51.05 50.52, 51.58 46.80 46.02, 47.58 < 0.001 51.38 50.79, 51.97 48.19 47.53, 48.84 < 0.001
E 49.54 49.00, 50.09 51.39 50.62, 52.16 < 0.001 49.40 48.80, 50.01 50.93 50.27, 51.59 0.003
O 51.77 51.27, 52.28 44.61 43.77, 45.45 < 0.001 52.84 52.31, 53.37 45.64 44.95, 46.33 < 0.001
A 48.98 48.45, 49.51 53.11 52.31, 53.91 < 0.001 48.59 48.00, 49.17 51.99 51.34, 52.65 < 0.001
C 48.37 47.84, 48.89 54.96 54.24, 55.69 < 0.001 47.61 47.04, 48.19 53.63 52.97, 54.28 < 0.001
Imp 51.64 51.12, 52.16 45.02 44.27, 45.76 < 0.001 52.46 51.89, 53.03 46.10 45.46, 46.74 < 0.001
SS 52.19 51.70, 52.68 43.35 42.56, 44.13 < 0.001 53.48 52.97, 53.98 44.23 43.55, 44.90 < 0.001
Table A.2: Mean T-scoresample (MT) and 95% CI for it for groups of users and non-
users with month and week based definitions of users
Factor Month based Week based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Alcohol
# 1551 334 1264 621
N 49.85 49.35, 50.35 50.69 49.61, 51.78 0.167 49.82 49.28, 50.36 50.37 49.56, 51.19 0.267
E 50.62 50.12, 51.11 47.14 46.11, 48.17 < 0.001 50.90 50.35, 51.44 48.17 47.38, 48.97 < 0.001
O 50.22 49.73, 50.72 48.96 47.87, 50.06 0.040 50.08 49.54, 50.63 49.83 49.03, 50.62 0.602
A 50.10 49.60, 50.60 49.55 48.50, 50.60 0.357 50.05 49.50, 50.60 49.89 49.09, 50.69 0.745
C 50.15 49.66, 50.65 49.28 48.22, 50.35 0.146 50.19 49.64, 50.74 49.61 48.81, 50.42 0.244
Imp 50.06 49.57, 50.56 49.71 48.61, 50.82 0.571 50.19 49.64, 50.73 49.62 48.81, 50.43 0.253
SS 50.34 49.85, 50.84 48.41 47.32, 49.50 0.002 50.52 49.97, 51.06 48.95 48.15, 49.75 0.001
Amphetamine
# 238 1647 163 1722
N 52.78 51.49, 54.07 49.60 49.12, 50.08 < 0.001 52.86 51.27, 54.45 49.73 49.26, 50.20 < 0.001
E 49.07 47.63, 50.51 50.13 49.66, 50.61 0.166 48.50 46.78, 50.21 50.14 49.68, 50.61 0.069
O 52.94 51.69, 54.19 49.57 49.09, 50.06 < 0.001 52.87 51.27, 54.47 49.73 49.26, 50.20 < 0.001
A 46.57 45.21, 47.92 50.50 50.02, 50.97 < 0.001 46.77 45.09, 48.45 50.31 49.84, 50.77 < 0.001
C 45.06 43.75, 46.37 50.71 50.24, 51.19 < 0.001 45.29 43.72, 46.85 50.45 49.98, 50.91 < 0.001
Imp 55.57 54.32, 56.83 49.19 48.72, 49.67 < 0.001 55.77 54.25, 57.29 49.45 48.99, 49.92 < 0.001
SS 55.37 54.23, 56.51 49.22 48.75, 49.70 < 0.001 54.47 53.07, 55.88 49.58 49.10, 50.05 < 0.001
Amyl nitrite
# 41 1844 17 1868
N 49.37 46.12, 52.61 50.01 49.56, 50.47 0.691 49.64 43.99, 55.28 50.00 49.55, 50.46 0.892
E 49.83 46.38, 53.28 50.00 49.55, 50.46 0.922 45.85 39.05, 52.64 50.04 49.59, 50.49 0.211
O 50.40 47.06, 53.73 49.99 49.53, 50.45 0.808 49.02 43.03, 55.02 50.01 49.56, 50.46 0.732
A 45.43 41.87, 49.00 50.10 49.65, 50.56 0.012 44.36 38.95, 49.77 50.05 49.60, 50.50 0.041
C 47.31 44.61, 50.01 50.06 49.60, 50.52 0.049 44.81 39.74, 49.89 50.05 49.59, 50.50 0.045
Imp 54.16 50.89, 57.43 49.91 49.45, 50.36 0.013 56.76 50.49, 63.03 49.94 49.49, 50.39 0.035
SS 57.33 54.76, 59.89 49.84 49.38, 50.29 < 0.001 57.30 53.19, 61.41 49.93 49.48, 50.39 0.002
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Table A.2. Continued
Factor Month based Week based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Benzodiazepines
# 299 1586 179 1706
N 55.26 54.11, 56.41 49.01 48.53, 49.48 < 0.001 56.56 55.08, 58.04 49.31 48.85, 49.77 < 0.001
E 48.06 46.79, 49.33 50.37 49.89, 50.84 0.001 46.15 44.61, 47.70 50.40 49.93, 50.87 < 0.001
O 52.68 51.58, 53.77 49.49 49.00, 49.99 < 0.001 52.18 50.72, 53.63 49.77 49.30, 50.25 0.002
A 46.72 45.47, 47.97 50.62 50.14, 51.09 < 0.001 46.57 44.94, 48.21 50.36 49.89, 50.83 < 0.001
C 46.54 45.40, 47.69 50.65 50.17, 51.14 < 0.001 46.20 44.75, 47.65 50.40 49.93, 50.87 < 0.001
Imp 54.06 52.96, 55.16 49.23 48.75, 49.72 < 0.001 53.89 52.47, 55.31 49.59 49.12, 50.06 < 0.001
SS 54.36 53.34, 55.38 49.18 48.69, 49.67 < 0.001 53.62 52.28, 54.95 49.62 49.14, 50.10 < 0.001
Cannabis
# 788 1097 648 1237
N 50.72 49.99, 51.45 49.48 48.91, 50.06 0.009 50.62 49.82, 51.42 49.68 49.13, 50.22 0.055
E 50.06 49.31, 50.80 49.96 49.40, 50.52 0.839 50.17 49.36, 50.97 49.91 49.37, 50.46 0.606
O 54.34 53.74, 54.94 46.88 46.30, 47.46 < 0.001 54.70 54.05, 55.35 47.54 46.99, 48.09 < 0.001
A 48.66 47.93, 49.38 50.97 50.39, 51.54 < 0.001 48.78 48.00, 49.56 50.64 50.09, 51.19 < 0.001
C 47.26 46.55, 47.97 51.97 51.41, 52.52 < 0.001 47.45 46.67, 48.23 51.34 50.80, 51.88 < 0.001
Imp 53.14 52.46, 53.82 47.74 47.17, 48.31 < 0.001 53.02 52.29, 53.75 48.42 47.87, 48.97 < 0.001
SS 54.82 54.25, 55.40 46.53 45.96, 47.11 < 0.001 54.87 54.22, 55.51 47.45 46.90, 48.00 < 0.001
Chocolate
# 1786 99 1490 395
N 49.98 49.52, 50.44 50.40 48.19, 52.60 0.714 49.95 49.44, 50.45 50.20 49.18, 51.23 0.660
E 50.03 49.57, 50.49 49.43 47.38, 51.49 0.574 50.22 49.72, 50.73 49.16 48.14, 50.17 0.065
O 50.05 49.58, 50.51 49.13 47.37, 50.90 0.323 49.89 49.37, 50.40 50.42 49.48, 51.36 0.327
A 50.04 49.57, 50.50 49.36 47.19, 51.53 0.548 50.20 49.70, 50.70 49.23 48.19, 50.27 0.099
C 49.95 49.49, 50.41 50.89 48.82, 52.97 0.380 50.13 49.62, 50.63 49.51 48.50, 50.53 0.286
Imp 49.97 49.50, 50.43 50.61 48.75, 52.46 0.508 49.93 49.43, 50.44 50.25 49.26, 51.24 0.580
SS 50.02 49.55, 50.48 49.72 47.63, 51.81 0.783 49.72 49.21, 50.22 51.07 50.06, 52.08 0.019
Cocaine
# 159 1726 60 1825
N 52.87 51.29, 54.46 49.74 49.27, 50.21 < 0.001 53.24 50.50, 55.98 49.89 49.44, 50.35 0.019
E 51.34 49.50, 53.18 49.88 49.41, 50.34 0.129 52.03 49.22, 54.84 49.93 49.48, 50.39 0.146
O 52.53 51.00, 54.06 49.77 49.30, 50.24 0.001 51.40 48.83, 53.97 49.95 49.49, 50.41 0.273
A 45.75 44.05, 47.46 50.39 49.93, 50.86 < 0.001 43.74 40.80, 46.68 50.21 49.75, 50.66 < 0.001
C 47.23 45.72, 48.75 50.25 49.78, 50.73 < 0.001 46.72 44.32, 49.11 50.11 49.65, 50.57 0.007
Imp 54.59 53.06, 56.11 49.58 49.11, 50.05 < 0.001 54.87 52.42, 57.32 49.84 49.38, 50.30 < 0.001
SS 56.48 55.10, 57.86 49.40 48.94, 49.87 < 0.001 57.38 55.14, 59.62 49.76 49.30, 50.21 < 0.001
Caffeine
# 1764 121 1658 227
N 50.05 49.59, 50.52 49.21 47.37, 51.05 0.379 50.07 49.59, 50.55 49.46 48.11, 50.81 0.400
E 50.16 49.69, 50.63 47.68 45.94, 49.43 0.008 50.20 49.72, 50.68 48.54 47.27, 49.81 0.016
O 50.12 49.65, 50.58 48.29 46.47, 50.11 0.056 50.04 49.56, 50.52 49.71 48.40, 51.03 0.645
A 49.98 49.51, 50.45 50.27 48.50, 52.04 0.754 49.93 49.45, 50.41 50.48 49.15, 51.81 0.446
C 49.95 49.49, 50.42 50.67 48.77, 52.56 0.473 49.95 49.47, 50.43 50.37 49.01, 51.72 0.569
Imp 50.22 49.75, 50.68 46.85 45.15, 48.55 < 0.001 50.17 49.69, 50.65 48.76 47.48, 50.04 0.043
SS 50.20 49.73, 50.66 47.09 45.29, 48.90 0.001 50.11 49.63, 50.60 49.16 47.89, 50.43 0.169
Continued on the next page
108 A Main tables
Table A.2. Continued
Factor Month based Week based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Crack
# 20 1865 11 1874
N 57.86 52.26, 63.45 49.92 49.46, 50.37 0.008 55.26 45.53, 64.99 49.97 49.52, 50.42 0.254
E 45.97 41.31, 50.64 50.04 49.59, 50.50 0.085 46.46 38.43, 54.50 50.02 49.57, 50.47 0.348
O 50.89 47.21, 54.57 49.99 49.54, 50.45 0.616 48.01 43.74, 52.28 50.01 49.56, 50.47 0.324
A 42.99 36.35, 49.62 50.08 49.62, 50.53 0.038 39.62 30.12, 49.11 50.06 49.61, 50.51 0.034
C 45.14 40.37, 49.91 50.05 49.60, 50.51 0.045 44.28 36.73, 51.83 50.03 49.58, 50.49 0.121
Imp 55.89 51.51, 60.27 49.94 49.48, 50.39 0.011 56.94 50.59, 63.29 49.96 49.51, 50.41 0.034
SS 57.01 54.05, 59.96 49.92 49.47, 50.38 < 0.001 58.03 54.16, 61.91 49.95 49.50, 50.41 0.001
Ecstasy
# 240 1645 84 1801
N 49.53 48.18, 50.89 50.07 49.59, 50.55 0.465 50.28 47.99, 52.58 49.99 49.53, 50.45 0.803
E 52.24 50.82, 53.65 49.67 49.20, 50.15 0.001 53.37 50.71, 56.02 49.84 49.39, 50.30 0.011
O 54.41 53.23, 55.59 49.36 48.88, 49.84 < 0.001 56.15 54.15, 58.15 49.71 49.25, 50.17 < 0.001
A 48.10 46.75, 49.45 50.28 49.80, 50.76 0.003 48.56 46.38, 50.75 50.07 49.61, 50.53 0.184
C 47.27 45.96, 48.59 50.40 49.92, 50.88 < 0.001 46.98 44.78, 49.18 50.14 49.68, 50.60 0.006
Imp 53.43 52.19, 54.68 49.50 49.02, 49.98 < 0.001 55.71 53.49, 57.93 49.73 49.28, 50.19 < 0.001
SS 55.63 54.62, 56.64 49.18 48.69, 49.66 < 0.001 56.57 54.81, 58.34 49.69 49.23, 50.15 < 0.001
Heroin
# 53 1832 29 1856
N 56.69 54.05, 59.34 49.81 49.35, 50.26 < 0.001 58.65 55.84, 61.47 49.86 49.41, 50.32 < 0.001
E 45.58 42.06, 49.10 50.13 49.67, 50.58 0.013 44.77 39.81, 49.73 50.08 49.63, 50.53 0.038
O 52.48 49.63, 55.34 49.93 49.47, 50.39 0.082 52.41 48.00, 56.81 49.96 49.51, 50.42 0.268
A 42.18 39.00, 45.35 50.23 49.77, 50.68 < 0.001 41.48 38.25, 44.70 50.13 49.68, 50.59 < 0.001
C 43.36 40.35, 46.37 50.19 49.74, 50.65 < 0.001 43.04 38.95, 47.12 50.11 49.66, 50.56 0.001
Imp 57.08 54.63, 59.53 49.80 49.34, 50.25 < 0.001 56.79 53.59, 59.99 49.89 49.44, 50.35 < 0.001
SS 57.30 54.94, 59.66 49.79 49.33, 50.25 < 0.001 56.36 52.91, 59.81 49.90 49.45, 50.36 0.001
Ketamine
# 79 1806 37 1848
N 51.29 49.14, 53.45 49.94 49.48, 50.41 0.227 50.47 46.78, 54.16 49.99 49.54, 50.45 0.795
E 49.62 46.74, 52.49 50.02 49.56, 50.47 0.785 47.23 42.01, 52.46 50.06 49.61, 50.50 0.282
O 54.79 52.59, 56.98 49.79 49.33, 50.25 < 0.001 54.39 50.87, 57.90 49.91 49.46, 50.37 0.015
A 46.90 44.15, 49.66 50.14 49.68, 50.59 0.024 44.50 40.15, 48.85 50.11 49.66, 50.56 0.013
C 45.03 42.50, 47.56 50.22 49.76, 50.67 < 0.001 44.99 41.13, 48.85 50.10 49.65, 50.55 0.011
Imp 53.39 51.39, 55.38 49.85 49.39, 50.31 0.001 53.74 50.75, 56.74 49.93 49.47, 50.38 0.015
SS 54.96 53.13, 56.80 49.78 49.32, 50.25 < 0.001 55.44 52.84, 58.04 49.89 49.43, 50.35 < 0.001
Legal highs
# 241 1644 131 1754
N 52.02 50.68, 53.36 49.70 49.23, 50.18 0.002 53.13 51.32, 54.94 49.77 49.30, 50.23 0.001
E 49.10 47.59, 50.61 50.13 49.66, 50.60 0.200 47.12 45.06, 49.18 50.22 49.76, 50.67 0.004
O 54.37 53.22, 55.53 49.36 48.88, 49.84 < 0.001 53.16 51.53, 54.79 49.76 49.30, 50.23 < 0.001
A 46.83 45.50, 48.16 50.46 49.99, 50.94 < 0.001 46.25 44.62, 47.87 50.28 49.81, 50.75 < 0.001
C 45.30 44.01, 46.60 50.69 50.21, 51.16 < 0.001 44.50 42.89, 46.11 50.41 49.95, 50.88 < 0.001
Imp 54.21 53.00, 55.41 49.38 48.90, 49.86 < 0.001 54.25 52.56, 55.94 49.68 49.22, 50.15 < 0.001
SS 56.05 55.05, 57.04 49.11 48.63, 49.60 < 0.001 55.37 53.99, 56.74 49.60 49.13, 50.07 < 0.001
Continued on the next page
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Table A.2. Continued
Factor Month based Week based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
LSD
# 166 1719 69 1816
N 50.55 48.97, 52.12 49.95 49.48, 50.42 0.472 50.28 47.82, 52.73 49.99 49.53, 50.45 0.820
E 51.28 49.53, 53.04 49.88 49.41, 50.34 0.128 52.70 49.90, 55.51 49.90 49.44, 50.35 0.053
O 57.28 56.15, 58.41 49.30 48.83, 49.77 < 0.001 57.56 55.78, 59.34 49.71 49.25, 50.17 < 0.001
A 48.92 47.35, 50.48 50.10 49.63, 50.58 0.153 50.03 47.88, 52.17 50.00 49.54, 50.46 0.979
C 47.10 45.59, 48.60 50.28 49.81, 50.75 < 0.001 46.98 44.90, 49.06 50.11 49.65, 50.58 0.004
Imp 53.35 51.90, 54.81 49.68 49.20, 50.15 < 0.001 52.51 50.18, 54.84 49.90 49.44, 50.36 0.032
SS 56.50 55.32, 57.68 49.37 48.90, 49.84 < 0.001 56.09 54.22, 57.96 49.77 49.31, 50.23 < 0.001
Methadone
# 171 1714 121 1764
N 54.53 53.00, 56.06 49.55 49.08, 50.02 < 0.001 54.99 53.14, 56.84 49.66 49.20, 50.12 < 0.001
E 46.86 45.08, 48.65 50.31 49.85, 50.78 < 0.001 45.27 43.11, 47.43 50.32 49.87, 50.78 < 0.001
O 52.89 51.37, 54.40 49.71 49.24, 50.18 < 0.001 51.87 50.02, 53.72 49.87 49.41, 50.34 0.040
A 46.18 44.50, 47.87 50.38 49.92, 50.85 < 0.001 46.00 43.84, 48.16 50.27 49.82, 50.73 < 0.001
C 45.44 43.83, 47.06 50.45 49.99, 50.92 < 0.001 45.74 43.89, 47.59 50.29 49.83, 50.76 < 0.001
Imp 53.89 52.36, 55.42 49.61 49.14, 50.08 < 0.001 53.55 51.76, 55.34 49.76 49.29, 50.22 < 0.001
SS 54.71 53.25, 56.17 49.53 49.06, 50.00 < 0.001 53.93 52.18, 55.67 49.73 49.27, 50.20 < 0.001
Magic mushrooms
# 159 1726 44 1841
N 49.91 48.41, 51.42 50.01 49.53, 50.48 0.906 49.79 46.82, 52.75 50.01 49.55, 50.46 0.884
E 50.31 48.50, 52.12 49.97 49.51, 50.44 0.720 53.71 50.31, 57.12 49.91 49.46, 50.37 0.031
O 56.92 55.77, 58.07 49.36 48.89, 49.83 < 0.001 57.89 55.73, 60.05 49.81 49.36, 50.27 < 0.001
A 48.57 46.94, 50.19 50.13 49.66, 50.60 0.070 50.14 46.71, 53.57 50.00 49.54, 50.45 0.935
C 46.85 45.25, 48.45 50.29 49.82, 50.76 < 0.001 48.03 45.33, 50.74 50.05 49.59, 50.51 0.146
Imp 53.61 52.13, 55.09 49.67 49.20, 50.14 < 0.001 55.44 52.56, 58.32 49.87 49.41, 50.33 < 0.001
SS 56.18 54.94, 57.41 49.43 48.96, 49.90 < 0.001 57.95 55.75, 60.15 49.81 49.35, 50.27 < 0.001
Nicotine
# 875 1010 767 1118
N 51.11 50.43, 51.79 49.04 48.44, 49.64 < 0.001 51.32 50.59, 52.04 49.10 48.52, 49.67 < 0.001
E 49.98 49.29, 50.66 50.02 49.42, 50.62 0.924 49.91 49.17, 50.65 50.06 49.49, 50.63 0.748
O 51.86 51.19, 52.52 48.39 47.79, 48.99 < 0.001 51.57 50.85, 52.28 48.92 48.35, 49.50 < 0.001
A 49.02 48.34, 49.71 50.85 50.25, 51.44 < 0.001 49.04 48.31, 49.78 50.66 50.09, 51.23 0.001
C 47.69 47.03, 48.34 52.00 51.41, 52.60 < 0.001 47.69 46.99, 48.38 51.59 51.01, 52.16 < 0.001
Imp 52.48 51.80, 53.15 47.86 47.28, 48.43 < 0.001 52.56 51.84, 53.28 48.24 47.68, 48.80 < 0.001
SS 52.88 52.24, 53.51 47.51 46.91, 48.10 < 0.001 52.81 52.13, 53.50 48.07 47.50, 48.64 < 0.001
VSA
# 34 1851 21 1864
N 51.34 47.49, 55.20 49.98 49.52, 50.43 0.479 50.92 46.02, 55.82 49.99 49.54, 50.44 0.697
E 51.80 48.00, 55.60 49.97 49.51, 50.42 0.338 52.59 47.66, 57.53 49.97 49.52, 50.42 0.283
O 54.65 51.65, 57.65 49.91 49.46, 50.37 0.003 56.30 53.63, 58.97 49.93 49.47, 50.38 < 0.001
A 45.91 42.12, 49.71 50.08 49.62, 50.53 0.034 46.36 41.38, 51.34 50.04 49.59, 50.49 0.141
C 47.22 43.63, 50.81 50.05 49.60, 50.51 0.121 49.99 45.49, 54.49 50.00 49.55, 50.45 0.995
Imp 55.93 53.25, 58.62 49.89 49.43, 50.35 < 0.001 55.21 51.37, 59.04 49.94 49.49, 50.40 0.010
SS 58.61 56.27, 60.95 49.84 49.39, 50.30 < 0.001 59.05 56.49, 61.61 49.90 49.44, 50.35 < 0.001
Continued on the next page
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Table A.2. Continued
Factor Month based Week based
Users Non-users p-value Users Non-users p-value
MT 95% CI MT 95% CI MT 95% CI MT 95% CI
Heroin pleiad
# 309 1576 184 1701
N 53.20 52.08, 54.32 49.37 48.88, 49.86 < 0.001 54.58 53.07, 56.08 49.50 49.04, 49.97 < 0.001
E 48.83 47.49, 50.18 50.23 49.76, 50.70 0.054 47.18 45.42, 48.95 50.30 49.84, 50.77 0.001
O 52.60 51.51, 53.69 49.49 49.00, 49.98 < 0.001 52.13 50.69, 53.57 49.77 49.29, 50.24 0.002
A 46.40 45.22, 47.59 50.71 50.22, 51.19 < 0.001 45.57 43.99, 47.16 50.48 50.01, 50.94 < 0.001
C 46.69 45.54, 47.84 50.65 50.16, 51.13 < 0.001 45.57 44.13, 47.01 50.48 50.01, 50.95 < 0.001
Imp 54.24 53.12, 55.35 49.17 48.69, 49.65 < 0.001 54.25 52.81, 55.68 49.54 49.07, 50.01 < 0.001
SS 55.31 54.27, 56.36 48.96 48.47, 49.44 < 0.001 55.04 53.66, 56.41 49.46 48.98, 49.93 < 0.001
Ecstasy pleiad
# 921 964 792 1093
N 50.98 50.30, 51.66 49.06 48.47, 49.66 < 0.001 50.94 50.22, 51.67 49.32 48.74, 49.89 0.001
E 49.72 49.02, 50.41 50.27 49.69, 50.85 0.234 49.69 48.94, 50.43 50.23 49.66, 50.79 0.255
O 53.86 53.29, 54.43 46.31 45.70, 46.92 < 0.001 54.07 53.46, 54.69 47.05 46.47, 47.63 < 0.001
A 48.32 47.65, 48.99 51.61 51.01, 52.20 < 0.001 48.34 47.63, 49.06 51.20 50.63, 51.77 < 0.001
C 47.08 46.42, 47.74 52.79 52.23, 53.35 < 0.001 47.08 46.38, 47.78 52.12 51.56, 52.67 < 0.001
Imp 53.25 52.61, 53.88 46.90 46.32, 47.48 < 0.001 53.23 52.55, 53.92 47.66 47.10, 48.22 < 0.001
SS 54.58 54.03, 55.14 45.62 45.03, 46.21 < 0.001 54.64 54.05, 55.24 46.63 46.06, 47.21 < 0.001
Benzodiazepines pleiad
# 528 1357 363 1522
N 53.44 52.58, 54.30 48.66 48.15, 49.18 < 0.001 54.57 53.51, 55.63 48.91 48.43, 49.39 < 0.001
E 48.88 47.92, 49.84 50.44 49.93, 50.94 0.005 47.72 46.57, 48.87 50.54 50.06, 51.03 < 0.001
O 52.57 51.74, 53.40 49.00 48.47, 49.53 < 0.001 52.13 51.09, 53.16 49.49 48.99, 49.99 < 0.001
A 47.15 46.26, 48.04 51.11 50.60, 51.62 < 0.001 46.76 45.68, 47.84 50.77 50.28, 51.26 < 0.001
C 46.46 45.60, 47.32 51.38 50.87, 51.89 < 0.001 45.64 44.58, 46.69 51.04 50.55, 51.53 < 0.001
Imp 53.90 53.06, 54.75 48.48 47.97, 48.99 < 0.001 54.50 53.48, 55.52 48.93 48.44, 49.42 < 0.001
SS 54.61 53.84, 55.39 48.20 47.68, 48.73 < 0.001 54.24 53.29, 55.20 48.99 48.49, 49.49 < 0.001
Illicit drugs
# 996 889 862 1023
N 51.33 50.67, 51.98 48.56 47.96, 49.15 < 0.001 51.41 50.70, 52.12 48.76 48.19, 49.33 < 0.001
E 49.43 48.76, 50.10 51.03 50.47, 51.59 0.002 49.28 48.56, 50.01 51.13 50.59, 51.67 0.001
O 53.46 52.90, 54.03 45.82 45.20, 46.45 < 0.001 53.67 53.06, 54.27 46.07 45.47, 46.66 < 0.001
A 48.36 47.72, 49.00 51.48 50.87, 52.10 < 0.001 48.34 47.65, 49.03 51.19 50.60, 51.78 < 0.001
C 47.22 46.58, 47.86 53.36 52.79, 53.92 < 0.001 47.09 46.41, 47.77 53.07 52.53, 53.60 < 0.001
Imp 52.97 52.36, 53.58 46.40 45.80, 46.99 < 0.001 53.08 52.42, 53.73 46.72 46.16, 47.28 < 0.001
SS 54.17 53.63, 54.71 44.78 44.17, 45.40 < 0.001 54.35 53.76, 54.93 45.22 44.65, 45.79 < 0.001
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A.3 Linear discriminants for user/non-user separation
Linear discriminants separate users from non-users by linear inequalities:
Θ +∑cizi > 0
for users and ≤ 0 for non-users, whereΘ are the threscholds, zi are the attributes, and ci are the coefficients.
Tables A.5-A.8 contain the coefficients ci of linear discriminants for user/nonuser separation in 10-dimensional
space (7 psychological attributes, age, education, gender). The attributes in these tables are quantified and
transformed to z-scores with zero mean and unite variance (positive values of the Gndr z-score corresponds
to female). The last rows of the tables include the standard deviaton of the coefficients in LOOCV. For
7-dimensional space of psychological attributes taken separately (T-scores), the linear discriminants are
presented in tables A.13-A.16.
Performance of linear discriminants in user/non-user separation is evaluated by several methods (tables
A.9–A.12 for 10-dimensional data space and tables A.17–A.20 for 7-dimensional space of T-scores of
psychological attributes). First of all, we calculated the linear discriminant using the whole sample (see
tables A.5–A.8) and find all their errors. For each solution of the classification problem we have several
numbers, P (positive), the number of samples recognised as positive, and N - negative, the number of samples
recognised as negative. P+N is the total number of samples. P=TP+FP (True Positive plus False Positive)
and N=TN+FN (True Negative plus False Negative). Sensitivity is Sn=TP/(TP+FN)×100% and Specificity
is Sp=TN/(TN+FP)×100%. Accuracy is Acc=(TP+TN)/(P+N)×100%. We calculate these performance
indicators for the total sample and for the LOOCV procedure. In LOOCV the linear discriminant is calculated
for the set of all samples excluding the example left out for testing. The test was performed for all samples with
the corresponding redefining of Sn, Sp, and Acc. In LOOCV the linear discriminants are calculated for each
testing example. Each of these discriminants is a separate classification model. Stability of classification can
be measured by the number of examples which change their class at least once. We took the basis model for
the total sample and find how many true positive examples of this model became FN examples of a LOOCV
model at least once. This number measured in % of TP+FP of the basic model is TP→FN. Analogously, we
defined FP→TN, TN→FP, and FN→TP. The last two numbers are measured in % of TN+FN of the basic
model.
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Table A.5 Coefficients of linear discriminant for user/non-user separation and decade-based definition of users (10 attributes)
Drug Θ Age Edu N E O A C Imp SS Gndr
Alcohol 0.358 -0.463 0.266 -0.042 0.030 -0.103 -0.117 -0.361 -0.031 0.710 0.230
Amphetamines -0.236 -0.569 -0.236 0.081 -0.146 0.307 -0.017 -0.202 0.119 0.559 -0.362
Amyl nitrite -0.261 -0.549 0.251 0.110 0.180 -0.142 -0.031 -0.229 -0.063 0.556 -0.451
Benz. -0.098 -0.067 -0.243 0.566 -0.152 0.595 -0.164 -0.128 0.088 0.378 -0.214
Cannabis 0.434 -0.639 -0.241 -0.043 -0.213 0.518 -0.127 -0.193 0.043 0.352 -0.196
Chocolate 0.210 -0.169 -0.387 -0.149 -0.303 0.673 0.135 -0.168 -0.408 0.109 0.170
Cocaine -0.198 -0.441 -0.121 0.220 0.068 0.276 -0.287 -0.235 0.090 0.682 -0.226
Caffeine 0.547 -0.522 -0.001 -0.262 0.388 0.331 0.070 -0.554 -0.074 0.266 0.097
Crack -0.659 0.059 -0.577 0.175 -0.129 0.308 -0.088 -0.112 0.384 0.435 -0.405
Ecstasy -0.171 -0.631 -0.188 0.053 0.018 0.351 -0.065 -0.210 -0.088 0.559 -0.265
Heroin -0.615 -0.210 -0.370 0.413 -0.211 0.477 -0.265 -0.029 0.222 0.381 -0.332
Ketamine -0.448 -0.560 -0.005 0.065 -0.022 0.367 -0.139 -0.223 0.037 0.507 -0.469
Legal highs -0.172 -0.655 -0.131 0.015 -0.174 0.427 0.006 -0.143 -0.052 0.429 -0.366
LSD -0.409 -0.581 -0.168 -0.069 -0.203 0.539 -0.060 -0.027 -0.000 0.419 -0.344
Methadone -0.433 -0.346 -0.382 0.225 -0.336 0.564 -0.212 -0.118 0.088 0.274 -0.332
MMushrooms -0.243 -0.616 -0.134 -0.119 -0.186 0.541 -0.064 -0.139 0.075 0.358 -0.321
Nicotine 0.324 -0.657 -0.365 0.123 -0.072 0.364 -0.082 -0.196 0.026 0.450 -0.184
VSA -0.818 -0.805 -0.143 0.059 -0.145 0.207 -0.066 -0.189 0.023 0.441 -0.172
Heroin pleiad -0.082 -0.377 -0.240 0.146 -0.117 0.450 -0.260 -0.240 0.062 0.605 -0.261
Ecstasy pleiad 0.494 -0.632 -0.223 -0.041 -0.201 0.504 -0.164 -0.228 0.034 0.372 -0.191
Benz. pleiad 0.151 -0.316 -0.292 0.274 -0.100 0.524 -0.175 -0.233 -0.008 0.552 -0.257
Illicit drugs 0.624 -0.573 -0.263 0.069 -0.243 0.523 -0.142 -0.243 0.070 0.360 -0.228
SD ≤ 0.009 ≤ 0.006 ≤ 0.006 ≤ 0.007 ≤ 0.006 ≤ 0.005 ≤ 0.006 ≤ 0.007 ≤ 0.007 ≤ 0.008 ≤ 0.006
Table A.6 Coefficients of linear discriminant for user/non-user separation and year-based definition of users (10 attributes)
Drug Θ Age Edu N E O A C Imp SS Gndr
Alcohol 0.218 -0.585 0.342 -0.228 0.101 -0.133 -0.031 -0.165 -0.211 0.575 0.241
Amphetamines -0.543 -0.643 -0.249 0.063 -0.176 0.347 -0.103 -0.201 0.241 0.418 -0.293
Amyl nitrite -0.527 -0.647 0.085 0.124 0.075 -0.036 -0.249 -0.142 -0.191 0.420 -0.507
Benz. -0.296 -0.272 -0.263 0.594 -0.110 0.437 -0.187 -0.007 0.102 0.419 -0.282
Cannabis 0.130 -0.569 -0.310 -0.069 -0.190 0.521 -0.020 -0.194 -0.034 0.411 -0.245
Chocolate 0.169 -0.259 -0.217 0.036 -0.168 0.575 0.064 -0.236 -0.571 0.072 0.367
Cocaine -0.494 -0.685 -0.007 0.211 0.177 0.077 -0.247 -0.175 0.086 0.521 -0.280
Caffeine 0.517 -0.323 0.129 -0.305 0.469 0.039 -0.061 -0.602 0.079 0.434 0.063
Crack -0.973 -0.153 -0.408 0.257 -0.014 0.090 -0.060 -0.079 0.346 0.376 -0.682
Ecstasy -0.464 -0.782 -0.101 -0.015 0.099 0.238 -0.025 -0.173 -0.004 0.453 -0.275
Heroin -0.849 -0.584 -0.168 0.352 -0.252 0.222 -0.275 0.014 0.216 0.359 -0.378
Ketamine -0.675 -0.790 0.033 0.070 0.046 0.214 -0.075 -0.189 0.038 0.354 -0.392
Legal highs -0.432 -0.656 -0.212 -0.035 -0.134 0.370 -0.054 -0.129 -0.026 0.481 -0.342
LSD -0.685 -0.757 -0.128 -0.112 -0.137 0.451 0.001 0.040 -0.015 0.302 -0.288
Methadone -0.527 -0.450 -0.322 0.244 -0.331 0.495 -0.246 -0.051 0.050 0.289 -0.360
MMushrooms -0.573 -0.712 -0.197 -0.106 -0.119 0.490 -0.033 -0.053 0.040 0.293 -0.310
Nicotine 0.149 -0.579 -0.446 0.096 -0.076 0.345 -0.017 -0.255 0.011 0.472 -0.209
VSA -0.847 -0.859 -0.111 0.268 0.002 0.087 -0.032 -0.095 -0.016 0.315 -0.247
Heroin pleiad -0.368 -0.601 -0.190 0.176 -0.088 0.299 -0.267 -0.169 0.092 0.506 -0.333
Ecstasy pleiad 0.230 -0.576 -0.296 -0.062 -0.222 0.512 -0.077 -0.185 0.013 0.396 -0.261
Benz. pleiad -0.069 -0.449 -0.284 0.292 -0.119 0.429 -0.207 -0.156 0.073 0.537 -0.271
Illicit drugs 0.348 -0.524 -0.335 0.032 -0.248 0.528 -0.092 -0.182 0.036 0.395 -0.271
SD ≤ 0.014 ≤ 0.007 ≤ 0.007 ≤ 0.009 ≤ 0.008 ≤ 0.007 ≤ 0.008 ≤ 0.008 ≤ 0.007 ≤ 0.010 ≤ 0.007
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Table A.7 Coefficients of linear discriminant for user/non-user separation and month-based definition of users (10 attributes)
Drug Θ Age Edu N E O A C Imp SS Gndr
Alcohol 0.130 -0.263 0.590 0.096 0.588 -0.111 0.078 -0.083 -0.193 0.402 0.058
Amphetamines -0.543 -0.643 -0.249 0.063 -0.176 0.347 -0.103 -0.201 0.241 0.418 -0.293
Amyl nitrite -0.821 -0.361 -0.229 -0.223 -0.114 -0.178 -0.144 -0.018 -0.088 0.749 -0.365
Benz. -0.416 -0.115 -0.243 0.711 -0.128 0.284 -0.180 0.072 0.167 0.418 -0.292
Cannabis -0.122 -0.542 -0.394 -0.132 -0.166 0.547 -0.037 -0.132 0.015 0.355 -0.250
Chocolate 0.132 0.138 -0.284 -0.161 0.107 0.379 -0.004 -0.440 -0.488 0.193 0.501
Cocaine -0.597 -0.624 0.029 0.345 0.212 -0.007 -0.305 0.054 0.062 0.523 -0.270
Caffeine 0.273 -0.019 0.369 0.261 0.637 -0.043 0.035 -0.239 0.424 0.385 0.042
Crack -0.836 0.154 -0.131 0.449 -0.114 -0.075 -0.253 0.156 0.076 0.581 -0.555
Ecstasy -0.633 -0.820 0.047 -0.139 0.093 0.284 -0.123 -0.165 -0.028 0.328 -0.257
Heroin -1.037 -0.560 -0.371 0.181 -0.350 0.159 -0.397 0.016 0.368 0.154 -0.226
Ketamine -0.793 -0.776 0.020 -0.097 -0.147 0.340 -0.098 -0.268 -0.039 0.139 -0.386
Legal highs -0.693 -0.519 -0.224 -0.012 -0.190 0.409 -0.136 -0.240 0.022 0.427 -0.467
LSD -0.851 -0.722 -0.173 0.006 -0.045 0.541 0.007 -0.032 -0.098 0.252 -0.284
Methadone -0.551 -0.404 -0.259 0.262 -0.443 0.417 -0.270 -0.105 0.003 0.399 -0.296
MMushrooms -0.764 -0.594 -0.233 -0.184 -0.236 0.604 -0.019 -0.066 0.070 0.239 -0.267
Nicotine -0.019 -0.461 -0.530 0.092 0.037 0.318 0.013 -0.375 0.157 0.389 -0.283
VSA -1.027 -0.785 0.003 0.081 0.059 0.174 -0.215 0.073 0.096 0.482 -0.222
Heroin pleiad -0.545 -0.525 -0.187 0.301 -0.180 0.224 -0.295 0.013 0.129 0.530 -0.364
Ecstasy pleiad 0.019 -0.576 -0.339 -0.133 -0.207 0.514 -0.098 -0.172 0.073 0.355 -0.241
Benz. pleiad -0.346 -0.309 -0.254 0.479 -0.125 0.274 -0.215 -0.123 0.171 0.534 -0.380
Illicit drugs 0.111 -0.513 -0.390 -0.034 -0.236 0.532 -0.097 -0.151 0.061 0.371 -0.267
SD ≤ 0.008 ≤ 0.006 ≤ 0.005 ≤ 0.006 ≤ 0.006 ≤ 0.006 ≤ 0.006 ≤ 0.006 ≤ 0.008 ≤ 0.008 ≤ 0.006
Table A.8 Coefficients of linear discriminant for user/non-user separation and week-based definition of users (10 attributes)
Drug Θ Age Edu N E O A C Imp SS Gndr
Alcohol 0.063 0.053 0.640 0.157 0.522 -0.283 0.069 -0.125 -0.105 0.412 -0.099
Amphetamines -0.546 -0.441 -0.070 -0.071 -0.295 0.348 -0.207 -0.359 0.584 0.120 -0.248
Amyl nitrite -0.747 0.023 0.173 -0.389 -0.351 -0.203 0.006 -0.213 0.214 0.695 -0.281
Benz. -0.546 0.027 -0.331 0.680 -0.371 0.273 -0.230 0.091 0.231 0.287 -0.137
Cannabis -0.240 -0.502 -0.402 -0.120 -0.172 0.594 -0.036 -0.108 -0.023 0.335 -0.253
Chocolate 0.109 0.390 0.195 0.117 0.444 -0.034 0.114 -0.172 0.283 -0.461 0.513
Cocaine -0.806 -0.543 0.015 0.358 0.274 -0.118 -0.299 -0.048 -0.042 0.534 -0.331
Caffeine 0.131 0.484 0.200 0.335 0.637 -0.079 -0.166 -0.277 0.088 0.273 0.122
Crack -1.170 0.151 -0.096 0.258 -0.068 -0.347 -0.312 0.133 0.111 0.438 -0.676
Ecstasy -0.779 -0.697 0.077 -0.115 0.161 0.545 -0.093 -0.252 0.217 0.230 -0.022
Heroin -1.096 -0.386 -0.077 0.467 -0.255 0.184 -0.412 0.013 0.437 -0.077 -0.400
Ketamine -0.732 -0.665 0.074 -0.176 -0.223 0.380 -0.264 -0.239 -0.087 0.117 -0.423
Legal highs -0.755 -0.377 -0.252 0.037 -0.302 0.300 -0.253 -0.295 -0.016 0.422 -0.531
LSD -1.085 -0.679 -0.310 0.039 0.043 0.421 0.053 -0.054 -0.168 0.127 -0.462
Methadone -0.606 -0.359 -0.247 0.290 -0.549 0.380 -0.242 -0.024 0.085 0.257 -0.384
MMushrooms -0.657 -0.296 -0.281 -0.136 -0.046 0.705 0.036 -0.030 0.070 0.529 -0.167
Nicotine -0.040 -0.252 -0.653 0.201 0.075 0.233 0.052 -0.335 0.194 0.403 -0.308
VSA -1.047 -0.620 -0.042 0.076 0.016 0.270 -0.204 0.301 -0.021 0.555 -0.306
Heroin pleiad -0.680 -0.390 -0.234 0.360 -0.304 0.248 -0.309 -0.119 0.136 0.431 -0.442
Ecstasy pleiad -0.113 -0.524 -0.387 -0.127 -0.219 0.545 -0.093 -0.159 0.047 0.341 -0.251
Benz. pleiad -0.423 -0.269 -0.305 0.504 -0.294 0.260 -0.233 -0.163 0.381 0.362 -0.265
Illicit drugs -0.051 -0.471 -0.414 -0.029 -0.266 0.540 -0.080 -0.142 0.048 0.378 -0.268
SD ≤ 0.018 ≤ 0.006 ≤ 0.005 ≤ 0.005 ≤ 0.005 ≤ 0.005 ≤ 0.006 ≤ 0.005 ≤ 0.006 ≤ 0.006 ≤ 0.005
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Table A.9 Performance and stability of linear discriminant for decade-based definition of users (10 attributes).
Total sample LOOCV Stability indicators
Drug Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Alcohol 65.1 67.6 65.2 64.9 57.4 64.6 5.8 8.5 11.8 7.4
Amphetamines 72.0 71.9 71.9 71.1 71.5 71.4 1.2 0.9 0.7 0.5
Amyl nitrite 63.8 63.6 63.6 62.2 63.0 62.9 2.4 1.6 1.3 1.8
Benz. 67.4 67.5 67.4 66.8 67.1 67.0 0.4 0.4 0.6 1.3
Cannabis 78.1 78.2 78.1 77.9 77.6 77.8 0.4 0.6 0.8 1.0
Chocolate 57.9 57.1 57.9 57.5 37.1 57.1 11.2 14.3 14.1 28.6
Cocaine 67.7 67.6 67.6 67.0 67.3 67.2 0.9 0.6 0.5 1.0
Caffeine 68.7 70.3 68.8 68.6 62.2 68.5 5.5 8.8 8.1 13.5
Crack 69.6 69.1 69.1 65.4 68.9 68.5 5.2 2.1 1.7 1.7
Ecstasy 74.4 74.7 74.6 74.2 74.3 74.2 0.3 0.7 0.5 0.4
Heroin 70.8 69.9 70.0 68.4 69.8 69.7 2.8 6.1 1.3 2.2
Ketamine 68.0 67.8 67.8 66.6 67.5 67.3 1.4 1.4 0.5 1.4
Legal highs 79.0 79.2 79.1 78.9 78.9 78.9 0.1 0.8 0.3 0.4
LSD 76.8 76.7 76.8 76.5 76.7 76.6 0.5 0.7 0.5 0.7
Methadone 70.5 70.8 70.7 69.3 70.2 70.0 1.2 0.7 1.4 0.5
MMushrooms 75.6 75.7 75.6 75.1 75.3 75.2 0.9 0.1 0.7 0.5
Nicotine 70.1 70.4 70.2 69.7 69.1 69.5 0.8 0.9 1.6 1.1
VSA 74.8 74.8 74.8 74.3 74.7 74.5 2.2 2.2 0.7 1.6
Heroin pleiad 69.6 70.1 69.9 69.1 69.4 69.3 0.5 0.7 0.9 0.4
Ecstasy pleiad 78.6 78.7 78.6 78.6 78.2 78.5 0.5 0.8 0.4 0.4
Benz. pleiad 70.7 70.7 70.7 70.2 69.8 70.0 0.9 0.8 0.9 0.8
Illicit drugs 77.9 78.2 78.1 77.5 77.8 77.7 0.4 0.6 0.7 0.9
Table A.10 Performance and stability of linear discriminant for year-based definition of users (10 attributes).
Total sample LOOCV Stability indicators
Drug Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Alcohol 63.1 63.2 63.1 62.7 58.1 62.4 3.3 4.6 5.9 4.4
Amphetamines 72.5 72.7 72.7 71.6 72.4 72.2 0.9 0.5 0.9 0.9
Amyl nitrite 69.2 68.6 68.6 62.4 68.3 67.9 4.5 2.3 2.7 2.6
Benz. 69.7 69.4 69.5 68.2 69.3 69.0 1.9 0.6 0.5 0.7
Cannabis 79.3 79.3 79.3 78.9 79.0 78.9 0.7 0.8 0.3 0.2
Chocolate 58.1 60.0 58.1 57.4 37.8 57.0 13.6 16.1 17.8 13.3
Cocaine 71.0 71.5 71.4 69.8 71.1 70.8 1.0 0.2 1.0 1.2
Caffeine 68.0 67.2 68.0 67.7 54.1 67.2 8.9 7.3 11.5 6.6
Crack 73.4 73.9 73.9 69.6 73.6 73.4 1.3 2.5 3.4 3.7
Ecstasy 75.4 75.7 75.6 75.0 75.6 75.4 0.2 0.6 0.8 0.3
Heroin 73.7 73.7 73.7 70.3 73.6 73.4 2.5 2.5 2.1 2.3
Ketamine 71.6 71.6 71.6 68.8 71.4 71.1 2.9 1.9 2.1 1.9
Legal highs 77.7 77.7 77.7 77.0 77.4 77.3 0.9 0.4 0.5 0.5
LSD 80.0 80.0 80.0 79.2 79.9 79.7 0.5 0.5 0.3 0.9
Methadone 70.6 70.6 70.6 69.7 70.4 70.3 0.9 0.9 0.7 1.7
MMushrooms 77.9 77.9 77.9 77.4 77.7 77.7 0.5 0.2 0.2 0.6
Nicotine 70.4 70.4 70.4 70.1 70.2 70.1 0.3 0.8 0.4 0.4
VSA 72.6 72.7 72.7 71.6 72.5 72.4 2.1 2.1 1.7 3.9
Heroin pleiad 71.5 72.0 71.8 71.3 71.7 71.6 0.3 0.7 0.8 1.0
Ecstasy pleiad 80.2 80.3 80.2 80.0 80.0 80.0 0.1 0.6 0.3 0.5
Benz. pleiad 73.0 72.7 72.8 72.4 72.3 72.4 0.6 0.4 0.5 0.4
Illicit drugs 80.2 79.6 79.8 79.5 79.4 79.4 1.0 0.4 0.4 0.3
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Table A.11 Performance and stability of linear discriminant for month-based definition of users (10 attributes).
Total sample LOOCV Stability indicators
Drug Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Alcohol 60.9 61.1 60.9 60.4 58.4 60.1 2.3 2.6 3.0 2.4
Amphetamines 68.9 68.1 68.2 65.5 68.0 67.7 2.9 3.4 1.2 2.0
Amyl nitrite 70.7 75.3 75.2 63.4 75.1 74.9 2.4 2.4 8.5 5.2
Benz. 68.9 68.7 68.8 68.2 68.5 68.5 1.3 1.3 1.1 2.0
Cannabis 78.6 78.3 78.4 77.7 77.9 77.8 1.1 0.0 0.6 0.9
Chocolate 57.9 56.6 57.8 57.2 48.5 56.7 9.7 8.0 9.1 8.1
Cocaine 69.8 70.0 70.0 67.3 69.9 69.7 3.1 2.5 2.3 2.7
Caffeine 60.8 60.3 60.7 60.5 54.5 60.2 7.3 5.2 6.6 5.8
Crack 80.0 75.3 75.4 65.0 75.2 75.1 15.0 15.0 4.8 11.6
Ecstasy 72.5 72.4 72.4 71.3 72.3 72.1 1.7 1.3 1.2 1.2
Heroin 79.2 77.6 77.7 69.8 77.5 77.2 9.4 7.5 3.2 3.8
Ketamine 72.2 73.3 73.2 64.6 73.1 72.8 3.8 1.3 3.4 2.7
Legal highs 72.6 72.5 72.5 71.4 72.4 72.3 1.2 1.7 0.9 1.2
LSD 76.5 76.4 76.4 74.7 76.3 76.2 1.2 1.2 1.0 1.9
Methadone 68.4 68.1 68.2 66.7 67.7 67.6 1.8 3.5 1.6 2.6
MMushrooms 75.5 74.3 74.4 73.6 74.3 74.2 2.5 2.5 0.9 2.0
Nicotine 66.4 66.2 66.3 65.8 66.0 65.9 1.1 0.7 0.3 0.7
VSA 76.5 75.6 75.6 58.8 75.6 75.3 5.9 5.9 2.9 6.1
Heroin pleiad 69.3 69.4 69.4 68.0 69.2 69.0 1.6 1.3 1.5 0.9
Ecstasy pleiad 79.4 79.6 79.5 79.2 79.1 79.2 0.5 0.5 0.7 0.7
Benz. pleiad 70.5 70.3 70.3 70.1 69.9 70.0 0.4 0.8 0.7 1.0
Illicit drugs 78.9 78.8 78.8 78.4 78.5 78.5 0.4 0.3 0.5 0.4
Table A.12 Performance and stability of linear discriminant for week-based definition of users (10 attributes).
Total sample LOOCV Stability indicators
Drug Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Alcohol 60.4 59.9 60.3 59.3 58.9 59.2 2.0 0.9 1.0 1.3
Amphetamines 66.9 66.7 66.7 62.0 66.5 66.1 4.3 2.5 3.0 2.8
Amyl nitrite 70.6 77.6 77.5 52.9 77.4 77.1 0.0 5.9 14.7 11.8
Benz. 70.4 70.1 70.1 67.0 69.8 69.5 3.4 1.7 2.1 2.7
Cannabis 75.9 75.9 75.9 75.3 75.5 75.4 0.9 0.0 0.5 0.5
Chocolate 57.8 57.7 57.8 57.2 54.4 56.6 3.6 2.5 3.3 1.3
Cocaine 75.0 75.1 75.1 61.7 75.1 74.6 8.3 6.7 4.1 4.4
Caffeine 59.5 58.1 59.4 58.5 52.0 57.7 5.8 2.8 6.2 5.3
Crack 90.9 85.9 85.9 54.5 85.8 85.6 27.3 9.1 4.1 7.7
Ecstasy 72.6 71.5 71.5 67.9 71.4 71.2 3.6 8.3 2.4 5.3
Heroin 79.3 80.1 80.1 65.5 80.0 79.8 6.9 6.9 4.6 4.8
Ketamine 73.0 71.9 71.9 62.2 71.6 71.5 8.1 8.1 3.5 6.5
Legal highs 70.2 71.0 71.0 66.4 70.9 70.6 3.8 5.3 2.5 1.9
LSD 81.2 80.6 80.6 76.8 80.3 80.2 4.3 2.9 1.5 2.2
Methadone 70.2 69.4 69.5 65.3 69.3 69.1 3.3 4.1 2.6 3.2
MMushrooms 70.5 68.7 68.7 61.4 68.4 68.2 6.8 9.1 4.4 7.9
Nicotine 63.9 63.8 63.8 63.5 63.5 63.5 0.5 0.8 0.3 0.6
VSA 81.0 78.7 78.7 61.9 78.6 78.4 4.8 0.0 5.2 7.7
Heroin pleiad 70.7 70.3 70.3 65.8 69.8 69.4 4.9 1.6 2.1 1.6
Ecstasy pleiad 77.3 77.3 77.3 76.6 77.0 76.9 0.6 0.3 0.6 0.8
Benz. pleiad 68.3 68.5 68.4 66.9 68.3 68.0 1.1 1.1 1.2 0.9
Illicit drugs 77.2 77.1 77.2 76.8 76.7 76.8 0.7 0.8 0.7 0.5
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Table A.13 Coefficients of linear discriminant for user/non-user separation and decade-based definition of users (7 attributes)
Drug Θ N E O A C Imp SS
Alcohol -22.282 0.124 0.149 -0.068 -0.102 -0.460 0.056 0.856
Amphetamines -36.596 0.040 -0.197 0.363 -0.063 -0.343 0.040 0.840
Amyl nitrite -29.255 0.083 0.177 -0.023 -0.104 -0.308 -0.195 0.904
Benz. -56.705 0.532 -0.211 0.597 -0.205 -0.186 0.105 0.478
Cannabis -22.278 -0.004 -0.242 0.571 -0.143 -0.357 -0.014 0.684
Chocolate 6.158 -0.133 -0.369 0.603 0.271 -0.308 -0.467 0.309
Cocaine -43.257 0.203 0.037 0.303 -0.288 -0.293 0.024 0.834
Caffeine -9.371 -0.121 0.479 0.313 0.026 -0.682 -0.139 0.416
Crack -48.494 0.145 -0.293 0.326 -0.202 -0.243 0.415 0.718
Ecstasy -35.896 0.045 -0.017 0.407 -0.085 -0.342 -0.156 0.827
Heroin -55.851 0.381 -0.283 0.526 -0.322 -0.124 0.249 0.563
Ketamine -34.711 -0.003 -0.094 0.478 -0.197 -0.333 -0.024 0.782
Legal highs -30.803 -0.017 -0.227 0.532 -0.040 -0.303 -0.118 0.747
LSD -34.972 -0.108 -0.258 0.632 -0.103 -0.162 -0.068 0.694
Methadone -27.409 0.208 -0.416 0.620 -0.262 -0.253 0.058 0.513
MMushrooms -29.576 -0.147 -0.239 0.631 -0.106 -0.265 0.002 0.665
Nicotine -38.644 0.171 -0.092 0.397 -0.093 -0.393 0.005 0.801
VSA -34.395 0.071 -0.209 0.326 -0.060 -0.392 0.012 0.829
Heroin pleiad -30.383 0.113 -0.149 0.441 -0.270 -0.331 0.007 0.767
Ecstasy pleiad -17.510 -0.002 -0.222 0.542 -0.180 -0.385 -0.028 0.689
Benz. pleiad -35.808 0.232 -0.136 0.492 -0.201 -0.347 -0.042 0.723
Illicit drugs -18.501 0.096 -0.272 0.537 -0.169 -0.409 0.014 0.657
SD ≤ 0.970 ≤ 0.008 ≤ 0.008 ≤ 0.007 ≤ 0.007 ≤ 0.008 ≤ 0.008 ≤ 0.009
Table A.14 Coefficients of linear discriminant for user/non-user separation and year-based definition of users (7 attributes)
Drug Θ N E O A C Imp SS
Alcohol -16.181 -0.136 0.270 -0.082 -0.024 -0.236 -0.314 0.865
Amphetamines -39.624 0.061 -0.213 0.424 -0.136 -0.365 0.166 0.769
Amyl nitrite -5.472 0.060 0.023 0.157 -0.388 -0.292 -0.319 0.796
Benz. -64.199 0.566 -0.171 0.456 -0.220 -0.112 0.089 0.611
Cannabis -24.008 -0.064 -0.230 0.555 -0.040 -0.354 -0.093 0.706
Chocolate 0.709 0.114 -0.159 0.582 0.264 -0.380 -0.606 0.203
Cocaine -46.414 0.224 0.152 0.187 -0.299 -0.292 0.030 0.846
Caffeine -8.114 -0.222 0.503 0.076 -0.063 -0.636 0.052 0.530
Crack -52.425 0.244 -0.153 0.140 -0.219 -0.282 0.399 0.782
Ecstasy -42.579 -0.019 0.078 0.373 -0.045 -0.356 -0.096 0.846
Heroin -44.733 0.361 -0.327 0.368 -0.397 -0.108 0.218 0.641
Ketamine -42.342 0.056 -0.003 0.417 -0.143 -0.363 -0.047 0.818
Legal highs -30.027 -0.062 -0.181 0.460 -0.091 -0.300 -0.098 0.803
LSD -40.183 -0.141 -0.220 0.650 -0.039 -0.118 -0.115 0.693
Methadone -28.093 0.234 -0.417 0.575 -0.296 -0.206 0.024 0.556
MMushrooms -36.864 -0.142 -0.182 0.669 -0.093 -0.215 -0.053 0.664
Nicotine -35.594 0.122 -0.126 0.376 -0.036 -0.441 0.019 0.795
VSA -55.631 0.382 0.009 0.213 -0.038 -0.379 -0.014 0.815
Heroin pleiad -32.917 0.154 -0.147 0.385 -0.310 -0.312 0.044 0.782
Ecstasy pleiad -20.439 -0.059 -0.264 0.548 -0.102 -0.354 -0.045 0.699
Benz. pleiad -41.126 0.256 -0.164 0.438 -0.230 -0.287 0.018 0.761
Illicit drugs -22.701 0.033 -0.295 0.549 -0.125 -0.351 -0.012 0.686
SD ≤ 1.250 ≤ 0.011 ≤ 0.011 ≤ 0.009 ≤ 0.009 ≤ 0.009 ≤ 0.008 ≤ 0.012
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Table A.15 Coefficients of linear discriminant for user/non-user separation and month-based definition of users (7 attributes)
Drug Θ N E O A C Imp SS
Alcohol -63.256 0.190 0.823 0.002 0.087 -0.005 -0.268 0.456
Amphetamines -24.230 0.011 -0.223 0.361 -0.254 -0.499 0.375 0.605
Amyl nitrite -6.284 -0.243 -0.183 -0.082 -0.187 -0.092 -0.117 0.918
Benz. -69.623 0.702 -0.189 0.286 -0.215 0.006 0.148 0.568
Cannabis -25.637 -0.145 -0.215 0.606 -0.069 -0.322 -0.051 0.674
Chocolate 19.518 -0.121 0.254 0.308 0.168 -0.595 -0.621 0.240
Cocaine -57.737 0.366 0.148 0.082 -0.370 -0.014 -0.001 0.837
Caffeine -91.137 0.351 0.687 0.026 0.052 -0.080 0.567 0.271
Crack -46.531 0.459 -0.220 -0.077 -0.357 0.096 0.066 0.771
Ecstasy -27.572 -0.169 0.101 0.462 -0.191 -0.354 -0.139 0.752
Heroin -30.020 0.302 -0.409 0.232 -0.499 -0.107 0.345 0.555
Ketamine -6.182 -0.169 -0.210 0.643 -0.232 -0.464 -0.044 0.493
Legal highs -17.306 -0.067 -0.240 0.474 -0.201 -0.388 -0.053 0.721
LSD -47.031 -0.012 -0.097 0.762 -0.023 -0.225 -0.155 0.578
Methadone -17.825 0.260 -0.501 0.436 -0.286 -0.238 -0.004 0.594
MMushrooms -29.897 -0.229 -0.273 0.762 -0.037 -0.217 -0.019 0.494
Nicotine -34.684 0.072 -0.032 0.342 -0.022 -0.590 0.204 0.698
VSA -70.559 0.137 0.068 0.230 -0.208 -0.073 0.182 0.918
Heroin pleiad -41.444 0.277 -0.272 0.284 -0.346 -0.105 0.113 0.791
Ecstasy pleiad -19.318 -0.141 -0.257 0.573 -0.125 -0.359 0.014 0.664
Benz. pleiad -47.877 0.416 -0.199 0.300 -0.258 -0.246 0.128 0.745
Illicit drugs -21.767 -0.051 -0.295 0.567 -0.129 -0.344 0.009 0.674
SD ≤ 1.041 ≤ 0.009 ≤ 0.009 ≤ 0.009 ≤ 0.008 ≤ 0.007 ≤ 0.007 ≤ 0.010
Table A.16 Coefficients of linear discriminant for user/non-user separation and week-based definition of users (7 attributes)
Drug Θ N E O A C Imp SS
Alcohol -52.758 0.202 0.791 -0.273 0.041 -0.002 -0.176 0.476
Amphetamines -17.930 -0.054 -0.311 0.402 -0.237 -0.472 0.577 0.356
Amyl nitrite 5.116 -0.466 -0.348 -0.188 -0.084 -0.186 0.249 0.723
Benz. -51.825 0.707 -0.438 0.240 -0.229 0.052 0.224 0.382
Cannabis -28.488 -0.136 -0.215 0.658 -0.074 -0.282 -0.079 0.641
Chocolate -22.538 0.221 0.565 -0.149 0.195 0.020 0.302 -0.693
Cocaine -42.900 0.347 0.198 -0.011 -0.407 -0.090 -0.103 0.810
Caffeine -53.485 0.422 0.821 -0.118 -0.135 -0.146 0.301 -0.061
Crack -22.095 0.304 -0.279 -0.282 -0.463 0.148 0.119 0.707
Ecstasy -60.127 -0.095 0.168 0.695 -0.128 -0.355 0.242 0.528
Heroin -37.099 0.548 -0.325 0.265 -0.547 -0.069 0.389 0.261
Ketamine 1.992 -0.284 -0.395 0.574 -0.307 -0.228 -0.030 0.535
Legal highs 0.347 -0.015 -0.352 0.406 -0.315 -0.454 -0.022 0.636
LSD -35.647 0.001 0.054 0.716 0.008 -0.371 -0.309 0.501
Methadone -14.932 0.317 -0.636 0.331 -0.310 -0.106 0.084 0.521
MMushrooms -66.891 -0.143 -0.071 0.715 0.073 -0.114 0.059 0.665
Nicotine -42.383 0.175 -0.013 0.222 0.012 -0.574 0.284 0.714
VSA -75.762 0.043 -0.068 0.419 -0.191 0.250 0.056 0.846
Heroin pleiad -25.458 0.341 -0.397 0.242 -0.379 -0.205 0.116 0.684
Ecstasy pleiad -19.877 -0.146 -0.272 0.603 -0.124 -0.338 -0.004 0.642
Benz. pleiad -43.258 0.498 -0.349 0.260 -0.250 -0.274 0.343 0.554
Illicit drugs -22.772 -0.055 -0.329 0.575 -0.113 -0.322 0.004 0.665
SD ≤ 0.707 ≤ 0.006 ≤ 0.006 ≤ 0.006 ≤ 0.007 ≤ 0.007 ≤ 0.009 ≤ 0.007
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Table A.17 Performance and stability of linear discriminant for decade-based definition of users (7 attributes).
Total sample LOOCV Stability indicators
Drug Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Alcohol 67.1 64.7 67.0 66.9 55.9 66.5 7.6 4.7 11.8 4.4
Amphetamines 69.1 69.3 69.2 68.5 68.7 68.6 0.7 1.0 1.1 1.2
Amyl nitrite 61.9 61.8 61.9 61.1 61.7 61.5 1.6 2.4 0.9 2.0
Benz. 67.6 67.3 67.4 67.0 66.8 66.9 0.8 0.7 0.8 0.9
Cannabis 75.0 75.2 75.1 74.9 74.4 74.7 0.5 0.5 0.8 0.6
Chocolate 56.7 54.3 56.7 56.4 42.9 56.2 11.4 13.1 5.7 20.0
Cocaine 66.4 66.5 66.5 66.1 66.2 66.2 0.4 0.6 0.7 0.7
Caffeine 69.9 70.3 69.9 69.7 56.8 69.4 6.5 7.5 10.8 8.1
Crack 66.0 65.9 65.9 62.8 65.6 65.3 4.7 1.6 2.1 2.6
Ecstasy 71.6 71.6 71.6 71.4 71.4 71.4 0.5 0.8 0.4 0.7
Heroin 70.3 70.8 70.7 68.4 70.6 70.3 1.9 1.4 2.1 1.6
Ketamine 66.9 66.8 66.8 65.1 66.6 66.4 2.3 2.0 1.2 1.1
Legal highs 73.4 73.3 73.3 73.0 72.9 72.9 0.4 0.1 0.5 0.6
LSD 72.4 72.4 72.4 71.6 72.2 72.0 0.7 0.4 0.6 0.9
Methadone 69.3 69.5 69.4 68.6 69.2 69.1 1.2 1.4 1.0 1.1
MMushrooms 71.0 70.9 71.0 70.0 70.6 70.4 1.2 0.9 1.1 0.9
Nicotine 66.3 66.0 66.2 66.1 65.2 65.8 0.9 0.7 1.0 1.1
VSA 70.4 70.5 70.5 67.8 70.4 70.1 3.0 1.7 1.9 0.8
Heroin pleiad 68.1 68.3 68.2 67.5 67.7 67.6 0.6 0.4 0.7 0.1
Ecstasy pleiad 76.2 75.5 76.0 75.8 75.2 75.6 1.1 0.3 0.2 0.5
Benz. pleiad 68.7 68.8 68.8 68.6 68.5 68.5 0.2 0.8 0.4 0.6
Illicit drugs 74.9 75.2 75.1 74.5 74.9 74.8 0.2 0.9 0.6 0.7
Table A.18 Performance and stability of linear discriminant for year-based definition of users (7 attributes).
Total sample LOOCV Stability indicators
Drug Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Alcohol 58.0 58.1 58.0 57.7 54.4 57.5 4.7 5.3 3.7 5.9
Amphetamines 70.6 70.4 70.5 69.5 70.2 70.0 1.8 0.9 0.8 0.9
Amyl nitrite 65.4 65.2 65.3 63.2 65.0 64.8 2.3 3.0 2.7 3.7
Benz. 68.0 68.2 68.2 67.3 67.9 67.7 1.3 1.1 0.8 0.9
Cannabis 75.0 74.8 74.9 74.9 74.6 74.7 0.4 0.5 0.2 0.3
Chocolate 58.0 60.0 58.0 57.9 40.0 57.5 15.5 15.3 20.0 6.7
Cocaine 68.1 68.3 68.3 67.4 68.1 68.0 0.2 0.7 1.3 1.1
Caffeine 65.2 65.6 65.3 65.1 63.9 65.1 5.4 7.0 3.3 6.6
Crack 69.6 68.4 68.5 62.0 68.3 68.0 5.1 2.5 2.9 5.3
Ecstasy 70.6 70.1 70.2 69.8 70.0 69.9 1.0 0.4 0.4 0.8
Heroin 71.2 70.9 70.9 64.4 70.7 70.3 6.8 3.4 2.4 2.4
Ketamine 68.3 68.8 68.8 67.3 68.6 68.5 1.4 1.0 2.0 2.0
Legal highs 73.0 73.3 73.2 72.5 72.7 72.7 0.7 0.7 1.1 0.7
LSD 72.1 72.0 72.0 71.1 71.8 71.6 1.1 1.1 0.9 1.0
Methadone 69.1 69.3 69.3 68.1 69.1 68.9 0.9 2.2 1.0 1.4
MMushrooms 71.7 71.8 71.8 71.0 71.7 71.5 0.9 0.9 0.8 0.9
Nicotine 67.5 67.8 67.6 67.3 67.3 67.3 0.3 0.5 0.8 0.4
VSA 68.4 68.5 68.5 63.2 68.3 68.1 5.3 5.3 2.8 3.5
Heroin pleiad 68.5 68.6 68.6 67.9 68.5 68.3 1.0 0.3 0.8 0.8
Ecstasy pleiad 75.9 76.1 76.0 75.7 75.6 75.6 0.4 0.6 0.9 0.4
Benz. pleiad 70.1 69.8 69.9 69.3 69.2 69.2 1.1 0.6 0.7 0.8
Illicit drugs 76.5 76.4 76.4 76.2 76.3 76.2 0.6 0.3 0.3 0.3
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Table A.19 Performance and stability of linear discriminant for month-based definition of users (7 attributes).
Total sample LOOCV Stability indicators
Drug Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Alcohol 58.5 57.8 58.4 57.8 56.0 57.5 2.4 1.7 3.3 2.4
Amphetamines 68.1 67.7 67.7 64.7 67.5 67.2 4.6 0.8 1.8 1.4
Amyl nitrite 70.7 70.8 70.8 61.0 70.6 70.4 2.4 2.4 3.9 6.7
Benz. 68.2 68.0 68.0 67.6 68.1 68.0 1.3 1.3 1.2 2.4
Cannabis 73.7 73.7 73.7 73.2 73.6 73.4 0.6 0.1 0.3 0.5
Chocolate 56.7 56.6 56.7 56.0 46.5 55.5 11.1 11.5 11.1 11.1
Cocaine 67.3 68.0 68.0 65.4 67.8 67.6 3.8 3.1 2.3 1.9
Caffeine 58.7 59.5 58.8 59.3 53.7 58.9 4.0 6.8 5.8 4.1
Crack 80.0 81.4 81.4 45.0 81.4 81.0 5.0 5.0 7.9 4.1
Ecstasy 66.7 66.6 66.6 65.4 66.5 66.4 1.7 1.7 1.6 1.6
Heroin 75.5 75.8 75.8 67.9 75.6 75.4 9.4 3.8 4.3 3.5
Ketamine 67.1 66.7 66.7 59.5 66.4 66.1 8.9 2.5 4.8 6.3
Legal highs 68.5 68.7 68.7 66.4 68.4 68.1 2.5 2.1 1.2 1.0
LSD 69.9 70.0 70.0 69.3 69.8 69.8 0.6 2.4 1.8 3.2
Methadone 66.7 66.9 66.9 63.7 66.6 66.4 2.9 2.3 2.1 1.6
MMushrooms 71.7 71.4 71.4 67.9 71.1 70.9 4.4 3.1 1.3 1.4
Nicotine 64.1 64.2 64.1 63.5 63.7 63.6 1.0 0.7 0.8 0.5
VSA 70.6 70.3 70.3 55.9 70.2 69.9 11.8 5.9 4.2 7.8
Heroin pleiad 67.3 67.0 67.1 64.7 66.6 66.3 3.2 1.9 1.5 1.3
Ecstasy pleiad 74.4 74.4 74.4 74.0 74.2 74.1 0.3 0.3 0.4 0.8
Benz. pleiad 68.9 69.0 69.0 68.6 68.8 68.7 0.2 0.6 1.0 1.8
Illicit drugs 74.6 74.4 74.5 74.2 74.2 74.2 0.6 0.4 0.2 0.6
Table A.20 Performance and stability of linear discriminant for week-based definition of users (7 attributes).
Total sample LOOCV Stability indicators
Drug Sn Sp Acc Sn Sp Acc TP→FN FN→TP FP→TN TN→FP
Alcohol 56.0 55.6 55.9 55.2 54.1 54.9 1.4 1.3 1.6 2.4
Amphetamines 66.3 66.3 66.3 63.2 65.9 65.6 4.9 3.1 2.3 2.5
Amyl nitrite 70.6 85.0 84.8 47.1 84.9 84.5 0.0 5.9 13.1 4.6
Benz. 69.8 69.5 69.5 67.0 69.3 69.1 3.9 1.7 2.0 2.6
Cannabis 71.1 71.2 71.2 70.8 70.7 70.8 0.8 0.3 0.5 0.5
Chocolate 54.7 54.9 54.7 54.3 51.4 53.7 3.0 3.4 3.8 3.0
Cocaine 71.7 69.0 69.1 65.0 68.8 68.7 6.7 3.3 3.2 6.5
Caffeine 54.3 53.7 54.2 53.8 50.2 53.4 4.6 5.4 2.6 5.7
Crack 81.8 82.3 82.3 45.5 82.2 82.0 9.1 9.1 7.7 6.7
Ecstasy 70.2 71.4 71.4 65.5 71.2 70.9 7.1 6.0 3.8 3.3
Heroin 79.3 80.7 80.6 65.5 80.6 80.4 6.9 0.0 5.3 3.0
Ketamine 64.9 66.7 66.6 56.8 66.5 66.3 5.4 10.8 8.0 6.7
Legal highs 69.5 68.6 68.7 63.4 68.5 68.1 4.6 2.3 2.3 3.1
LSD 69.6 70.6 70.6 65.2 70.5 70.3 4.3 2.9 4.4 3.3
Methadone 68.6 68.0 68.1 64.5 67.9 67.7 5.8 2.5 2.7 4.0
MMushrooms 72.7 72.9 72.9 63.6 72.8 72.6 6.8 2.3 5.5 4.9
Nicotine 62.5 62.7 62.6 62.1 62.3 62.2 0.4 1.2 0.9 0.9
VSA 71.4 74.3 74.3 61.9 74.2 74.1 9.5 4.8 8.3 5.5
Heroin pleiad 68.5 68.4 68.4 65.2 68.1 67.9 3.3 2.7 1.8 1.8
Ecstasy pleiad 72.3 72.5 72.4 72.0 72.1 72.0 0.5 0.1 0.5 0.4
Benz. pleiad 68.0 68.3 68.3 66.9 68.1 67.9 0.8 0.3 1.0 1.2
Illicit drugs 73.4 72.9 73.2 72.8 72.6 72.7 0.9 0.2 0.2 0.7
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